roche annual report innovate healthcare life countskey figure roche group index sale mchf equity ratio research development mchf total employee remuneration mchf operating profit mchf total dividend mchf income taxis mchf number employee net income mchf patient clinical trial core earning share chf ecoefficiency rate index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase key figure index figure annual report propose board director index global reporting initiative gri development phase iv indicator report calculation ecoefficiency rate wwwrochecomreportingandindice wwwrochecomenvironment wwwglobalreportscom brief group roche report strong result challenge market environment group sale significantly increase local currency exclude tamiflu pandemic sale strong organic growth key product outweigh low tamiflu pandemic sale include tamiflu pandemic sale group sale local currency rise operating profit exceed year record local currency reach billion swiss franc despite increase level rd investment net income swiss franc billion swiss franc primarily strong swiss franc lower net financial income core earning share constant exchange rate previous year record level pharmaceutical pharmaceutical sale advance twice global market growth rate sixth doubledigit increase year oncology product sale grow billion swiss franc time cancer product achieve sale billion swiss franc operating profit margin increase percentage point despite significantly low tamiflu pandemic sale increase investment development pipeline avastin receive accelerate approval breast cancer application approval brain cancer file eu actemraroactemra approve rheumatoid arthritis japan eu switzerland additional datum besubmitte fda major phase iii programme initiate acquisition pirame mirus arius significantly strengthen rd pipeline new compound technology platform diagnostic divisional sale doubledigit growth rise operating profit margin decline percentage point acquisition impact strong competition diabete care market integration tissue diagnostic ventana complete new businesss performance exceed expectation outlook abovemarket sale growth division midsingledigit sale growth division group core earning share target remain high level spite increase investment inresearch development expect low net financial result bar unforeseen event state growth rate local currency exclude tamiflu pandemic sale core earning share target base constant exchange rateswwwglobalreportscomyour life stake s work day day well treatment test innovate healthcare express purpose company aim achieve pharmaceutical pipeline key indicator innovative strength file major new marketing application receive major regulatory approval innovation priority diagnostic division launch new test instrument early detection prevention disease diagnosis treatment treatment monitor roche deliver wide range healthcare solutionswwwglobalreportscomfor researcher step forward patient huge relief imagine need injection week instead twice day control blood sugar lose weight time appeal prospect people type diabete hopefully soon reality innovate healthcare taspoglutide investigational new diabetes medicine currently phase iii clinical trial well quality life reach people type diabeteswe close look treatment last long necessary wwwglobalreportscomthank combine expertise pharmaceutical diagnostic patient hepatitis c spare extended therapy innovate healthcare fourmonth course treatment innovative medicine pegasys copegus patient need low level virus blood treatment viral level monitor roche highly sensitive test hepatitis c virus go month treatment patient consider curedinnovation not molecule people wwwglobalreportscomwe try look person interconnect factor determine fall ill stay healthy explore risk factor metabolic disease learn influence early cardiovascular disease preventable innovate healthcare dalcetrapib new molecule increase good cholesterol protect heart great hope patient justify hope compound phase iii clinical trialswwwglobalreportscomstandard therapy not work offer solution monoclonal antibody offer new way treat disease establish cancer therapy prove effective rheumatoid arthritis innovate healthcare mabtherarituxan actemraroactemra distinct monoclonal antibodie target different part inflammation process stop disease progressing offer patient well chance achieve remission disease novel medicine physician new option patient respond standard treatment chance improve quality lifewwwglobalreportscomthe future write star clue disease code gene successful innovator need follow lead industry promising lead come analyse genetic profile disease diseasecause pathogen focus area researcher innovate healthcare help roche nimblegen microarray miniaturised genetic research lab chip roche develop novel rapid method deepen understanding disease enable development new treatmentswwwglobalreportscomwe not end cancer prevent important medical discovery recent time infection certain type human papilloma virus lead cervical cancer woman give doctor practical way apply knowledge roche help help patient innovate healthcare test roche help physician diagnose woman infect certain strain virus high risk progress cervical cancer early diagnosis treatment save live spare woman tremendous sufferingwwwglobalreportscomwe innovate good reason reliable accurate safe demand preventive screening test high innovate healthcare reduce risk viral infection contaminate blood transfusion roche develop test simultaneously check donate blood hiv hepatitis c b virus test country worldwide improve safety blood supplieswhen sick question new answer wwwglobalreportscomthe integration ventana give roche access late advanced knowhow tissuebase diagnostic enable help physician patient new precise answer question vital importance innovate healthcare tissuebase diagnostic aid tumour characterisation monitoring change malignancy give cancer patient continue hope target treatmentsit take decade turn idea medicine good not easily wwwglobalreportscomwe innovate healthcare roche mean explore uncharted territory day objective clear outcome predict outset particular compound actually benefit patient safe use sustain dynamic innovation strategy like not vision financial strength risky longterm investment take drive staying power venture unknown help patient count ustable content key figure brief letter shareholder roche group group results outlook group strategy pharmaceuticals pharmaceutical division brief result therapeutic area research development diagnostic diagnostic division brief result business area corporate governance remuneration report corporate governance remuneration report corporate responsibility brief responsible practice patient people society safety security health environmental protection independent assurance report gri statement pharmaceutical diagnostic pipeline inside cover wwwglobalreportscom letter shareholders franz b humer severin schwan dear shareholder past year dominate global financial economic crisis com pany continue perform strongly building achievement previous year pharmaceutical diagnostic division sale grow ahead respective market group sale rise local currency exclude pandemic tamiflu sale expect decline sharply include pandemic tamiflu sale increase billion swiss franc group operating profit increase billion swiss franc increase research development spending promise project strong development pipeline net income billion swiss franc slightly previous year record high despite mark appreciation swiss franc major currency low financial income core earning share constant exchange rate high year view late strong result board director propose dividend increase swiss franc share nonvoting equity security swiss franc subject approval annual general meeting shareholder roche nd consecutive annual dividend increase today turbulent economic climate vital stay focused develop product significantly improve treatment option available patient recent year strategy yield major advance notably diagnosis treatment cancer particularly excite largescale clinical trial group conduct avastin target cancer medicine halt development new blood vessel roche business report letter shareholder tumour trial require substantial investment time money hold promise long well life countless patient suffer wide variety cancer ventana usbased leader tissue diagnostic acquire billion swiss franc february continue perform strongly expect access tissuebase diagnostic test technology help effort develop sonalise treatment particularly cancer roche considerable progress develop biological medicine treatment rheumatoid arthritis ra autoimmune disease affect million people worldwide novel medicine actemraroactemra approve treatment ra japan european union mabtherarituxan lead cancer medicine continue benefit ra patient datum phase iii clinical trial example mabtherarituxan prevent structural damage joint patient early ra tell project enter final stage clinical development roche include promising new molecule treatment breast cancer pertuzumab type diabete taspoglutide cardiovascular risk reduction dalcetrapib july year roche announce intention purchase outstanding share genen tech company hold majority stake nearly year remain committed completing transaction believe bring genentech entirely roche group significantly enhance group ability remain innovative long term necessary care preserve genentech unique innovation culture group continue encourage promote diver sity research approach helps create ideal climate medical progress ensure exist research network technology expertise pharmaceutical diagnostic business share group time leverage scale combine operation improve operational efficiency roche take step position strength conviction propose transaction good interest company employee patient share holder roche board director corporate executive committee confident transaction bring significantly close goal world lead health care company remain committed operating business responsible sustainable manner respect need stakeholder product great contribution society provide significant benefit patient tangibly improve people health increase quality length life recognise responsibility help expand global access product primarily partnership collaboration stakeholder wwwglobalreportscom year achieve environmental goal improve energy efficiency reduce emission greenhouse gas firmly believe sustainable policy business practice create longterm corporate value support innovation recognition effort roche select inclusion dow jones world sustainability index fifth consecutive year finally like additional opportunity thank roche employee worldwide tremendous dedication professionalism effort roche world successful company recruit retain develop talented people remain important task bar unforeseen event expect group continue perform strongly pharmaceutical diagnostic division expect fullyear sale grow ahead market increase midsingledigit range local currency continue invest largescale confirmatory clinical trial vital roche longterm success despite high research development cost involve expect decrease net financial income aim core earning share core eps constant exchange rate remain high level expect genentech transaction positive impact core epswithin year closing franz b humer severin schwan chairman board chief executive officerroche group roche group continue strong underlying operating performance recent year roche expect sale phar maceutical diagnostic division grow ahead market roche personalised healthcare cornerstone innovation strategy key enabler help increase success rate drug develop ment bring clinically differentiate medicine patient wwwglobalreportscom group result financial crisis minimal adverse effect net financial income conservative group continue strong sale investment approach limited exposure equity formance total sale grow local currency security net financial income reach swiss franc dollar bil billion swissfranc reduction billion lion swiss francs pharmaceutical division swiss franc compare primarily represent group sale diagnostic tolower interest income result low liquid division contribute sale increase fund reduction interest rate underlie business compensate anticipate decline tamiflu pandemic sale strong swiss franc low net billion swiss franc local currency sale growth financial income group net income decrease exclude tamiflu pandemic sale billion swiss franc core ep increase pharmaceutical diagnostic division grow local currency swiss franc ahead respective market group continue strong balance sheet demand group oncology drug avastin compare internationally equity mabtherarituxan herceptin tarceva xeloda include noncontrolle interest represent continue strong additional growth driver total asset total asset finance pharmaceutical division bonvivaboniva longterm inmetabolismbone cellcept transplantation diagnostic division main growth area professional diagnostic apply science outlook business area grow ahead theirrespective market follow acquisition bar unforeseen event roche group expect ventana begin february sale continue perform strongly fullyear inthe tissue diagnostic business grow significantly sale pharmaceutical diagnostic fast market contribute percentage division expect grow ahead market point sale growth diagnostic division increase midsingledigit range local currency roche continue invest large group operating profit increase local scale confirmatory clinical trial vital currency billion swiss franc operating group longterm success despite high profit margin decline slightly percentage research development cost involve point margin reduction expect low net financial result group diagnostic division percentage point aim core earning share core ep main reason impact recent acquisition constant exchange rate remain high strong competition diabetes care market level follow propose purchase portfolio mix effect pharmaceutical margin outstanding genentech share roche expect improved percentage point despite transaction positive impact significantly low tamiflu pandemic sale core ep year closing roche increase investment strong development willupdate target transaction pipeline beenclose operate free cash flow increase billion swiss franc despite significant currency translation effect roche business report roche group personalise healthcare key element group strategy roche company recognise potential personalised healthcare phc today phc central group strategy key enabler help increase success rate drug development bring clinically differentiate medi cine patient recent roundtable severin schwan ceo roche group william burns ceo pharmaceutical division jrgen schwiezer ceo diagnostic division talk roche phc strategy implementation phc create value healthcare stakeholder create value roche roche actively pursue personalise health care cornerstone strategy innovation prom ise personalised healthcare schwan chance roche take lead role personalise healthcare pharmaceutical diagnostic division begin invest early molecular biology expertise give put strong position today personalise healthcare forward wm burnsscience understand disease william burns ceo pharmaceutical division molecular level grow exponentially open severin schwan ceo roche group e real opportunity treat illness effec jrgen schwiezer ceo diagnostic division tively right opportunity lie largely learn adjust use today medicine well fit need particular patient possibly help new diagnostic ultimately aim design treatment tomorrow promise personalise healthcare root science intelligently bring true innovation medicine well tracking disease able well job tailor treatment option different patient population identify patient likely respond particular option important time clinical hurdle bring ing new medicine market get high j schwiezer medicine not work produce unacceptable effect depend disease drug response rate low wwwglobalreportscom patient promise phc high week course therapy pegasys response rate few patient needlessly expose recently approve genotype nonresponder risk effect government personalise option available healthcare payer promise able patient combination innovative use resource effectively pay interven medicine genotype viral load monitoring tion provide benefit intervention virology prove not predictive disease area like oncology diagnostic pivotal role play wealth knowledge finding clinically rele not new decade doctor vant biomarker track easy target blood sugar test determine insulin need breast cancer medication herceptin com patient insulindependent diabete viral panion test identify patient likely benefit load monitor viral genotype testing particularly herceptin exception rule hiv hepatitis c recent early stage discovery science example diagnostic guide therapy test definitely point direction phc need measure virus patient blood harness science work patient detect viral resistance particular medicine not miss opportunity capi information help doctor decide long talise great asset special com aggressively treat patient infection drug bination strength pharmaceutical diagnos combination use change drug tic dosage need schwan expertise ve build year schwan fully agree jrgen sense pharmaceutical diagnostic give sustain personalise healthcare new doctor able competitive advantage try fit therapy patient possible company duplicate easily quickly depth s happen recently ve begin breadth pharma diagnostic capability level deep explore ideally equip forefront phc biology disease treatment molecular level question lead real que drug research powerful new technolo tion want lead answer gy select molecule body yes good drug target design clinical trial differentiate manner progress science wm burn give complexity know opening opportunity tailor treatment specific address company hard patient population well imagine pharma company deal separate diagnostic company find way plug wm burn hepatitis c jrgen touch play complexity likely mag briefly good reallife example ve nifie shared library clinical sample abil medicine personalise hepatitis c discov ity design pharma study validate ered year ago help diagnostic marker join thing correctly genotype able tell patient week number opportunitie create sus ll respond treatment pegasys tainable competitive advantage patient hcv genotype know short course therapy likely successful roche business report roche group personalise healthcare create value hurdle roadblock roche overcome phc happen wm burns pharma perspective goal schwan big challenge think com toachieve kind clinical differentiation plexity science easy develop truly dif difference practice medicine ferentiate medicine find biomarker guide able health economic case prod use think building block uct able distinguish subset patient likely place phc happen important area respond medicine subset not ve progress jrgen mention try way enhance chance extend portfolio diagnostic technolo achieve clinical differentiation obviously ideal gy acquire company like nimblegen pharmaceutical pair companion diagnostic life science recently ventana need realistic expectation ve think second element demonstrate com success hiv hepatitis today science mitment phc organisational alignment ve not go translate overnight drugdiag carry year division nostic combination pursue project support smooth integrate cooperation phar immediately entirely successful unlock pro maceutical diagnostic building block find value organisation need place time phc happen continue focus interest patient j schwiezer roche diagnostic role create novel instrument assays vitro diagnostic market world leader important job support pharma ceutical division achieve goal provide tool need drug discovery development process roche diagnostic ve take step fill role well include acqui sition technology give wide range capability need fullservice partner pharma fact organisation give distinct advantage able work early discovery launch shareholder s additional advantage benefit intellectual property generate discovery development regardless division commer cialis wwwglobalreportscom people different disease people react differently medication patient benefit experience unwanted effect today response rate treatment vary depend drug disease roche commit expertise molecular biology gain deep insight disease difference patient broad commitment personalise healthcare phc seek well drug target clinically relevant biomarker day enable doctor tailor treatment closely patient needs predict patient benefit one will not essence phc area oncology virology patient benefit safe effective treatment thank commitment phc diagnostic play key role personalise healthcare people react differently medication group patient benefit treatment experience unwanted effect roche personalise healthcare fitting treatment patientspharmaceutical division deliver strong underlying sale operate profit growth advance key project promise rd portfolio roche continue develop clinically differentiate solution address significant unmet need treatment cancer complex disease roche group pharma ceutical division roche pharmaceutical represent country majority shareholding genentech united states chugai japan wwwglobalreportscom pharmaceuticals division brief sale million chf operating profit million chf number employee key figure change change millions chf chf local currency sale sale roche pharmaceutical genentech chugai operating profit operate free cash flow research development pharma executive committee december william burns ceo division roche pharmaceutical george b abercrombie north america jennifer allerton informatics silvia ayyoubi human resource lee e babiss pharma research henryvincent charbonn strategic marketing jeanjacque garaud development peter hug western europe jonathan kc knowles group research dominic p moorhead finance control christopher murray commercial operation chugai pascal soriot commercial operation jan van koeveringe global technical operation daniel zabrowski pharma partner extended team roche business report pharmaceutical pharmaceutical division sale region pharmaceutical pharmaceutical division translate division strong underlying sale growth strong north america deliver strong creasein operating profit addition division asiapacific performance pass keyregulatory development milestone latin america exclude pandemic inproject expect support roche group sale tamiflu pharmaceutical sale future growth important cemai grow twice themarkete approval gain chugai theglobal market rochefor novel rheumatoid arthritis medicine growth rate divi actemraroactemra japan switzerland western europe sion operate european union ongoing development key japan profitalso increase market product result regulatory filing strongly italic growth rate andapproval important new indication cemai central eastern europe middle east africa mabtherarituxan avastin united states central asia indian subcontinent european union division initiate major new phase iii project include clinical trial novel compound pertuzumab region division sale performance broadly forbreast cancer taspoglutide type diabetes base product generate annual dalcetrapib cardiovascular risk reduction turnover billion swiss franc diversified pipeline major line extension achieve sale ofover billion franc innovative new molecular entity latestage development division unique opportunity pharmaceutical division operate sustained growth year come profit advance fast sale rise local currency swiss franc billion swiss franc correspond margin increase result percentage point compare despite significantly low tamiflu pandemic sale pharmaceutical division maintain strong andincreased investment research develop performance solid growth ment information division operate underlie business compensating forthe result p finance report expect sharp decline pandemic sale oftamiflu thisannual report togovernment corporation divisional sale increase local currency swiss franc dollar billion swiss francsexclud therapeutic area e pandemic sale tamiflu pharmaceutical sale grow local currency twice oncology key product post sustain global market growth rate sixth doubledigit doubledigit growth increase year growth drive primarily cancer accord late international key product division oncology inflammation agency research cancer estimate transplant virology metabolismbone portfolio million people worldwide diagnose forfullyear sale growth rate ofindividual prod cancer million die uct table topselle pharmaceutical disease iarc anticipate cancer product roche group p basis division record abovemarket growth key state growth rate local currency wwwglobalreportscom roche continue strengthen position world lead supplier medicine treat cancer sale therapeutic area oncology inflammatory autoimmune disease transplantation central nervous system respiratory metabolic disease bone disease infectious disease cardiovascular disease virology renal anemia ophthalmology italic growth rate surpass heart disease leading cause early currently affect death worldwide forecast million people worldwide million new case million death year cancer chronic lymphocytic leukemia europe people expect common type leukemia adult accounting develop cancer lifetime cancer approximately form leukemia disease group incidence cll western country distinct disorder medical twice com challenge mon man woman roche continue strengthen position mabtherarituxanrituximab lead asthe world lead supplier medicine treat treatment patient nonhodgkin lymphoma cancer sale pharmaceutical division nhl selective b cell therapy oncology portfoliorose billion swiss approve treatment rheumatoid arthritis franc year total pharmaceutical p combine sale product sale key brand contribute doubledigit inthe oncology inflammationautoimmune growth importantly group advanced segment grow versus prioryear period keydevelopment programme file marketing billion swiss franc strong solid growth application aim make effective wasrecorde europerest world row treatmentoption available doctor cancer theus japan growth oncology patient expand range condition drive sustained expansion use innovative medicine mabthera ofmabtherarituxan induction maintenance rituxan avastin herceptin tarceva xeloda canbe prescribe oncology portfolio main product mabtherarituxan nonhodgkin lymphoma group herceptin avastin tarceva xeloda neorecormon kytril neutrogin neupogen bondronat roferona furtulon vesanoid cancer affect lymphatic system roche define europer world cover europe class cancer grow incidence country japan united states roche business report pharmaceutical division therapy nhl improve access emerge kidney cancer type cancer newly key cancer medicine market approve indication diagnose people cause contribute double death worldwide year rate digit sale growth year roche partner genentech expect increase renal cell carcinoma inaddition roche biogen idec achieve important milestone account kidney cancer partner achieve important intheongoe development mabtherarituxan milestone injanuary roche announce result major global sale avastin bevacizumab world development phaseiii trial cll mabthera firstline lead antiangiogenesis treatment advanced mabtherarituxan treatment forchronic lymphocytic leukemia cll colorectal breast lung kidney cancer rise avastin herceptin study show combine treatment strongly advance bil tarceva xeloda mabthera current standard chemotherapy lion swiss franc key region contribute innew treatment achieve significantly well outcome chemo dynamic sale growth europerow indication therapy roche datum support drive primarily increase use medicine anapplication file july add new indication formetastatic colorectal breast cancer sale medicine eu marketing authorisation jan europe benefit rollout new uary eus committee medicinal product indication increase uptake nonsmall cell human use chmp recommend approval lung cancer renal cell carcinoma united mabthera indication indecember roche state solid doubledigit growth continue receive approval switzerland mabthera ini drive primarily increase use metastatic non tial firstline treatment certainpatient cll small cell lung metastatic breast cancer follow accelerate approval food anddrug october study mabtherarituxan patients administration fda japan whereavastin relapse refractory cll reach meet approve metastatic colorectal cancersale primary endpoint demonstrate patient treat continue grow strongly mabthera combine current standard chemotherapy show significant improvement avastin receive additional regulatory approval inprogressionfree survival time patient key market year january eu livewithout cancer get bad compare authority approve extension product receive chemotherapy metastatic colorectal cancer indication permit thesedata form basis regulatory filing thecombination avastin commonly inthe eu indication submit roche chemotherapy regimen line treatment january results cll andreach result virtually patient metastatic present american society hematology colorectal cancer access prove annual meeting december genentech biogen survival benefit avastin february genentech idec evaluate datum trial receive accelerated approval fda expect submit supplementary biologic license avastin combination paclitaxel chemotherapy application indication inthe firstline treatment patient thethird quarter negative metastatic breast cancer colorectal cancer cancer large intestine july roche file application expand rectum account million update current eu approval avastin meta new case newly diagnose static breast cancer final datum avado cancer worldwide year second study present meet common cause cancer death europe american society clinical oncology asco common worldwide june phase iii clinical study confirm wwwglobalreportscom pharmaceutical product generate sale billion swiss franc include sale billion franc topselle pharmaceutical product roche group sale change millions local product active substance indication chf currency mabtherarituxan rituximab nonhodgkin lymphoma chronic lymphocytic leukemia rheumatoid arthritis avastin bevacizumab colorectal cancer breast cancer nonsmall cell lung cancer kidney cancer herceptin trastuzumab herpositive breast cancer cellcept mycophenolate mofetil transplantation neorecormon epogin epoetin beta anemia pegasys peginterferon alfaa hepatitis b c tarceva erlotinib advanced nonsmall cell lung cancer advance pancreatic cancer xeloda capecitabine colorectal cancer breast cancer stomach cancer bonvivaboniva ibandronic acid osteoporosis lucentis ranibizumab wet agerelate macular degeneration tamiflu oseltamivir treatment prevention influenza b xolair omalizumab asthma valcyte cymevene valganciclovir ganciclovir cytomegalovirus infection xenical orlistat weight loss weight control pulmozyme dornase alfadnase cystic fibrosis nutropin somatropin growth hormone deficiency neutrogin lenograstim neutropenia associate chemotherapy rocephin ceftriaxone bacterial infection activase tnkase alteplase tenecteplase acute myocardial infarction heart attack madopar levodopa benserazide parkinson disease jointly market genentech novartis result early trial e show forexpansion product marketing approval avastin combine taxane chemotherapy signifi include nonsmall cell lung cancer cantly improve progressionfree survival set september genentech file suppleman important clinical datum benefit tary application fda approval avastin avastin breast lung cancer publish combination interferon alfa treat advanced year november roche announce renal cell carcinoma november genentech thata phase iii trial ribbon investigate avastin apply approval medicine mono firstline metastatic hernegative breast cancer therapy people previously treat relapse incombination commonly chemotherapy glioblastoma aggressive form brain meet primary endpoint increase time tumour base positive result phase ii woman breast cancer live disease clinical trial brain roche apply eu approval advance progressionfree survival compare avastin combine chemotherapy withchemotherapy avado e forthe indication december november ribbon study confirm benefit chugai file supplementary application japan ofavastin combine chemotherapy woman roche business report pharmaceutical metastatic breast cancer october roche combination hasbeen show reduce rate announce result phase iii study heart problemsobserve herceptin give beta lung investigate use avastin withanthracyclinecontaining regimen plustarceva secondline treatment patient potentiallyallowe patient benefit advanced nonsmall cell lung cancer herceptin combination meet primary endpoint overall survival clear evidence clinical final analysis phase iii trial gbg activity improvement secondary end present asco june confirm points progressionfree survival response rate herceptin help woman metastatic tarceva add avastin positive breast cancer live long cancerprogresse progressionfree survival breast cancer common cancer theresult show herceptin continue woman worldwide million woman tobe effective woman need additional newly diagnose die treatment theircancer progress disease year different previous herceptin treatment result gepar type breast cancer knowledge tumour quattro noah trial present medical characteristic important treatment deci conference april december respectively sion woman breast cancer show herceptin givenin combination tumour abnormally high level standard chemotherapy surgery know protein know herpositive tumour asneoadjuvant therapy helpsshrink locally particularly aggressive fastgrowing advanced tumour enable breastconserve likely relapse surgery improve longterm outcome final analysis noah datum show add herceptintrastuzumab early advanced herceptin chemotherapy eradicate tumour herpositive breast cancer post solid doubledigit innearly twice patient treatment sale growth total chemotherapy billion swiss franc growth especially strong japan continue uptake approval lung cancer common form cancer herceptin early breast cancer february solid worldwide lead cause cancer death singledigit growth record united states estimate million new case doubledigit gain wereachieve annually nonsmall cell lung cancer europerow main contribution growth common form account approximately region come cemaicountrie case key emerge market modest growth western europe reflect product high pancreatic cancer particularly aggressive market penetration region particularly disease extremely difficult treat kill early breast cancer set adoption herceptin high proportion patient year metastatic breast cancer remain stable january diagnosis cancer fifth fda approve use herceptin single lead cause cancer death develop agent adjuvant treatment herpositive world pancreatic cancer claim nearly breast cancer follow multimodality anthracycline live year base therapy genentech receive fda approval supplemental regimen adjuvant herpositive breast cancer combine herceptin central eastern europe middle east africa central asia docetaxel carboplatin chemotherapy indian subcontinent wwwglobalreportscom tarcevaerlotinib oral medicine target amarketing application new indication ingthe epidermal growth factor receptor prove osipharmaceutical collaboration genentech andsignificant survival symptom benefit roche expect submit supplemental broad range patient nonsmall cell lung newdrug application fda half cancer nsclc initial launch year base saturn datum ago tarceva approve country treat quarter million gastric stomach cancer account close patient addition combination chemo million new case death therapy tarceva treatment decade year make secondlarg cause show significant survival benefit treat cancer death worldwide vast majority patient pancreatic cancer sale tarceva case occur asia lung cancer continue increase strongly grow lead malignancy billion swiss franc overall main contribution come western europe xelodacapecitabine oral chemotherapy asiapacific region market uptake particularly medicine colorectal stomach breast cancer strong japan china market penetration record sustain doubledigit sale growth western europe continue expand strongly sale increase bil doubledigit sale growth maintain lion swiss franc growth japan particularly united states expand uptake region reflect strong solid increase achieve doctor grow experience confidence united states europerow product november uks national institute sales drive expand indication approve health clinical excellence nice issue notably stomach cancer finalguidance tarceva alternative doce advanced colorectal cancer continue taxel chemotherapy secondline treatment uptake breast cancer growth help ofnsclc open way reimbursement new clinical datum reimbursement approval bythenational health service ascombination regimen xeloda gain accept ance standard therapy indication new data phase ii fastact trial present xelodais generate strong doubledigit sale growth asco european society medical china follow approval september oncology meeting show firstline treatment foradvance stomach cancer february eu tarceva alternate chemotherapy fol authority approve xeloda treatment low tarceva maintenance therapy significantly metastatic colorectal cancer combination improve progressionfree survival asian patient anychemotherapy line treatment advanced nsclc compare chemotherapy withoutavastin approval provide new treat irrespective tumour type mutation status mentoption large number patient november roche announce phase iii metastatic disease february chugai file saturn study meet primary endpoint demon anapplication japan expand product strate firstline maintenance treatment approval allow combination oxaliplatin tarceva give immediately follow initial treatment chemotherapy avastin platinumbase chemotherapy significantly treatment ofmetastatic colorectal cancer extend progressionfree survival patient advance nsclc result transplantation cellcept continue expand timethat early treatment tarceva delay market share lungcancer progression roche discuss cellceptmycophenolate mofetil lead com datawithregulatory agency plan submit ponent immunosuppressant combination therapy roche business report pharmaceutical broad commitment fight cancer product clinical development phase ii iii cancer type market product include additional indication market product gastrointestinal tract avastin furtulon tarceva xeloda avastin herceptin xeloda breast avastin furtulon herceptin xeloda avastin pertuzumab trastuzumabdm xeloda r antiigfr lung avastin tarceva avastin apomab apoltrail tarceva r blood immune system mabtherarituxan vesanoid avastin mabtherarituxan r rd generation anticd dacetuzumab apomab apoltrail genitourinary system avastin furtulon roferona avastin pertuzumab r skin soft tissue r apomab r hedgehog pathway inhibitor brain avastin childhood cancer r xeloda avastin supportive care bondronat kytril neorecormon epogin neulastim neupogen neutrogin include colon rectum stomach pancrea liver include nonhodgkin lymphoma chronic lymphocytic leukemia acute promyelocytic leukemia include kidney prostate ovary cervix information development project major development activity p pharmaceutical pipeline inside cover toprevent rejection solid organ transplant roche group anemia franchise include record doubledigit increase sale erythropoietinstimulate agent esa roche advance billion swiss franc growth mirceramethoxy polyethylene glycolepoetin beta wasdriven primarily strong demand theus continuous erythropoietin receptor andjapan p review ofvalcyte activatorand establish shorteracte esa cymevene neorecormonand epogin epoetin beta fromroche chugai respectively anemia overall sale decline competitive medicine treat symptomatic anemia costsensitive market patient withchronic kidney disease addition anemia occur level red blood cell neorecormonis approve treat chemotherapy andor hemoglobin contain fall induce anemia cancer patient normal starve organ tissue oxygen itis see patient chronic kidney combine sale neorecormon epogin renal disease affect million decline billion swiss franc people worldwide addition anemia affect inanincreasingly competitive highly costsensitive cancer patient undergo chemo market characterise heavily discount contract therapy patient untreated anemia tender group purchase new guideline needblood transfusion potential longterm theuse esa cancer renal patient issue effect anemia include cardiovascular disease year european medicine agency inrenal patient patient cancer emea regulator contribute isassociate diminish quality life theoverall contraction global anemia market ineuroperow erosion neorecormon sale wwwglobalreportscom roche diagnostic highly sensitive cobas pcr test help personalise treatment pegasys people chronic hcv infection moderate despite entry key emerge market combine solid market pegasys maintain biosimilar version epoetin alfa late share growth united states pegasys clear leadership injapan epoginremain market leader account new prescription global pegylate interferon market decline sale medicine hepatitis c june eu authority approve andcontinue gain primarily sustained pricing pressure govern shorten course treatment pegasys plus market share world mentmandate price cut come effect copegus patient genotype hcv wide expect inapril january mirceraha infection low virus level sale tamiflu approve country worldwide launch rapid virological response approval personalise continue decline include major eu market physician therapy patient offer chance substantially reduce pandemic feedback early launch market positive curewith month treatment new stockpiling order salesare modest progressing prod approach possible roche diagnostic government uctsglobal rollout continue highly sensitive realtime cobas pcr diagnostic test corporation november roche receive eu approval virology pegasys maintain clear market theretreatment patient chronic hcv leadership expand market share infection respond previous treatment hepatitis b c hepatitis b c viruse interferon alfa pegylate nonpegylate hbv hcv commonly transmit orin combination ribavirin pegasy thefirst bloodtoblood contact cause acute pegylate interferon indicatedfor chronic liver disease potentially lead liver retreatment week allow therapy failure cirrhosis liver cancer worldwide bepersonalise optimise recommend million people think chronically retreatment period depend hcv genotype infect hbv highly infectious virus type previous treatment andthepatient responsible estimate million death virological response retreatment annually million people world infect hcv million influenza flu highly contagious debilitat new case occur year hepatitis c main ing viral illness occur mainly autumn reason liver transplantation recent study winter month temperate climate hcvrelate burden disease euro yearround tropical area particularly pean country estimate seven dangerous young child elderly million people population people chronic health problem year infect hcv million people fall ill flu europe japan estimate pegasyspeginterferon alfaa indicate people globally die year treatment chronic hepatitis b c disease complication pandemic treatment hepatitis b com global epidemic cause novel strain bination copegus ribavirin treatment influenza people immunity ofhepatitis c addition pegasys pegylate pandemic associate significant level interferon choice use clinical trial illness death occur year new generation direct antiviral agent world health organization medical p expect increase cure rate expert continue warn influenza andor shorten treatment duration pegasys pandemic imminent maintain clear leadership global pegylate interferon market continue gain market share forecast total sale antiinfluenza medicine worldwide global sale advance billion tamifluoseltamivir continue decline swiss franc drive strong growth japan fall million swiss franc roche business report pharmaceutical worldwide uptake tosubstantially reduce pandemic stockpiling order inflammation autoimmune disorder ofmabtherarituxan government corporation expect actemraroactemra approve rheumatoid rheumatoid sharp falloff pandemic sale billion arthritis japan switzerland eu arthritis isstrong swiss franc compare autoimmune disorder occur result itisnow themarket weigh significant increase seasonal sale mistaken immune response bodys leader outside rise million swiss franc main tissue cause unknown rheumatoid usfor treatment ra contribution seasonal sale come united arthritis multiple sclerosis lupus erythematosus respond adequately state flu season partic common autoimmune dis tnf inhibitor ularly severe policy help ensure order affect million people worldwide therapy actemra pandemic readiness roche continue work roactemra government worldwide appropriate tamiflu rheumatoid arthritis ra chronic progressive approve ra stockpile line recommendation base inflammatory disease joint surround injapan switzerland datum provide roche chugai authori ing tissue associate intense pain eu ties united states japan canada australia irreversible joint destruction systemic compli january increase shelflife cation b cell type immune cell know government stockpile tamiflu seven year play key role inflammation associate roche file datum support similar shelflife ra key cytokine protein extension country involve include tnf alfa interleukin il interleukin il il iden combine sale valcyte valgancyclovir tifie pivotal role inflammation cymeveneganciclovir standard care process million people worldwide thetreatment cytomegalovirus cmv retinitis thought affect ra patient hivaid prevention cmv disease atrisk transplant patient rise estimate salesof mabtherarituxan rituximab million swiss franc robust growth inthe inflammationautoimmune segment amount year drive mainly demand approximately million swiss franc ineuroperow strong gain record drive strong worldwide uptake product ingermany spain july fda grant treatment severe rheumatoid arthritis thefirst pediatric exclusivity valcyte united states selective b cell therapy approve inthis extend medicine patent protection indication mabtherarituxan rapidly establish sixmonth september prove choice ra patient inade quate response tumour necrosis factor tnf quarter follow extensive inhibitor therapy market leaderin toxicology study roche eu indication outside observational datum show swiss authority confirm presence superiority mabtherarituxan sequential ofachemical impurity batch hiv use tnf inhibitor product increasingly medicine viracept nelfinavir year positive longterm efficacy safety profile present risk patient authority deter convincing rheumatologist mine need follow patient patient mabtherarituxan follow inadequate inregistrie discovery impurity lead response tnf inhibitor theuse aglobal recall viracept june mabtherarituxan setting support viracept reintroduce eu switzer grow body evidence include new clinical trial landand market roche supply datum present medical conference product base datum genentech roche territory wwwglobalreportscom major new marketing application file major regulatory approval gain major regulatory filing product active substance indication andor dosage form country avastin bevacizumab metastatic breast cancer combination docetaxel eu switzerland metastatic colorectal cancer combination japan xeloda oxaliplatin firstline metastatic renal cell carcinoma usa combination interferon alfaa relapse glioblastoma multiforme usa eu nonsmall cell lung cancer japan rituxan rituximab rheumatoid arthritis patient inadequate response usa diseasemodifye antirheumatic drug mabthera rituximab firstline chronic lymphocytic leukemia eu switzerland relapse refractory chronic lymphocytic leukemia eu xeloda capecitabine metastatic colorectal cancer monotherapy combination japan avastin oxaliplatin major regulatory approval product active substance indication andor dosage form country actemra tocilizumab rheumatoid arthritis polyarticularcourse juvenile japan idiopathic arthritis systemic juvenile idiopathic arthritis roactemra tocilizumab rheumatoid arthritis switzerland eu avastin bevacizumab renal cell carcinoma switzerland secondline metastatic colorectal cancer eu switzerland combination oxaliplatin hernegative metastatic breast cancer firstline usa switzerland combination paclitaxel herceptin trastuzumab adjuvant herpositive breast cancer single agent usa follow multimodality anthracyclinebase therapy adjuvant herpositive breast cancer combined usa nonanthracycline regimen contain docetaxel carboplatin docetaxel follow regiman contain doxorubicin cyclophosphamide adjuvant herpositive breast cancer japan mabthera rituximab firstline chronic lymphocytic leukemia switzerland xeloda capecitabine metastatic colorectal cancer secondline eu switzerland combination treatment include supplemental indication update january january accelerate approval fda roche business report pharmaceutical group rd show sustain improve reduction disease letter roche marketing application activity focus activity repeat treatment course sus actemra fda request additional documan create clinically taine inhibition progression ofjoint damage tation follow discussion result differentiate medi ofthe fda evolve risk evaluation mitigation cine base small roche genentech biogen idec continue devel strategy rem requirement medication molecule therapeu tic protein opment programme evaluate additional ra setting december agency ask roche prepare generation biologic mabtherarituxan provide benefit rem plan actemra addition base addition roche patient major trial phase iii programme evolving requirement approval new biologic rd explore investigate medicine use ra patient fda ask roche nonclinical animal rna interference withless advanced disease meet primary end model datum include apromise new point january result serene original marketing application roche perform approach use study patient inadequate response pre request preclinical study expect sub target gene silence vious therapy diseasemodifye antirheumatic mit complete response actemra fda drug dmard show significantly quarter fda request morepatient treat mabtherarituxan plus additional clinical study prior approval methotrexate mtx achieve improvement disease sign symptom compare metabolic disorder bonvivaboniva maintain receive mtx december roche robust growth competitive market announce image radiographic study osteoporosis systemic skeletal disease assess ability mabtherarituxan inhibit characterise loss bone mass lead structural joint damage patient previously bone weakness susceptibility fracture treat mtx meet primary endpoint million people worldwide affect roche plan use sign symptom data postmenopausal woman inconjunction radiographic datum support man age acombine eu regulatory filing additional ra indication september base bonvivabonivaibandronic acid highly effective serene datum genentech file supplementary tolerate medicine woman post marketing application seek approval menopausal osteoporosis available forrituxan ra patient inadequate response monthly tablet threemonthly injection dmard therapy increasingly competitive market environment bonviva boniva record solid overall sale performance actemraroactemratocilizumab firstinclass sale increase billion swiss therapy base il inhibition represent novel franc marketshare gain support robust approach treatment patient moderate growth europerow united states despite severe ra follow approval april actemra entry generic version competitor product ra adult relate pediatric disorder europe new datum retrospective subsequent rollout chugai sale uptake observational study postmenopausal injapan encourage december woman vibe present major european theswiss authority approve roactemra rheumatology congress june provide additional treatment moderately severe severe active evidence effectiveness oncemonthly rheumatoid arthritis adult patient bonviva compare weekly bisphosphonate respond adequately treatment dmard inprevente vertebral nonvertebral hip frac ortnf inhibitor roche receive eumarkete ture november fda expand exist approval roactemra indication marketing approval oncemonthly boniva january september complete response include prevention postmenopausal osteoporosis wwwglobalreportscom roche uniquely position help realise promise personalise healthcare research development great value future meet grow global develop stakeholder expectation safe effective ment programme pharmaceutical division continue andmore costefficient treatment foravastin include clinical build value research development trial portfolio advance project area major development activity patient oncology metabolic inflammatoryautoimmune oncology global development programme different disease phase iii clinical testing pharma foravastincurrently include clinical tumour type ceutical pipeline foldout end trial patient different phaseiii study businessreport tumour type phase iii study disease avastin colon ovarian prostate asovarian prostate gastric stomach cancer stomach cancer month roche pharmaceutical schedule report year final areschedule decentralise management rd project result key clinical trial avastin early toreport bycreate disease biology area dbas colon cancer set nsabp c expect nexttwo year theoncology viral disease inflammation metabolic result trial disease andcentral nervous system dbas set set avant important milestone priority portfolio decision spe pass avastin programme cific disease helping streamline beth global phase iii trial avastin combine theresearch portfolio expect increase herceptin adjuvant herpositive breast number quality programme advanced cancer start patient recruitment clinical development phase iii avagast trial firstline advanced gastric cancer complete december bernie group rd activity focus create aphase ii trial assess avastin combination clinically differentiate medicine base small mol standard chemotherapy child adolescent ecule chemical compound therapeutic pro sarcoma commence july october tein mainly monoclonal antibodie peptide euauthoritie approve pediatric investigation include glycoengineere nextgeneration bio planfor avastin study include eventually logic addition roche rd explore small provide physician new datum dosing interfere ribonucleic acid molecule know safety improve clinical outcome specifically asrna interference rnai promising approach child base concept target gene silence thatit hoped eventually yield powerful new collaboration osi pharmaceutical therapeutic option genentech roche conduct extensive devel opment programme clinical study addition roche uniquely position help tarceva early stage lung cancer realise promise personalise healthcare andincombination treatment include approach seek tailor treatment specific avastin evaluate lifeextende benefit patient subpopulation base knowledge tarceva patient nsclc ongoing thebiological difference patient plan phase iii study tarceva development characteristic disease personalised programme include randomise phase iii trial healthcare p roche group combine atlas evaluate addition tarceva avastin pharmaceutical diagnostic expertise give maintenance therapy follow firstline treatment usaclear competitive advantage area roche avastin chemotherapy patient hasalready achieve notable success advanced nsclc initial result trial approach oncology virology expect expect half ourfocus personalise healthcare contribute roche business report pharmaceutical phase iii trial study currently evaluate herceptin progress range pertuzumab combination avastin pertuzumab patient oncology project early stage development herpositive breast herpositive breast cancer addition beth include soon phase iii cancer begin avastin cleopatra neosphere thelast stage clinical testing marketing progress pertuzumab herceptin application file trastuzumabdmtdm oncology study global phase iii study averel r isa novel antibodydrug conjugate link project early stage develop combination avastin firstline treatment trastuzumab active ingredient herceptin ment include ofadvanced breast cancer herceptin andthe cytotoxic agent dm target novel antibodydrug investigate herpositive advanced gastric cancer protein express tumour conjugate conjugate tdm phase iii toga study patient deliverschemotherapy cancer cell precise soon gastric cancer herpositive disease manner tdm show promise clinical enterthe phase efficacyand good tolerability phase ii clinical trial development interim result phase iii trial woman herpositive metastatic breast patient finnish breast cancer group pre cancer roche genentech decide sente san antonio breast cancer symposium tdm phase iii development secondline december suggest xeloda herpositive metastatic breast cancer trial approve advanced breast cancer programme schedule start reduce cancer recurrence extend survival halfof patient early breast cancer similar roche sponsor study xeloda early breast cancer ris monoclonal antibody target igfr ongoing roche plan seek regula receptor igf pathway important growth tory approval xeloda indication phase iii survival variety cancer r trial medicine early colon cancer tolerate currently phase ii development report datum phase iv sarcoma nonsmall cell lung cancer breast adjuvant study patient gastric cancer cancer expect rga fully humanise type ii glyco pertuzumabr currently study com engineer thirdgeneration anticd monoclonal bination herceptin standard chemotherapy antibody develop glycart roche herpositive breast cancer enter phase iii codevelope chugai genentech biogen development pertuzumab inhibit pair idec treatment cdpositive hemato receptors key mechanism logical malignancy include cll nhl tumour growth cleopatra phase iii study rtarget b cell protein cd evaluating addition pertuzumab herceptin mabtherarituxan engineer chemotherapy firstline treatment patient increase direct andindirect tumour cell death advanced disease commence quar enhance efficacy phase study r ter addition neosphere phase ii trial show good tolerability encourage investigate neoadjuvant presurgical treatment clinical activity inpatient treatment pertuzumab start half year data option previously receive mabthera phase ii trial present asco rituxan phase ii development nhl commenced show half patient advance indecember positive breast cancer disease progress previous treatment regimen include ris novel inhibitor braf kinase herceptin benefit combination herceptin codevelope plexxikon roche currently pertuzumab phasei testing r selectively target product wwwglobalreportscom roche currently compound target mechanism action development type diabetes themutant brafvegene abnormality discontinue negative result show drive certain cancer themutation atrialwith mabtherarituxan similar patient occur tumour cell find inmany thyroid population cancer malignant melanomas small proportion colorectal cancer adiagnostic test promise earlystage project inflamma isbeing develop collaboration roche tionautoimmune area proceed track molecular diagnostic select patientswho carry includingr currently phase ii clinical testing brafvemutation aretherefore likely emphysema rhumab antioxl respond treatment withr anovel biologic jointly develop roche genentech treatment asthma currently rtb human monoclonal antibody phase november actelion roche agree target placental growth factor plgf enter progress r selective sp receptor agonist roche portfolio june licensing agree phase ii clinical development autoimmune ment thrombogenic bioinvent malignancy disease solid tumour dependent new blood ve selformation process know angiogenesis metabolic cardiovascular disease andplgf important growth factor process people elevated level certain blood anticipate r combina fatsremain risk heart attack stroke despite tion antiangiogenic treatment treatment currently available medication avastin r currently test phase thisrisk reduce new treatment study patient solid tumour increase highdensity lipoprotein cholesterol hdlc call good cholesterol dalcetrapib inflammation autoimmune disease r jtt license japan tobacco second quarter roche genentech increase level hdlc block action decide discontinue development mabthera cholesteryl ester transfer protein cetp rituxanin systemic lupus erythematosus potentially reduce risk cardiovascular phase iiiii study fail reach primary endpoint diseaseand deathin highrisk patient phase iii phase iii development drug lupus nephritis morbidity mortality study dalcetrapib continue plan result clinical daloutcome start april patient trial lunar investigate benefit add recruitment proceeding phase ii datum mabtherarituxan cellcept expect present american congress cardiology half inmarch thatdalcetrapib tolerate andhas good general cardiovascular safety ocrelizumabr humanise anticd profile give combination monoclonal antibody develop roche statin additional datapresente atthe american genentech chugai treatment auto heart association meeting november show immune disease like mabtherarituxan ocrelizu thatdalcetrapib hasaunique chemical structure mab target b cell humanise antibody unlike certain cetp inhibitor itha potential immunogenic activateenzyme gene involve bloodpressure bettertolerate convenient administer regulation extensive phase iii programme involve patient rheumatoid arthritis diabetes recognise global epidemic ongoing recruitment phase iii trial lupus world health organization interna nephritis continue plan phase iii tional diabetes federation estimate trial ocrelizumab systemic lupus erythematosus million people worldwide diabete roche business report pharmaceutical accord type adult withintermune phase clinical development onset diabete account bothofthese oral agent investigate case incombination pegasys copegus addition roche start clinical trialwith com taspoglutider bim license bined rand r important step ipsen onceweekly human glucagonlike inevaluate therapeutic potential ofanalloral peptide glp hormone analogue interferonfree combination treatment hepa develop roche type diabete struc titis c ture molecule similar natural human hormone clinical trial date taspo central nervous system evidence evolve glutidewa generally tolerate significantly onthe role b cell multiple sclerosis disease improve glucose control weight loss process base promising phase ii datum week treatment roche initiate extensive mabtherarituxanin relapsingremitte multiple phase iii clinical development programme taspo sclerosis rrm roche partner glutide july late fda issue new conducting phase ii dosefinding study guidance clinical testing new treatment thenextgeneration anticd antibody ocrelizu fortype diabete roche review taspo mabinthis disease april phase iiiii study glutide programme comply recomman olympus ofmabtherarituxan primary pro dation gressive ms ppms lead genentech didnot meetit primary endpoint secondary roche currently compound target analysis suggest medicine maybenefit mechanism action development use certain patient subgroup genentech roche patient type diabete alegli areevaluating possibility development tazarr dual ppar agonist ofanticd therapy progressive ms demonstrate effect blood fat blood pressure blood glucose phase ii clinical testing near r inhibitor glycine transporter type completion roche expect decision glyt phase ii development treatment inthe half phase iii development schizophrenia preclinical clinical evidence ofthe compound phase ii development r suggest novel mechanism action adipeptidyl peptidase iv dppiv inhibitor improve negative symptom schizophrenia complete second half year areaof high unmet medical need adequately whiledemonstrate adequate glucose reduction address current treatment r nicotinic andexcellent tolerability compound alpha receptor agonist develop treat satisfy roche internal clinical differentiation criterion cognitive impairment schizophrenia alzheimer transition phase iii testing roche disease r expect provide significant decide outlicense improvement memory ability perform activity daily live compare current treat virology development r polymerase ment result phase ii trial investigat inhibitor investigate treatment ingthe benefit r cognitive impairment hepatitis c infection terminate year associate schizophrenia expect new unexpected safety finding towardsthe middle phase iib study aphase iib study roche pipeline direct antiviral alzheimer disease isschedule start agent hcv remain robust polymerase firstpart inhibitor r collaboration pharmasset andthe protease inhibitor r collaboration wwwglobalreportscom division currently operate major biotech manufacturing facility worldwide manufacturing infrastructure inmannheim nutley transfer biotech manufacturing use cellculture tech site addition cenexi galenical manufacturing nology produce bulk quantity genetically site fontenay sous bois france sell engineer active pharmaceutical ingredient inadditionto step strengthen monoclonal antibodie andfocus manufacture network roche therapeutic protein meet strict quality improve supply chain management system requirement manufacturing process ensure continuous worldwide supply innovative comprise cell growth fermentation purification medicine fill operation take place highly control condition facility subject rigorous regulatory inspection approval procedure roche group pharmaceutical division currently operate major biotech manufacturing facility worldwide include roche phamaceutical basel penzberg site genentechs plant south san francisco vacaville oceanside chugais utsunomiya facility roche new biotech production facility penzberg germany basel switzerland fully operational roche receive european medicine agency emea approval production trastuzumab active ingredient herceptin atthe penzberg facility european market year start construction work roche file approval production beva cizumabthe active ingredient avastin newbasel facility emea december group progress impor tant infrastructure project construction new tech nical research development building roche basel site commence october addition new sterile vial filling capacity instal roche kaiseraugst switzerland genentechs hillsboro oregon usa chugais utsunomiya japan site roche pharmaceutical continue optimise global manufacturing network year thedecision take close manufacturing nutley new jersey usa phase chemical manufacturing mannheim germany overthree year product currently manufactureddiagnostic diagnostic increasingly critical component medical care central roche strategy diagnostic division launch wide array new product clinical use research achieve market sale growth division knowhow support pharma ceutical rd roche example help search relevant biomarker accelerate development important drug case yield companion diagnostic enable target therapy wwwglobalreportscom diagnostic division brief sale million chf operating profit million chf number employee key figure change change millions chf chf local currency sale sale professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic na na operate profit operate free cash flow research development diagnostic executive committee december jrgen schwiezer ceo division roche diagnostic perolof attinger ventana integration manfre baier apply science roland diggelmann asiapacific dirk h ehler professional diagnostic christopher gleeson tissue diagnostic christian hebich finance service michael heuer emea europe middle east africa latin america alexander keller global platform support frank lennartz human resource daniel oday molecular diagnostic frank pitzer regulatory affair quality management clausjoerg ruetsch legal michael tillmann north america robert yates business development tenure end december january hany massarany associate member january roche business report diagnostic diagnostic division sale region roche diagnostic roche diagnostic division lead supplier division remain ofin vitrodiagnostic ivds product europemiddle world number tot body fluid tissue sample obtain infor eastafrica ivd company mation purpose prevent diagnose japan sale growth treat monitoring disease approximately asiapacific pace market medical decision guide result broad base extend test account latin america major region healthcare spending division leadership extend ivd spectrum cen north america divisional business tralise laboratory testing pointofcare diag area nostics molecular diagnostic diabete self italic growth rate management addition supply cuttingedge research tool life scientist pursue tomorrow medical advance post rise sale big contribution research development facility europe togrowth come professional diagnostic theunite state augment expand apply science tissue diagnostic unit network alliance partnership afford broad business immunoassay systems dna access key new technology roche use sequence product advance stain remain capability develop product high medical value major growth driver respectively roche dia patient physician platform help bete care post modest sale decline overall laboratory test site operate ahighly competitive market achieve strong efficiently productively growth new product roche molecular diagnostic growth continue drive sale automate realtime pcr virology blood result screen system roche tissue diagnostic ventana usbased leader automate tissue roche diagnostic division record sale stain acquire february post sale billion swiss franc increase local million swiss franc month currency swiss franc dollar december account previous yearonce fast division fullyear sale global ivd market growth estimate atbetween despite recent sector division continue invest heavily innova consolidation division maintain lead tionin research development rd market position costsincrease million swiss franc reflect investment sequence business divisional sale continue grow ahead new immunoassay molecular diagnostic test linewith market region doubledigit andplatform infectious disease cancer gain north america include positive impact newproduct diabetes care advanced ventana acquisition asiapacific latin stainingsystem laboratory information man america strong midsingledigit growth agement solution area continue emea region europe middle east africa japan divisional business area state growth rate local currency wwwglobalreportscom divisional rd spending reach nearly sale new technology new test major focus area investment berd priority rdspende latin america show strong doubledigit growth percentage ofsale increase gain region high singledigit range operating profit diagnostic division decrease december roche complete acquisition million swiss franc germanbase swisslab gmbh lead provider operating margin decrease percentage point oflaboratory information system lis relate half margin decline service acquisition complement roche exist resulted impact recent acquisition e lis portfolio significantly strengthen include amortisation acquire intangible asset position supplier solution laboratory investment develop acquire business automation datum management large laboratory rest mainly strong competition organisation intheus diabete care market portfolio mix effect serum work area sale serum work area solution clinical chemistry immunoassay information divisional operating result system professional diagnostic large business p finance report annual segment grow significantly fast market report information product launch increase compare estimate market launch plan table growth immunoassay sale instrument inside cover test year eighth consecutive year doubledigit sale growth roche immunoassay portfolio new placement business area cobas instrument help drive growth strong uptake antihcv assay diagnosis professional diagnostic new test help ofhepatitis c virus infection launch emea fuel eighth year doubledigit immunoassay region market half sale growth theelecsys cardiac assay not probnp roche professional diagnostic supply instrument troponin remain major growth driver clini system test software workflow automation cal chemistry sale advance amid continue service help clinical laboratory deliver accurate price erosion market diagnostic result quickly efficiently cost effectively leader grow market roche continue lead supplier clinical fordecentralise testing product support clinical chemistry immunoassay system market decisionmake close patient doctor united states global market share office intensive care unit primary approximately specialty care setting dedicate group developslaboratory information workflow demand cobas analyser series datamanagement solution connectivity mediumworkload laboratory component tomaximise testing efficiency test day remain strong introduce support interpretation increasingly complex modular roche testresult platform design integrate improve efficiency immunoassay clinical chemistry roche professional diagnostic sale rise testing differentsize laboratory new million swiss franc compare esti configuration launch complete mate market growth sale asiapacific theserie increase competitiveness roche business report diagnostic roche roll rollout small cobas series instru lowprice competitor commercial launch dozen serum ment small tomediumworkload laboratory cobas u standalone urinalysis system small work area test continue successful july launch mediumworkload laboratory successfully eu important clin cobas c clinical chemistry analyser market complete outside united states uptake ical use diag united states launch schedule system significantly exceed expectation nose kidney failure quarter detect hepatitis roughly half decentralise testing sale decentralise test roche professional diagnostic supply testing product rise help continue launch comprehensive menus clinical chemistry trend diagnostic testing point care test launch immunoassay test industry new fully follow automate serum work area assay launch pointofcare cardiac assay post strong double market late roll year digit growth fuel increase uptake europe market major new roche cardiac probnp assay diagnosis assess assay include elecsys antitsh receptor anti ment heart failure cobas h portable body assay diagnosis grave disease cardiac testing device launch cobas common autoimmune thyroid disease h provide highly reliable result elecsy anticcp antibody assay highly specific toten minute test menu include testto aid diagnosis rheumatoid arthritis major blood marker heart attack heart roche cystatin c clinical chemistry test early failure assess patient risk future cardio detection impaired kidney function fourth vascular event quarter roche professional diagnostic launch anticmv igg anticmv igm immunoassay overall sale ambulatory caremonitore solution diagnosis cytomegalovirus infection show solid doubledigit growth coagulation moni half assay roll europe tore instrument test strip continue post yearwere launch united states strong doubledigit sale increase drive mainly bythe coaguchek xs monitor professional use coagulation hematology urinalysis roche patient selftesting accutrend plus handheld laboratory coagulation portfolio generate solid device measure important indicator cardiac growth placement instru risk cholesterol glucose triglyceride tissue menttype significantly previous year hypoxia lactate contribute high singledigit sale sale grow particularly strongly europe latin growth ambulatory care segment america highvolume analyser coasys launch market november plusc fully automate lowvolume coagulation device professional selftesting environment analyser launch quarter available worldwide wereimportant growth driver uptake accuchek inform ii hematology sale show solid midsingledigit wireless system hospital glucose testing moni growth placement new instrument tore particularly intensive care setting strongly expect growth see strong device launch outside region cover roche exclusive distribution united states june approval launch agreement sysmex corporation japan growth expect march continue drive mainly sysmex xs line compact fully automate analy research development roche professional ser launch urinalysis roche maintain diagnostic single important launch number position despite strong pressure cobas series modular serum work wwwglobalreportscom roche pointofcare test heart failure heart attack provide reliable result minute area instrument highvolume laboratory diabetes care new product deliver cobas series thisaddition cobas instrument family strong growth instrument ofthe fast integrate system available diabetes result bodys inability regulate offer large lab speed efficiency offer awider choice configuration blood glucose lead complica unmatched flexibility highworkload solution currently market tion include heart kidney disease stroke roche itreplace exist roche system expect blindness worldwide diabete affect million aneven strong tosignificantly enhance roche competitiveness people lead cause premature death competitor inboth immunoassay clinical chemistry number people disease immunoassay launch inmost key market outside united expect reach million cure clinical chemistry segment state areplanne launch people diabete step manage number new expect disease low risk complication diagnostic system debut significant new system system enhance roche diabete care product design ment reach market include living diabete easy portfolio cover cobas p cobas p postanalytical sample entire diabete selfmanagement spectrum storage retrieval module launch glucose monitor insulin delivery monitor globally cobas b multiparameter blood system integrate lancet test strip gas analyser use critical care setting sche software store analyse datum uled launch year europe japan important roche diabetes care portfolio united states cobas elabperformance portal improve blood glucose control forbenchmarke serum work area result user addition offer great convenience roll quarter roche diabetes care remain global market roche continue expand immunoassay leader sale reach million swiss clinical chemistry menu number important franc decline singledigit sale new test schedule launch table increase emea region asiapacific major product launch schedule japan doubledigit increase latin america inside cover offset low sale follow strong second quarter sale fall fourth roche professional diagnostic pharma quarter result accelerate decline sale ceutical division work closely number old monitoring product strong competition ofareas support group strategic focus continue pricing pressure old product personalise healthcare include joint market phase portfolio account ing activity use elecsys bone marker forless roche diabetes care sale tomonitor osteoporosis patient receive bonvivaboniva include joint exploratory blood glucose monitor new generation biomarker programme innovative multiplex ofaccuchek blood glucose monitoring system technology develop roche programme deliver robust growth accuchek aviva roche support latestage drug development project diabetes care largestselle glucose monitor rheumatoid arthritis oncology additionally system post strong doubledigit sale increase synergy division utilise accuchek performa launch develop new highmedicalvalue diagnostic mostmarket half important disease area experience strong uptake global rollout con tinue december launch china isnowalmost complete roche business report diagnostic topselle global rollout accuchek compact plus control premarkete activity start accuchek aviva system complete november combine sale secure current customer base preparation deliver strong accuchek compact plus test strip grow launch new system growth itwill adoubledigit rate country device joined waslaunche late research development research devel fournew meter opment spending go support new target different market segment come month roche diabete care product launch plan develop asroche continue launch important new diabete monitor future technology platform nearterm investment torevitalise glucose product accuchek aviva nano accuchek focus particularly new accuchek mobile monitoring portfolio performa nano blood glucose meter available integrate blood glucose monitoring system european union market start update accuchek aviva accuchek performa inthe quarter offer func platform slate launch quarter tionality accuchek aviva accuchek roche diabetes care step investment performa system sleeker discreet design incommercially develop proprietary continuous nano meter aim especially young high glucose monitor technology longterm frequency tester new accuchek active project aim produce small easytouse target particularly emerge market continuous monitoring system suitable broad begin roll quarter spectrum customer roche continue investi gate value blood glucose monitor dia fourth new offering accuchek mobile expec betes management particularly type diabete ted strengthen roche diabetes care lead inclinical trial activity aim integrate glucose market segment integrate blood glucose moni monitor datum management insulin delivery tore system accuchek mobile offer complete ongoing day result system integration testing lance single device closely mimic way healthy pancrea regulate feature unique stripfree technology blood glucose level employ continuous tape test instead singleuse test strip molecular diagnostic year major assay launch quarter roche diabetes care roche molecular diagnostic develop commer willstart update glucose monitoring system cialis innovative diagnostic blood screen new testing method avoid risk maltose platform test base roche proprietary interference offer additional safety certain realtime polymerase chain reaction pcr techno dialysis patient monitor blood glucose logy product directly detect genetic material dna rna infect patho insulin delivery innovative accuchek combo gen hiv hepatitis viruse iden system schedule launch european union tify quantify infection early specifi quarter strong addition cally test base bodys immune response roche diabete care insulin delivery portfolio infection result patient treat accuchek combo combine accuchek spirit monitor great precision risk insulin pump highend glucose meter infect blood organ donation remotecontrol bolus calculator capability reduce addition test hiv hepatitis user deliver bolus insulin dose anytime roche molecular diagnostic portfolio include test touch pump infectious disease test identify accuchek combo offer small dose increment patient likely respond particular cancer optimise insulin dosing finetune glucose therapy wwwglobalreportscom cobas taqscreen mpx test comprehensive blood screening test kind roche molecular diagnostic remain industry european union new hiv test unique october leader share fastgrowing dualtarget design enable simultaneous detection roche suite increasingly competitive market sale total oftwo separate region hiv genome automate viral load test hiv hepatitis c million swiss franc increase provide great test reliability viral mutation hepatitis b ayear early sale show doubledigit present addition new test available health growth asiapacific latin america broad dynamic range ability quantify low professional singledigit growth north america emea high viral load earliergeneration uptake region test critical advantage high hepatitis test low level virus indicate need launch inthe second half virology virology testing roche molecular diag aggressive therapy regulatory filing nostic large segment sale remain new capctm hiv hbv test currently strong second significant contributor growth virology sale grow review japan generation version lead demand automate realtime pcr ofthe hiv hepa platform test hiv common blood screen sale blood screen prod titis b tests formof virus cause aids human uct molecular diagnostic secondlarg segment approve launch eu hepatitis c hepatitis b virus hcv hbv roche sale advanced year additional indecember molecular diagnostic virology portfolio include blood centre europe asia pacific latin systems automate sample preparation america begin routine screen multiplex realtime pcr analysis combine cobas cobas taqscreen mpx test fully automate ampliprepcobas taqman capctm system cobas platform decline see theonly platform available worldwide offer segment early year result price customer fully automate realtime pcr testing pressure ongoing effect account lose forclinical diagnostic use levelling growth expect october food drug administration fda approve capctm hcv test quan december fda approve cobas taqscreen tifie hepatitis c virus viral load mpx test use cobas system test apatient blood month early september comprehensive nucleic acid test kind cobas taqman hbv test hepatitis b available today offer unique ability detect viral load test receive fda approval hiv group hiv hcv hbv fully automate capctm hiv test single automate assay originally launch europe approve complete initial automation cobas taqscreen mpx test roche major virology product market widely adopt demonstrate excellent physician use test establish baseline level performance blood centre worldwide japan infection prior treatment monitor patient test september fully inte response therapy tracking change grate cobas system screen virus level treatment numerous labora japanese blood supply tory sign contract hcv hbv test include nation large sexually transmit disease oncology reference laboratory convert roche cobas taqman ct test v improve detection hbv test week approve ofchlamydia trachomatisct launch clini cal use europe asiapacific latin america secondgeneration version capctm hiv second half transition new hbv test receive ce mark certification test run automate cobas taqman december allow sell clinical use realtime pcr analyser complete roche business report diagnostic majority market available continue trial evaluate test cobas taqman ct test v simultaneously detect performance detect highgrade cervical disease target chlamydiacryptic plasmid woman undergo routine cervical cancer screen genome target dna result able detect ing infection cause known strain ct ifthere unexpected change bacterial development test screen methicillinresist genome case recently discover ant staphylococcus aureus mrsa form staph swedish variant chlamydial infection infection difficult treat commonly report sexually transmit deadly track launch reduce disease leave untreated lead spread mrsa major public health concern complication pelvic inflammatory disease worldwide infertility woman business area continue work closely amplicor linear array test detect roche pharmaceutical division com andidentifye low highrisk strain human panion test new therapeutic microarray papillomavirus hpv show doubledigit growth base test identify mutation p tumour persistent infection certain highrisk strain suppressor gene example explore hpv progress precancerous condition companion diagnostic new class anticancer cervical cancer amplicor hpv test approve drug call nutlin currently early development launch japan september roche work progress realtime pcr test screen common cancercausing mutation june roche sign exclusive deal dxs braf kinase gene braf test aid ltduk distribution therascreen kra development target cancer therapy mutation test roche begin distribute roche plexxikon inc working december therascreen egfr mutation selectively inhibit mutate form braf gene test test realtime pcr assay cemark certification conjunction apply science sequence quantitative pcr clinically relevant information kra egfr muta arrays drive strong growth genomic tion testing aid doctor determine patient life science encompass discipline range suitability certain cancer therapy biology biotechnology medical research major disease area like cancer virology roche research development roche molecular diag apply science supply broad grow array nostic pursue new test automation platform instrument highly specific reagent test improve diagnosis treatment ofdisease kit use diverse research market prod focus infectious disease oncology uct portfolio capability especially strong ingenomic proteomic sciences development cobas system new plat transform understand treatment form combine fully automate dna extraction ofdisease realtime pcr amplification detection track european launch plan ini roche apply science record sale tially offer assays hpv chlamydia million swiss franc increase trachomatis neisseria gonorrhoeae year time estimate market growth rate sale dna sequence enrolment roche clinical trial support regi products lead ultrafast genome stration hpv test way sequencer flx gs flx nearly double despite wwwglobalreportscom xcelligence cell analyser reduce need animal testing research increase pressure competitor roche apply cell analysis second half roche new product science market leader placement ofnext apply science successfully launch single launch worldwide generation sequence system product real multiplate version xcelligence cell analyser roche lead edge genome time quantitative pcr qpcr analysis particularly system codevelope acea biosciences inc sequencer flx thelightcycler instrument reagent deliv analyser use technology eliminate system offer laborato ere robust doubledigit growth strong sale need labour costintensive step like cell rie great efficiency increase north america china total instru labelling cell fixation measure change well ment placement roughly double microarray incell morphology cell proliferation cell death result low cost system significant contribution tofullyear inreal time importantly significantly sale sequential quarterly sale growth reduce use animal testing pharmaceutical product steady strong roche research toxicology area initial acquire nimblegen august placement occur region biochemical industrial reagent account research development effort roche major roche apply sciences revenue apply sciences research development facility show moderate growth overall market impact penzberg germany branford madison flat government funding life science research remain focused enhance efficiency expand range use lightcycler genomics portfolio late september roche genome sequencer nimblegen microarray tech apply science launch gs flx titanium series nologie result example nextgeneration sequence product include launch new generation genome discovery new reagent software compare standard array nimblegen hd combine speed gs flx sequence titanium increase throughput efficiency multiplex platform ability factor roche nimblegens seqcap deliver highresolution highquality datum sequence capture array help laboratory ongoing priority integrate increase totake advantage sequence capacity throughput lightcycler magna pure plat introduce initial market march form support roche group strategic focus available worldwide highdensity array personalise healthcare roche apply science produce target sequencingready sample pharmaceutical division pursue proj fast costeffectively conventional ect aim discover validate biomarker method sample preparation ease major facilitate drug development poten bottleneck genomic research tial diagnostic application particularly area oncology inflammatory disease addition major launch include magna pure potential use microarray genome sequenc redesign improve instrument automate ing investigate pharma qpcr sample preparation new ceutical division major research area interest family preplate readytouse qpcr assay call similar joint evaluation xcelligence realtime ready realtime assay analyser way lightcycler system competitive expect important sale driver light tissue diagnostic strong yearonyear growth cycler series strengthen launch launch major new system ofthe lightcycler ii half ventana medical system know roche thenew lightcycl instrument feature enhance tissue diagnostic world lead tissue analysis software great efficiency range base cancer diagnostic company roche tissue ofapplication diagnostic develop manufacture medical roche business report diagnostic roche tissue diagnostic instrument reagent system benchmark ultra new system perform diagnostic strength provide leadingedge automation technology use immunohistochemistry situ hybridisation testing ene core diagnosis prognosis cancer infec simultaneously single continuous random advanced stain tious disease addition company offer premier access platform launch united states business workflow solution design improve laboratory canada august europe november launch bench testing efficiency provide automate safeguard benchmark ultra individual staining mark ultra system help laborato enhance quality patient healthcare worldwide chamber access rie work effi discovery research aids pharmaceutical timewithout interrupting workflow result ciently shorten andbiotech company accelerate identification testturnaround time reduce significantly time diagnosis potential biomarker new drug target stat sample require rush testing add time expedite patient diagnosis roche tissue diagnostic demonstrate strong market response benchmark ultra yearof solid revenue product development positive significant number place formance acquire february commer ment substantial sale acceleration cial operation integrate roche expect effort way expand business intonew markets europe latin america asia roche tissue diagnostic expand pacific business area remain headquarter immunohistochemistry menu total new inthe united states continue tooperate confirm antibodie cancer include ventana medical systems inc innorthamerica thyroid lung prostate breast cancer lymphoma roche consolidated fullyear result include roche tissue diagnostic sale million primary stain placement symphony swiss franc represent sale date instrument hematoxylin eosin stain acceler acquisition february december ate second half follow upgrade additional sale contribute percentage point enhance system reliability stain tothe diagnostic division localcurrency sale interpretation symphony commercial performance growth standalone basis roche tissue diag highvolume primary stain market expec nostic sale entire year reach million ted improve launch europe dollar increase local currency australia plan second dollar significantly quarter year overall sale primary fast estimate market growth rate staininginstrument reagent sale increase abovemarket rate north forthe year america emea asiapacific help new product advance primary stain workflow management uptake vantage workflow management workflow solution launch united states april strong expect advanced stain advanced tissue stain order forecast vantage immunohistochemistry situ hybridisation complete workflow information management system remain business area big growth driver anatomical pathology laboratory provide deliver robust reagent sale strong tracking capability streamline integrate lab increase instrument sale sale fully auto work information flow great productivity mate benchmark xt benchmark lt instruments patient safety product roll immunohistochemistry reagent increase europe australia start quarter high doubledigit growth rate wwwglobalreportscom research development roche tissue diag nostics multiple platform technology stage development continue advance anatomical pathology increase test efficiency enhance medical value roche pharmaceutical division business area continue develop exploratory test view capture longterm companion diag nostic opportunity roche therapy notable project include development dual colour immunohistochemistry situ hybridisation assay test trend personalise healthcare evaluate analyte diagnostic kit quantum dot qdot assay expand multiplexe oncology work isunder way automate qdot assay detect protein level human tissue sample mono clonal antibody collaboration way enhance test expect available outside united states second quarter corporate governance roche commitment stakeholder reflect operate business focus value creation management culture conform modern standard corporate governance group policy communicating transparently remuneration report roche success depend ability dedication people recognition form basis remuneration policy system wwwglobalreportscom corporate governance roche complie relevant corporate gover effective date reason role nance requirement particular applic responsibilitie independent lead director ablelaw swiss stock exchange swiss position hold bruno gehrig incorporate exchange directive include commentary role chairman board thereto swiss code good practice ofthe independent lead director remit corporate governance promulgate swiss reassign vicechairmen bruno gehrig business federation economiesuisse companys andr hoffmann internal governance framework particularly article incorporation bylaw embody organise meeting immediately follow theprinciple need ensure company agm board director approve business manage supervise manner committee structure committee membership consistent good corporate governance includ show ingthe necessary check balance agm march board print annual report contain select link director nominate john bell andr hoffmann tothe roche website wwwrochecom readers franz b humer reelection board provide snapshot com pany reporting date direct source consult time corporate executive todate information corporate governance committee roche annual report cover single financial year end december website con tain information permanent nature severin schwan succeed franz b humer ceo late roche news amendment com ofthe roche group agm march panys article incorporation bylaw change curriculum vitae member jrgen schwiezer appoint corporate board director corporate executive com executive committee ceo division roche diag mittee publish timely fashion website nostic effective january access look information gottlieb keller appoint position ofroche general counsel effective march ashead corporate service continue serve board director corporate executive committee role secretary board director expand thannual general meeting agm toinclude additional task responsibility rocheholding ltd march shareholders ofthechairman board approve reduction board director term office year reelect agm gottlieb keller step bruno gehrig lodewijk jr de vink walter frey head corporate human resource silvia ayyoubi andandrea oeri member board appoint corporate executive com director mittee head corporate human resource effec tive march senior human agm march franz b humer resource executive role group step ceo roche group focus role chairman board director wwwrochecomcorporategovernance roche business report corporate governance board director december leave dr franz b humer prof bruno gehrig andr hoffmann prof pius baschera prof sir john irving bell peter brabeckletmathe lodewijk jr de vink dr andreas oeri dr deanne julius walter frey prof beatrice weder di mauro prof horst teltschik dr wolfgang ruttenstorfer wwwglobalreportscom board director year birth term end elect board director dr franz b humer e chairman profbruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e dr wolfgang ruttenstorfer b e prof horst teltschik b e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january roche business report corporate governance corporate executive committee year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head ofthe corporate executive committee william burns ceo division roche pharmaceutical dr jrgen schwiezer ceo division roche diagnostic prof jonathan kc knowles head group research dr gottlieb keller general counsel head corporate service silvia ayyoubi head human resource enlarge corporate executive burkhard g piper head business area roche diabete care committee pascal soriot head commercial operation pharmaceutical division rolf schlpfer head corporate communication osamu nagayama president ceo chugai secretary corporate executive committee ren kissle statutory auditor kpmg klynveld peat marwick goerdeler sa roche holding ltd principal auditor john morris group compliance officer dr urs jaisli wwwglobalreportscom corporate executive committee december leave dr severin schwan william burns dr jrgen schwiezer dr erich hunziker silvia ayyoubi prof jonathan knowle burkhard g piper pascal soriot dr gottlieb keller osamu nagayama rolf schlpfer ren kissle roche business report corporate governance rolf schlpfer head corporate communication consolidate financial statement relate resign position end effec party note financial tive january perolof attinger appoint statement roche holding ltd board head corporate communication member andexecutive remuneration enlarge corporate executive committee report relationship exist theshareholder ing severin schwan ceo roche group pool voting right succeed rolf schlpfer crossshareholding capital structure information relate information roche capital structure pro vide finance report note financial corporate governance statement roche holding ltd additional detail contain group structure shareholder article incorporation roche holding ltd roche operate business organise change equity detailed finance division pharmaceutical diagnostic report note financial statement roche pharmaceutical division comprise holding ltd business segment roche pharmaceutical company share capital genentech chugai swiss franc divide fully pay diagnostic division consist follow bearer share nominal value swiss business area apply science diabete franceach restriction care molecular diagnostic professional exercise voting right share diagnostic business activity carry upondeposit share vote group subsidiary associate compa restriction ny significant subsidiary associate com authorise conditional capital panie list finance report note addition nonvoting equity securi tothe roche group consolidate financial state tie nes issue bearer form ment subsidiary associate page donot form share capital confer voting right ne confer right major shareholder list finance asone share participate available earning report note roche group con andin liquidation proceed follow repayment solidate financial statement equity attributable share capital roche ne right roche shareholder relate party pertainingthereto include provision protect page note financial ing interest ne holder describe statement roche holding ltd significant article incorporation roche holding shareholders ltd andr hoffmann vicechairman board information debt instrument ofdirector andrea oeri chairman issue outstanding bond provide board corporate governance sustainability inthefinance report note roche committee serve respective capacity groupconsolidate financial statement debt board committee representative ofthe shareholder group pool vote additional information employee stock option right receive remuneration set forth provide finance report note theremuneration report financereport note roche group wwwrochecomarticleofincorporation wwwglobalreportscom roche group consolidate financial statement board director roche holding ltd employee stock option equity com organise ensure group busi pensation benefit ness conduct responsibly focus roche issue option apart employee longterm value creation end stock option stocksettle stock appreciation rocheboard delegate certain responsibility right ssar option issue connection committee composition debt instrument chairperson january describe option award employee committee authority debt instrument issue responsibility define detail bylaw effect roche share capital board director committee presidium board director corporate executive chair independent director committee accord bylaw board direc information member board torsat request member board director include year meeting chairman present elect year term end convene roche board meet year member corporate executive assess chairman performance meeting committee list page curricula attend chairman chair vitae information include information vicechairman board membership available board director establish system internet ofcontrol continuously monitor annual general meeting elect member audit committee corporate governance board director stagger election sustainability committee consist inwhich nominee vote separately follow element article incorporation roche report financial operating risk risk hold ltdand minute thannual management system general meeting roche holding ltd hold system internal control financial report march ing finance march director serve report executive capacity roche majority internal audits seat board director hold inde compliance officer pendent director safety health environmental protection franz b humer member department board director member roches corporate sustainability committee corporate executive committee serve scientific ethic advisory group seag executive capacity group subsidiary issue relate genetic genetic financial year precede current engineering establish reporting period internal organisation board director division authority responsibility wwwrochecomboardofdirector board management remit wwwrochecomexecutivecommittee ofthe board committees information wwwrochecomarticleofincorporation control mechanism available board wwwrochecomannualgeneralmeeting wwwrochecomarticleofincorporation dealing corporate management govern wwwrochecomcommittee bylaw wwwrochecomarticleofincorporation roche business report corporate governance year blackout period impose therisk management system subject senior employee prohibit continuous review finding present trade company stock follow blackout audit committee board period effect internalauditregularly brief audit com january february mitteewith reference ongoing audit report april april members internal audit attend audit july july committeemeeting asdo external auditor october october forinformation external auditor blackout period change chair man board director circumstance management contract fall warrant scope subsection board director meet meet directive information relate corporate ing hour length governance afullday meeting threeday official trip include board director remuneration shareholding loan meet board committee meet follow detail remuneration shareholding loan set forth separate remunera presidium board directorsnomination tion report page finance committee meeting approx hour report note roche group consolidate financial statement equity attribut audit committee meeting approx able roche shareholder related party hour page list note corporate governance sustainability financial statement roche committee meeting approx hour holding ltd board executive remunera tionand board executive shareholdings remuneration committee meeting page approx hour chairman secretary board participatory right shareholder director present board meeting participatory right shareholder define board discuss roche article incorporationas roche formance remuneration member share issue bearer restric ofthe corporate executive committee invite tion admission annual general meeting attend report person exception share deposit agenda item concern situation specify period date warrant member enlarge corporate meeting admittance card issue executive committee invite attend inthe shareholder provide board committee invite chairman article incorporation shareholder board corporate executive committee member deliver report committee meeting remuneration committee member permit elect commission independent expert contribute attend remuneration committee meeting report service consultant atwhich matter concerning deliberate decide additional information provide finance report figure indicate actual length meeting noteto roche group consolidated financial statement include director extensive premeete preparation risk management postmeete followup activity wwwrochecomarticleofincorporation wwwglobalreportscom elect represent shareholder kpmg receive follow remuneration atan annual general meeting article incor service statutory auditor roche hold poration contain restriction exercise ing ltd roche company vote right quorum requirement stipulate conformity swiss code obligation millions chf article incorporation auditing service shareholder represent share nominal auditrelated service value million swiss franc tax consultancy service requestthe placement item agenda total ofan annual general meeting doneno later day date statutory auditor elect year themeete annual general meeting change control defensive measure ernst young ltd receive follow remuner article incorporation contain provision ation service auditor genen mandatory bid rule swiss law apply tech chugai changeofcontrol clause component remuneration base roche ne terminate event acquisition millions chf vest period restriction preexist genentech chugai award remove option audits exercise immediately consult service provide genentech relationship statutory auditor chugai annual general meeting roche hold total ltd march shareholder vote appoint kpmg klynveld peat marwick goerdeler information policy sa kpmg statutory auditor information provide article incorpo long auditor principal auditor rationcorporate notice publish serve capacity provide swiss official gazette commerceand statutory auditor participate audit daily newspaper designate board committee meeting prepare write oral director basler zeitung finanz und wirtschaft report result audits audit lagefi le temps neue zrcher zeitung committee oversee assess auditor roche report halfyear fullyear result make recommendation board forinforma inbusiness report publish print online tion responsibility audit committee format medium event addition detailed article bylaw thestatutory thirdquarter sale figure publish auditor participate meeting year april october current audit committee list publication date available english report statutory auditor con andgerman internet solidate financial statement financialstatement find page wwwrochecomarticleofincorporation respectively year finance wwwrochecomarticleofincorporation report wwwrochecommedia roche business report corporate governance relevant information document includ ingall medium release investor updatesand presentation analyst investor conference available internet publication order email fax telephone baselwebmasterrochecom tel fax contact address investor relation f hoffmannla roche ltd investor relation corporate finance basel switzerland tel fax additional information include detail specificcontact person available internet group compliance officer group compliance officer commit ensure roche corporate principle consistently comply roche group serve contact person shareholder employee customer supplier andthe general public issue relate implementation compliance principle employee party aware ofviolation roche corporate principle bring attention theirmanagersorsupervisor report group compliance officer ur jaisli direct phone number email ursjaislirochecom disclosure treat confidentially employee disclosure penalise company person notimmune prosecution forlegal violation thegroup compliance officer report regularly tothe corporate governance andsustainability committee nonapplicabilitynegative disclosure expressly note information contain mention nonapplicable orit omission construe negative declaration provide swiss exchange corporate governance directive wwwrochecominvestor thecommentary thereto wwwrochecomcontacts wwwglobalreportscom remuneration report roche success depend ability dedi base pay cation people recognition form base pay level determine accord market basis remuneration policy system data specific position individual employee remuneration report inform shareholder ability experience performance time pay andintereste member general public increase link individual performance remuneration pay director senior account prevail market condition executive finance report note affordability company situation tothe roche group consolidate financial state ment relate party note bonus financial statement roche holding ltd bonus award recognition individual con board executive remuneration board tribution value creation normal job andexecutive shareholding page expectation mean incentive thisremuneration report separately sub create strengthen new business opportunity mittedfor approval annual general strive outstanding result bonus amount link meeting group divisional business performance achievement individual functional performance remuneration policy objective time remuneration roche revise global remuneration policy committee board director define framework employee policy aim corporate executive committee member bonuse motivate retain current employee attract january base result achieve prior talented new one help roche employee year bonus show perform consistently high level remunera compensation pay tion policy design foster value creation inforce culture performance innovation stocksettle stock appreciation right ssar apply nonmanagerial employee stocksettle stock appreciation right intro manager key principle underpin policy duce january establish uniform system remuneration roche ssar focus value creation entitle holder benefit financially increase pay performance value roche nonvoting equity security enable employee share company grant date exercise date detailed success information available fairness transparency remuneration decision performance share plan remuneration target market median level member corporate executive committee balanced mix long shortterm remunera member senior management currently tion component individual worldwide participate marketcompetitiveness performance share plan psp psp estab lishe period year base pay bonus award stocksettle stock base year comparison total share appreciation right ssar performance holder return tsr compete company share plan support principle remunera tion component link company financial peer set abbott laboratories amgen astella performance commercial success align astrazeneca bayer beckton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline interest roche employee johnson johnson merck co novartis pfizer sanofiaventis shareholder scheringplough takeda wyeth roche business report remuneration report overlapping performance follow page provide detailed information cycle psp psp remuneration pay member board psp psp close director member corporate ondecember executive committee figure previous year detail psp calculation additional information set forth remuneration remuneration member corporate executive committee remuneration member board cperformance share plan psp director member board directorsreceive remuneration show remuneration board director table remuneration member board corporate executive committee director board activity year remuneration committee entirely comprise independent external member exception chairman ofthe board director set remuneration vicechairman member board director member board director corporate receive remuneration executive committee cash payment bonuse thetotal remuneration pay member option stocksettle stock appreciation right theboard director show f high total policy decision pension benefit term remuneration member board director ofthe performance share plan determine annually total remuneration board director board director act recomman page dation remuneration committee remu neration committee continuously track salary trend nonexecutive member board director market report board ofdirector award share nonvoting equity formation committee remit andit procedure security stocksettle stock appreciation right make remuneration decision befound ssarsor stock option bylaw roche board director horst teltschik receive honoraria include follow detailed review include market com expense amount euro swiss parison world major pharmaceutical com franc serve board roche panie remuneration committee conclude subsidiary germany roche current remuneration policy continue tobe appropriate suitable achieve additional remuneration pay intend objective member board director addition base salary allocation stock remuneration member corporate settle stock appreciation right determination executive committee general provision bonus allocation nonvoting equity assign authority decision corporate execu security psp link achieve tive committee remuneration remuneration ment sale profit individual goal toroche current future tsr performance relative define peer set company wwwrochecomarticleofincorporation seepage type compensation list member position committee membership chairmanship receive member corporate executive stock optionsstocksettle stock appreciation right committee set report ssar wwwglobalreportscom remuneration member board director additional compensation remuneration member remuneration committee memberschair board director chf chf additional special compensation fb humer remuneration chairman board directors ceo march b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik compensation serve board roche subsidiary b weder di mauro exception members presidium vicechairmen board member receive chf year committee serve chf year committee chair chairman board receive chf f high total remuneration member board directorstotal remuneration board director remuneration serve independent lead director march vicechairman board remuneration serve vicechairman board remuneration member corporate executive committee cash payment chf annual salary annual salary annual salary bonus bonus bonus schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee roche business report remuneration report b stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee stock optionsstocksettle stock appreciation right ssar blackschole value describe stock optionsstocksettle stock appreciation right ssar value accord annual report business report committee board director outline provision plan number non remuneration report vote equity security nes reserve participant cycle number securi year member corporate tie actually award depend executive committeereceive salary bonus extent investment roche security share stocksettle stock appreciation right non ne outperform average return voting equity security show table investment security issue peer set com parator companiescomparison base security market price dividend yield ie member corporate executive committee total shareholder return tsr reduce effect additionally receive annual expense allowance shortterm market fluctuation security price swiss franc member ofthe average month october decem corporate executive committee receive expense ber prior start performance cycle allowance total swiss franc month october december end cycle roche security perform c performance share plan psp orbetter peer set member corporate executive committee addition roche tsr increase member senior management currently acycle board director elect increase individual worldwide participate maximum nes award twofold performance share plan psp inthe event investment roche security underperform average return deliver psp move overlap threeyear peer company few ne award performance cycle new cycle beginning year cycle progress ne reserve plan mem psp psp psp ber corporate executive committee show psp end december list member position footnote wwwglobalreportscom table board director decide swiss franc tsr roche security actual level ne cash equivalent award nesand share rank compare cycle peer set company operate industry close financial year respec tively aim psp provide incentive chart show roche market participant achieve steady value growth capitalisation decline begin consequently originally target psp threeyear cycle end ne award psp participant december base result achieve performance cycle current value entire period member corporate ne reserve psp participant respect executive committee receive originally performance cycle target ne permit term reduce addition ssar programme plan table detail create value participant year result corporate executive committee end psp cycle base members compensation turn athreemonth move average constant exchange lower report past year rate distribute dividend total billion absolute decline price roche swiss franc billion swiss franc security period important billion swiss franc billion toremember psp performance share plan psp total estimate total estimate value value value psp number ne psp award psp awards award award psp target number target number ne psp ne psp total number year period value chf value chf value chf schwan sayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee total estimate value psp originally target ne award spread relevant period time ie year value calculate yearend price december chf nonvoting equity security ne psp estimate value calculate yearend price december chf non vote equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time ie year board ofdirector vote actual allocation ne originally target december december respectively accord tsr achieve detailed calculation annual report business report roche business report remuneration report roche performance roche tsr average tsr peer group company jan dec jan dec roches average market capitalisation billion chf q q roche security price average month octdec octdec nonvoting equity security ne share price translate constant chf exchange rate include roche base daily month average tsr stock price appreciation plus dividend performance cycle end psp cycle committee show table indirect benefit ofthe equity incentive programme remain inplace andprovide powerful incentive participant contribute improve roche future performance roche connect voluntary stock purchase planoffere employee opportunity buy dindirect benefit rochenonvote equity security ne employer contribution social anamount equal annual salary securityscheme pension plan groupwide ata discountnespurchase plan employee stock purchase plan roche connect subjectto hold period inrespect member corporate executive yearsinswitzerland indirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service chf chf chf chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit wwwglobalreportscom e remuneration emolument loan onmarch receive additional pension total swiss ssar ne new psp cycle francswere pay corporate executive long enrol roche stock option plan committee member orssar erich hunziker william burn salary show include jonathan kc knowle receive total hisremuneration ceo march usd swiss franc serve inaddition possible future value psp award onthechugai board receive past ceo subject change inallocation computation relate f high total remuneration member threeyear performance share plan psp period board directorstotal remuneration ofthe board director franz b humer chairman member member board director ofthe board high total remuneration receive remuneration totalling swiss remuneration member board franc ofdirector chairman remuneration consist base salary bonus award chair man board handover executive remuneration member board director function ceo annual general meeting page high total remuneration member board director chf cash payment salary bonus ssar performance share plan total pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo annual report business report page franz b humer psp psp originally target ne award ne spread relevant period oftime ie year value calculate yearend price december chf nonvoting equity security ne psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target ne subject change number value ne awardable plan december spread relevant period time ie year board ofdirector vote actual allocation ne originally target december accord tsr achieve mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance payment tax consulting service remuneration serve chugai board notincluding employer contribution ahvivalv chf roche business report remuneration report g total remuneration member corporate attheend group hold share executive committeetotal remuneration issue share detailed information corporate executive committee aboutthis group find finance report severin schwan ceo member note roche group consolidate financial corporate executive committee high total statement relate party remuneration remuneration note financial statement roche member corporate executive committee holdingltd significant shareholder ae inaddition december member high total remuneration member corporate executive committee chf cash payment salary bonus stock optionsssar blackschole valueat grant minus performance share plan total pension fundsmgb roche connect total value blackschole value describe stock optionsstocksettle stock appreciation right ssar basic rule detailed calculation remuneration member corporate executive committee c performance share plan footnote respectively mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance payment tax consulting service exclude ahvivalv payment remuneration show subject ofthe board director person closely asso future change allocation computation ciate member executive relate threeyear performance share plan committee person closely associate psp period themheld share ne show table member corporate executive committee receive remuneration totalling stock optionsstocksettle stock appreciation swiss franc right ssar december franz b humer member board additional remuneration pay current director hold option january member corporate executive commit ssar position ceo tee member corporate executive committee hold option stocksettle stock appreciation right security holding director andr hoffmann ssar introduce january andrea oeri member founder family closely associate belong remuneration member corporate executive ashareholder group pool voting right committee ae exclude ahvivalv wwwglobalreportscom security holding december close relative share ne security holding number number numbertype number member board director fb humer stock option ssar b gehrig hoffmann ubs longshort certificate roche bearer share versus roche nonvoting equity securities isin ch valor otc option ubs ag roche nonvoting equity securities valor p baschera ji bell p brabeckletmathe ljr de vink american depository receipts adr rhhby isin w frey da julius oeri ubs longshort certificate roche bearer share versus roche nonvoting equity securities valor w ruttenstorfer h teltschik b weder di mauro total member corporate executive committee schwan ne stock option ssar ayyoubi stock option ssar wm burn stock option ssar e hunziker stock option ssar ga keller ne stock option ssar jkc knowle stock option ssar j schwiezer stock option ssar total ne figure include share hold shareholder group pool voting right sharesettle loan transaction august report swiss exchange roche business report remuneration report show table stock option ssar period year unvested option lapse compensation employment terminate voluntarily reason retirement vest option show table issue option exercise limited period roche employee stock option option time fair value option calculate entitle holder purchase roche nonvoting date issue blackschole formula equity security ne option tradable deduction average twoyear vest period term multiyear option plan strike price option show closing price ssar show table intro roche ne day trade prior duce roche january place stock roche annual media conference option option ssar entitle holder benefit financially show nontradable onethird option increase value roche ne subject vest period year onethird grant date exercise date vest period year onethird vest strike price ssar term multi stock option ssar number stock option ssar hold current member corporate executive committee december ssar issue total schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer fb humer total strike price chf market price ne december chf expiry date grant value option start ssar chf blackschole value minus ssar stock option franz b humer receive additional ssar wwwglobalreportscom year plan closing price roche ne day trading roche annual media conference ssar vest year grant date ie onethird vest end year onethird end year onethird end year vested ssar exercise convert ne seven year grant date unexercised ssar lapse compen sation fair value option calculate date issue blackschole formula option tradable deduc tion average twoyear vest period strike price expiry date grant value foroption ssar show table number option ssar calculate time issue enter value table remuneration member thecorporate executive committee b stocksettle stock appreciation right ssar corporate responsibility lead healthcare company goal develop available product service address unmet medical need real value society aim provide tangible improvement patient health quality length life core contribution responsible sustainable manner respect need individual society environment possible committed finding retain talented people develop skill wwwglobalreportscom brief approach datum monitor manage topic key roche view sustainable longterm sustainability success table show highly responsible company industry progress approach corporate responsibility provide value stakeholder million people management responsibility world influence inter corporate responsibility integral est business engage key group business csc line management benchmark achievement industry identifie assess significant social ethical good practice convince constructive dia environmental risk opportunity long logue improve way formulate implement term business reputation responsible com business strategy help well understand pany fourth consecutive year csc hold need community weoperate twoday workshop employee corporate sustainability committee csc variety function discuss emerge sustainability identify area high importance business relate issue ensure continue progress stakeholder key performance strategy performance csc pro indicator kpi measure progress area pose new update position guideline begin collect datum kpi important topic implement csc corporate executive committee use group table progress achievement responsible practice establish excellence innovation award include djsi world index fifth consecutive year ftsegood introduce new guideline work government official revise position paper guideline work patient group establishedonline database introduce compliance initiative include webbase system report business ethic incident develop influenza preparedness plan roche employee worldwide establish awebsite business collaboration european centre disease prevention launch r award animal welfare patient access begin partnership oneworld health healthcare run care programme information exchange share good practice africa develop roll new position paper access tomedicine diagnostic price rd neglect disease develop new principle health technology assessment drug indication approve major phase iii project initiate people roche name sixth genentech sciencemagazine rank good employer inthe healthcare industry launch new mark employer brand campaign society launch chocos project people affect earthquake inperu continue project malawi collaboration ecpp unicef launch international postdoctoral fellowship programme safety security develop position paper pharmaceutical environment health environ achieve greenhouse gas voc emission reduction target mental protection achieve energyefficiency target roche business report corporate responsibility responsible practice healthcare company like roche base clinical research associate collect input research innovation responsibility fromthe field feed new clinical risk opportunitie innovation base science development technology support product pipeline advisory board opinion leader feedback overthe decade emerge technology development programme publication support product development onward plan thislongterm focus require sustainable business disease management programme manage practice section describe manage care agency relate responsibility health awareness program government department customer relationship management support education caregiver consider customer need expectation help improve customer satisfaction commercial customer satisfaction integral diagnostic effectiveness highly value customer feedback division half diagnostic use range initiative respond question employee work customer service sup request use customer input develop local portinconsumer business diabete regional action plan build strength carecustomer satisfaction directly link identify potential weakness customer loyalty reason local sale office carry market analysis assess satisfied set quantitative qualitative target regu customer product result feed larly measure progress carry com backto customer service support prehensive market research analysis implementation divisional local level good meet specific market need uk example oncology division public private healthcare payer run annual satisfaction survey lead oncol important decision grant deny access ogist analyse feedback individual prod health technology profound implication uct overall portfolio bet patient family society engage ter meet patient need work payer product lifecycle include lead clinician opinion leader guidance assess value product important business provide input andservice health technology assessment hta target product profile improve attractive priorto decide reimbursement funding ness relevant stakeholder include payer condition clinical development plan eg design participate trial business integrity compliance publication trial result corporate principle directive guideline regulatory filing strategy andpolicie form code conduct guide development health outcome study allemployee act integrity time disease awareness plan product message andhow voice concern employee complete initial treatment guideline mandatory training ensure understand ourcode conduct available engage customer onour intranet video raise awareness ofthe legal medical liaison gather information business risk carelessly write email clinician patient share internally education development programme take step strengthen opinion leader integrity introduce online business wwwglobalreportscom ethic incident reporting system beir enable organisation help establish preparedness group compliance officer capture track plan increase capacity manufacture monitor allege violation initial report local tamiflu oseltamivir antiviral prevent compliance officer resolution beir treat influenza government system lead increase ethical incident report stockpile drug case pandemic take corrective government corporation measure necessary employment manufacturing capacity outstrip current contract terminate unethical behaviour demand quickly change pandemic compare wetherefore continue stress importance ofstockpile tamiflu work government risk crisis management toensure preparedness risk management charter define risk management approach responsibilitie typical responsible marketing risk business include investment research roche commit high standard marketing yield result product safety issue activity strict regulation sale extensive list risk website marketing pharmaceutical diagnostic product help sure healthcare professional pre business unit global function conduct scribe administer medicine correctly arisk assessment year develop patient understand associated benefit risk plan address risk aremanage locally expertise available list external guideline code practice linemanager responsible taking require follow marketing product available action corporate risk management team coor website dinate process report result corporate executive committee audit european federation pharmaceutical industry committee board review association efpia issue late revision effectiveness risk management system code practice late member asso ciations country update code corporate sustainability committee hold regular accordingly pharmaceutical research meeting workshop identify assess social manufacturers america phrma revise environmental ethical risk opportunitie code interaction healthcare professional base expertise experience adapt internal guideline stakeholder feedback material risk identify standard operating procedure globally align include group risk management process revision introduce additional employee training ensure compliance introduce risk management section ourintranet raise awareness july uk affiliate accept prescription employee site contain risk management medicine code practice authoritys decision guideline framework tool suspend association british pharma calendar riskrelate lecture discussion ceutical industry month breach andenable employee share good practice code unintentionally sell slimme drug xenical unlicensed clinic roche uk respond help manage risk potential immediately implement broad intensive crisis influenza pandemic example training base update compliance policy wework government corporation health procedure roche business report corporate responsibility advertising directly patient allow provision supplier meet safety health accurate balanced easily digestible informa environmental protection standard tion motivate patient learn include procurement contract disease discuss healthcare new program labour standard human right provider public advertising diagnostic legal supplier region problem inmost market educational area common plan extend sustainable forexample million diabetes patient worldwide procurement activity supplier nonproduction benefit frominformation provide accuchek material service brand patient brochure diabete diary andregular newsletter cover topic pharmaceutical division carry audits diabetesmanagement recipe lifestyle identify correct problem businesscritical behaviourtip supplier assess new one support supplier implement require improvement unlike country usa permit advertise share expertise documentation run ment prescription medicine directly consumer workshop provide training audit endorse law regulate pharmaceutical safety health environmental standard key advertising usa member company supplier exist supplier seven pharmaceutical research manufacturer potential supplier follow america phrma fully endorse strength previous audits ene directtoconsumer dtc guide principle announce december effective carry audits total march confident dtc adver thelast year half produce good tising complie principle good result supplier applicable law food drug administration barely meet meet acceptable standard regulation include division drug werejecte stop business sup marketing advertising communication addi plier unable help improve main tion wewelcome eu commission proposal area improvement identify audits directive information patient lack knowledge insufficient industrial hygiene anopportunity improve eu citizen access worker protection especially handle highquality information health prescription hazardous substance medicine diagnostic division plan incorporate sustain sustainable procurement ability element regular supplier audit pharmaceutical diagnostic division start important sup spendroughly billion swiss franc annually plier basedon spending business criticality product service supplier range wewillroll process supplier fromitem raw material active pharma necessary ceutical ingredient equipment laboratory office supply computer equipment service roche host world environment center likeconsultancy travel marketing global roundtable discussion effectively integrate strategic procurement organisation help select sustainability procurement sustainability reliable supplier secure supply increase representative industry government science supplier performance financial control improve consultancy conclude advanced procurement expertise apply good practice company struggle successfully integrate worldwide theconcept sustainability procurement wwwglobalreportscom butthat risk significant participation organisation economic group review good practice example cooperation development oecd working group guideline human biobank public policy genetic research database honest transparent dialogue govern participation project relate future ment private sector fundamental health technology assessment hta europe development public policy general public sponsor eu commission health policy particular private sector vital role play develop law regulation combat counterfeit counterfeit pharma policy enable good possible patient care ceutical diagnostic product illegal wetake dialogue appropriate poseasignificant global public health problem professional manner theyendanger patient undermine confidence inhealthcare system company infringe introduce good practice guideline onintellectual property right waste valuable work government official distri healthcare budgets bute general country site manager implementation area responsibility andare continuously monitor improve product secu available website rity technology quickly identify counterfeit participate national international industry carry public policy work governmental effort develop strong law membership industry body improve enforcement educate public efpia european diagnostic manufacturer train local official association edma international federation pharmaceutical manufacturer association european commission hold public ifpma national member consultation combat counterfeit medicine meet directly policymaker include member develop propose legislation support legislative ofthe european parliament health body reform believe focus integrity theeuropean centre disease control world original packaging pharmaceutical sup health organization policy think tank health ply chain efpia stringent policy academic example public policy control manufacture trade distribution engagement include active pharmaceutical ingredient andmedicine response european commission ec consultation information patient generic biosimilar product patent peri prescription medicine od innovative biological product contribution uk house lords inquiry protein antibodie starting come onthe impact genomic clinical practice end relatively easy manufacturer personalise healthcare copy chemical product biological product response ec consultation medical complex molecular structure obtain device legislation include vitro living system extremely complex process diagnostic support development welldefine trans comment japanese draft guideline parent regulatory framework development followon biologics approval postauthorisation procedure participation meeting world health biosimilar base original organization guideline abbreviate licensing product pathway certain biological therapeutic roche business report corporate responsibility hold meeting opinion leader global ethic liaison office receive query health authority representative parliamentarian resolve escalation different country discuss issue exchange information welcome creag meet annually review concern feedback issue relate safety efficacy raise global ethic liaison office andquality biosimilar complex understand todiscuss relevant ethical topic manage meeting creag brief recent workof global ethic liaison office employee date dedi review current topic include revision cat section intranet recently update declaration ofhelsinki world medical version position statement available association conduct clinical trial website develop country political contribution federal law prohibit panel independent advisor science usfrom make political contribution federal ethic advisory group seag advise didate employee personal guide genetics genomics proteomic contribution hoffmannla roche good follow discussion seag government committee ggc voluntary political publish revise group policy standardise action committee participate roche action procedure human speciman repository reposi programme employee contribute torie biological material tissue organ dollar mechanism blood bodily fluid invaluable explore aspect disease eventually research practice lead well treatment contain sensitive develop innovative medicine diag information person sample nostic push scientific boundary belong dedicated protect right explore new technology ethical concern privacy donor provide informa arise result explore manage tion aspect speciman donation effectively capture opportunity theyagree sample ourresearch bring animal welfare recognise seriously ethic rd global position clinical public concern animal research important research commit tohigh ethical standard explain ongoing need animal research make clear position specific area industry effort develop alternative method concern scientific limit alternative clear procedure resolve ethical time animal development dilemma employee encounter work drugsand technology necessary scientific ifan issue resolve affected andlegal reason able develop team employee contact global ethic lifesave medicine cancer drug liaison office consult peer internal animal testing commit animal expert find solution remain concern appropriately responsibly comply elevate internal committee finally applicable law meeting exceed industry independent advisor clinical research standard commitment apply employee ethic advisory group creag provide external contractor perform animal testing continual online ethic train employee wwwglobalreportscom breakdown animal research enter new field point whenthey develop apply inour work soon todevelop micerat lead position nanotechnology manipulation material ascale time small diameter human hair potential area particularly dog innovative drug delivery update rabbit internal position nanotechnology primate explore technology changethe way drug work administer total number animal research webought american company mirus drop animal llcto build work ribonucleic acid inter researcher contractor use experiment ference rnai technology rnai potential mice rat provide new type treatment difficulttotreat disease introduce rs award innovation con tinual improvement animal welfare roche begin trial partnership halozyme rs concept mean replace animal therapeutic drug formulation allow medi test possible reduce number animal cine previously administer intravenous require refining exist scientific practice injectionto inject skin recently animal welfare husbandry twentyfour team exciting progress development ofscientist animal care specialist ofa new treatment nonhodgkin lymphoma research site enter award category follow theacquisition glycart biotechnology wehave develop compound enhance scientific category place go project ability kill target cell predict bone marrow toxicity artificial environment mathematical modelling reduce consider stem cell biology important opportu number animal need win project nity research tool potential novel inthe lab care animal management category therapeutic approach particularly field involve special behavioural training primate regenerative medicine currently use allow researcher interact animal human embryonic stem cell purpose help new environment stem cell taskforce actively monitor assess peopleand procedure take blood innovation area particularly production sample implement project stem cell alternative source example operation possible run recently sign cooperative research agreement ther award develop new technology adult cell fatty tissue zerbini foundation paulo innovation new technology closely university hospital heart institute monitor development evolve technology nanotechnology stemcell research roche join consortium pharmaceu system biology identify potential bene ticalcompanie biotechnology firm uk fit pharmaceutical diagnostic allow government aim advance application roche business report corporate responsibility stem cell technology toxicology testing work take place independent notfor profitcompany call stem cell safe medicine wwwscsmorg provide guidance funding research stem cell suitable toxicol ogy testing hope initiative help gain insight role stem cell play drug development especially assess safety new medicine reduce need animal testing web sustainability principle strategy management wwwrochecomprinciple stakeholder engagement wwwrochecomstakeholderdialogue responsible marketing risk management compliance wwwrochecombusinessintegrityandmarketingpractice wwwrochecomriskmanagementandcompliance patent counterfeit biosimilar wwwrochecommedicalvaluepatentsandpricing wwwrochecompatent innovation new product technology wwwrochecomcsrresearchanddevelopment wwwrochecominnovationandtechnologie list position wwwrochecompoliciesguidelinesandposition website business pandemic plan wwwpandemictoolkitcom wwwglobalreportscom patient product service provide vital benefit global access healthcare tosociety patient healthcare commit improve access spectrum diagnostic test screen product longterm strategy include detect diagnose select treatment monitor improve reimbursement system advocate disease medicine prevent cure disease great patient access majority healthcare alleviate symptom hasten recovery system recognise clear medical economic value product result engagement primary role develop product clear example cancer drug medical benefit responsibility herceptin xeloda ease pressure health helpimprove global access product supply care budget delay reduce prevent safe medicine reliable test value hospital visit surgery need palliative money provide factual information product care case help patient return carry clinical trial ethically importantly workmore quickly understand respond patient view patient access product doctor value medicine diagnostic hospital laboratory pharmacy roughly unique approach personalise healthcare country majority business phc help develop novel product patient isin develop country advanced need government regulator demand phc healthcare system public health policy standard mean tailor treatment patient improve clin healthcare vary greatly public awareness ical outcome expertise diagnostic give ofthe cause prevention treatment disease great competitive advantage use diagnos healthcare industry important role play tic deepen understanding disease help raise standard medicine work difference patient amuch big picture systemic help develop well safe drug target problem prevent equal access healthcare patient benefit globally good patient appeal payer regulator great efficacy work government nongovernmental costeffectiveness organisation ngo patient group healthcare provider tackle health inequality increase understand tough decision healthcare access product provide sustainable provider employ experienced health healthcare economist work partnership local health authority address specific need issue position statement access access medicine team involve tomedicine diagnostic develop development process right new drug reach input broad range employee market liaise local sale marketing division design provide information team payer clinician patient perform market stakeholder seek research incorporate patient payer perspective development ensure clinical trial access need world design demonstrate economic health develop country ldcs hard hit benefit information generate clinical tri disease poor healthcare system al evidence research activity deal burden hospital economic modeling todemonstrate total laboratory healthcare professional meet value product lifecycle demand international aid focus aid roche business report corporate responsibility tuberculosis malaria public health policy provide drug neglect disease limit local investment initiative free access compound knowledge treat chaga disease aim provide sustainable access healthcare sleep sickness poor country develop hiv testing drug formulation fair patent pricing policy infant significantly neglect area identify research development ngo partnership government ngos provide diagnostic early detection education training knowledgetransfer andmonitore hiv tuberculosis file enforce patent begin research collaboration develop country define united nations institute oneworld health increase rd inaddition file enforce patentson neglect disease oneworld health screen ourantiretroviral drug subsaharan african compound roche library identify new country region affect drug treat acute diarrhea diarrhea kill hivaid approximately million child develop country year currently update position statement effective drug widely available pricingto include guide principle apply toboth division result review aid technology transfer initiative tti assess structure feasibility special example work provide pricing scheme improve access product sustainable healthcare share service especially affluent economy knowledge require produce hiv treatment continue supply antiretroviral therapy saquinavir local manufacturer ldc forhivaid noprofit price ldcs subsaharan africa free charge not subsaharan africa pricing policy cover enforce patent country manufacturer ofpeople hiv globally freely produce generic version drug increase local supply early sign update position rd neglect agreement manufacturer bring tropical disease focus rd total expand tti include area expertise search differentiate training seminar good manufacturing practice innovative medicine lifethreatening disease aim improve quality locally inareas unmet medical need produce essential medicine seminar wecan difference disease take place tanzania south africa include oncology viral disease hepatitis b attend delegate organisation c disease central nervous system participant bangladesh comment far likealzheimer diabetes reach asiam aware roche company offer epidemic proportion develop develop training seminar country announce agreement clinton foun longstanding commitment address dation hivaid initiative chai february diagnosis treatment neglect disease provide dry blood spot test ea develop antimalaria drug lariam ily administer store transport substan fansidar offpatent available tially reduce price diagnose hiv local generic production child young month fast reliable wwwglobalreportscom testing infant essential fight ificneeds work partnership govern hivaids child susceptible ment help establish process education disease start treatment soon possible clinical trial program example estab agreement aim improve access testing lishe dedicated medical affair group develop subsaharan africa roughly hiv specific programme target individual emerge infected child live country supply product private healthcare system country early offer valcyte substantially reduce price international ngo continue supply hiv medicine reduce treat aidsrelated cmv cytomegalovirus price low lowertomiddle income coun discount exclusive use aid patient try define world bank develop country subsaharan africa recently extend low low middle access develop world work closely income country cover people live local payer demonstrate thevalue hivaids worldwide product agree level reimbursement enable access arestill people facilitate information exchange develop country afford healthcare symposium partnership pharmaccess insurance pay usa foundation attend healthcare thereis currently universal healthcare system professional african asian country weprovide drug charge need whoshare insight good practice hivaid roche patient assistance program pap management lowerincome country roche set standard assisting patient need partner physicians albert einstein company college medicine train ethiopian inthe usa establish pap pro doctor nurse clinical officer finalyear medical gramme provide free drug worth billion student usdollar patient benefit pap wealso support industry effort unique employee secondment policy enable toraise awareness assistance program available roche employee use skill expertise partnership prescription assistance primarily ldc interested employee partner organisation aim prevent manage genentech access solution programme disease world poor country company provide patient healthcare weapprove new secondment communica provider coverage reimbursement support tion manager roche sweden second patient assistance informational resource project focus mental health child patient assistance support eligible patient traumatise aids crisis swaziland united states insurance information system specialist roche canada coverage afford outofpocket begin work world vision canada systems copay cost product helpimprove health nutrition africa wasapprove genentech donate approximately asiaand south america billion dollar free medicine uninsured patient genentech access care foun access emerge market middleincome dation gatcf charitable programme country require different business model gatcf help approximately new develop market country healthcare system patient different stage development spec roche business report corporate responsibility example access programme sion diabete hepatitis hivaids influenza obesity website visit hivinfecte patient live country eligible patient globally access detail noprofit medicine trialsin patient ifpma clinical trial hivinfecte patient portal wwwifpmaorgclinicaltrial living country eligible usanational institute health global registry reducedprice medicine atwwwclinicaltrialsgov commit patient benefit usa publishing clinical trial datum good bad patient assistance programme inreputable peerreviewe journal clinical trial collect information gain clinical clinical trial new medicine demonstrate trial postmarkete surveillance feed safety efficacy drug provide thisback development program educational financial medical support forpartici provide information regulatory authority pat hospital access late treatment asrequire cancer arthritis disease patient take trial receive freemedical apply strict datum protection principle treatment trialuntil personal medical datum collect clinical drug available sale prescription trialsin line directive protection wedonot perform clinical trial country ofpersonal data principle apply equally wewill seek marketing approval todata ourcustomer supplier employee patient benefit clinical trial patient safety medicine effect number clinical trial patient priority certain bene number healthcare centre fit take drug outweigh undesirable involved effect reduce likelihood number patient ofadverse event rigorously test monitor phase iiv clinical trial analyse effect product relevant patient group development continue patient seek new clinical trial participate tomonitor launch inand people wish learn result complete trial access information investigate report adverse event ascer wwwrochetrialscom trial registry result tain relate product database host party ensure link reevaluate benefit drug independence outweigh risk robust proce dure place promptly inform patient physician december site contain detail healthcare provider regulator new pharmaceutical protocol diagnostic protocol product safety information trial result study cover condition include alzheimer disease asthma report recall hiv drug cancer cardiovascular disease depre viracept follow evidence contamination wwwglobalreportscom thechemical ethyl methansulphonate begin work european genetic theprocess establish register patient alliance network egan produce patient tookthe drug affect time period faqand glossary clinical trial patient representa wecould monitor support tive provide question patient ask takencontaminated drug research supply answer address docu confirm ill effect take ment aim provide clear straightforward informa affectedbatche viracept relevant tion aboutenrolle clinical trial example health authority tell registry egan publish document website arean unnecessary precaution effort genetic interest group affect inform member organisation process number roche company launch local patient advocacy initiative support patient patient group patient group important partner roche country example roche austria launch weshare interest help patient leben hilfe life rescue fund provide financial standand manage disease gain access aid cancer patient return regular life tothe information treatment need beat disease weonlywork patient group activity benefit thepatient group represent web policyis betransparent activity personalise healthcare torespect theindependence patient orga wwwrochecomphcinrd roche position statement access medicine nisation diagnostic pricing neglect disease work patient group revise position statement guide wwwrochecomaccesstohealthcare line work patient group adapt wwwrochecommedicalvaluepatentsandpricing wwwrochecomrocheaccesshealthcarepdf tothe recently approve efpia code major programme ldc wwwrochecom change publicly list patient group programmesinleastdevelopedanddevelopedcountrie support financially previously programme develop country wwwpparxorg onlydisclose receive swiss franc wwwgenentechaccesssolutionscom list patient group receive financial roche trial patient safety sponsorship march patient group wwwrochetrialscom nonfinancial support publicly list wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety thesupport significant meaningful guide work patient byefpia member association wwwrochecompatientgroups egan website launch internal database wwweganeupublicationspublicationsandpresentationshtm track patient group partnership roche affiliate western europe database contain detail patient group work funding give year individual project work group provide clear understanding ofour partnership patient group help share learn experience database isfully run western europe plan toroll region roche business report corporate responsibility people people core factor business success employee fulltime equivalent fte need people enthusiastic job region employer enthusiasm infec tious customer pick help build trust roche wolfgang troebs general manager roche asia diagnostics switzerland latin america total employee fte number north america growth rate europe growth relate acquisition employee contract type headcount employee fte operating division variance permanent temporary genentech apprentice time chugai time employer choice roche determine remain employer choice diagnostic seek attract recruit retain right roche pharmaceutical employee drive innovation business build talent management achieving start value proposition roche talent management help identify recruit current prospective employee slogan develop lead reward employee whilethe focus mark improve live employer brand identify employee key position talent embody differentiate roche management involve develop thepotential employer present win company offer employee help achieve ourgoal ing opportunity professional personal growth collaborative stimulate work envi corporate executive committee identify ronment new employer brand integrate talent management key people priority local career website end forroche drive measure progress area attraction retention group value leadership competency formance management compensation succession introduce reinforce roche principle management learn development andthe work environment seek offer integrate talent management attraction competition talent world process fierce size global workingage popula wwwglobalreportscom global standardized process system recruitment rate internal versus external performance talent compensation management external internal attraction leadership pipeline retention succession learn management development career website opportunitie cumulative tion develop country decrease talented people emerge market increasingly register people return home country shortage site mean difficult attract right people new employee recruit innovative researchdriven healthcare com internal move pany roche operate industry adirect benefit live million people introduce standardised recruit worldwide aspect business play process roll organisation critical attract retain enable roche drive quality motivated people position lead multi consistency recruit operation national company enable offer help hire candidate line renew prospect grow industry career oppor value leadership competency tunitie globally overall roche new hire career website remain widestreache effective tool recruitment retention year characterise million visitor acquisition significant optimisation restructuring initiative pharma division global career site enable prospective cur reduce primary care sale force optimise rent employee search position role local operation finance hr region roche use application country headoffice function manufacturing reorganisation attract source hire candidate initiate latin america united employees system differ state voluntary severance plan offer ent position roche group thelatter overall optimisation restructuring initiative account employerdriven approximately percent total new hire movement source externally talent pool prospective candidate register deal acquisition reorganization detail career site place emphasis ability retain value roche business report corporate responsibility employee roche offer support measure employee country asrelocation retention incentive new career eligible participate roche connect orientation support turnover nonvoting equity security award man ager base performance roche longterm plan introduce total total take europe join time latin america north america move provide definedbenefit asia plan pay depend formula define employee salary age retirement factor definedcontribution plan reason leave payout accord contribution subsequent investment define benefit plan honour foremployee enrol employerrelate employeerelate range programme encourage neutral staff look wellbee include free medical checkup workplace ergonomic evaluation compensation benefit wellbee total counselling healthy option available staff compensation package pay benefit offer restaurant make significant contribution attract retain talent group equally important offer parttime flexitime homeworke longterm job stability development opportunity option appropriate approximately good work environment employee work parttime sabbatical regularly arrange past year roche salary roche reflect employee contribution introduce paternity leave country business pay rise bonus reflect business maternity leave statutory minimum personal performance pay performance country philosophy encapsulate regular benchmark confirm roche offer competitive pensionand performance development help employee benefit programme employee country achieve potential provide regular feed usually supplement local socialsecurity pro performance encourage gramme follow local market practice discuss career goal development opportunity manager employee remuneration package offer local affiliate take performance management programme align group remuneration policy formal career development planning revise total remu neration cost billion swiss franc staff performance development employee responsibility management accounta roche connect programme employee bility performance management process country purchase roche nonvoting review increase dialogue man equity security discount ager employee tight line management allow wwwglobalreportscom differentiate high low performer secondment programme give employee appropriate feedback support employee chance work capability healthcare build professional growth programme develop country month new secondment succession management strengthen approve talentpipeline critical seekto maintain competitive success continue drive culture learning development roche invest ofinnovation weintroduce acorporate million swiss franc skill train educa wide approach talent management enable tion provide total approximately mil tonurture highpotential employee lion hour nearly hour employee talent framework provide global training include technical skill programme approach identify develop guide highpoten meetcompliance requirement language course tialemployee framework highlight talented interpersonal skill train individual coaching individual provide access broad pool programme leadership change management ofemployee key position intheshort long term training course run global func tionsbusiness area individual affiliate step talent pipeline support tailor meet local need groupwide development programme pro gramme target employee roche affiliate offer comprehensive appren approximately total spending ticeship roche normally offer apprentice learning development alternative include temporary assignment addi tional time university oneyear internship development opportunity offer company half apprentice hire international assignment helping distinguish roche finish training currently roche attractive employer apprentice work group include new apprentice approximately employee long shortterm international assignments coun diversity try want ensure employee international work different part globe assignment perform successfully new sur experience value diversity strengthen rounding introduce cultural awareness anorganisation richness idea course facilitate integration host country opinion bring people different gender interactive training give employee tool ethnic cultural origin understand local culture social busi pascal soriot head commercial operation ness point view launch year pharmaceutical division berolle widely diverse workforce critical success establish support programme help aglobal company like roche visible char partner employee international assignment acteristic age race gender diversity integrate new country programme comprise experience competency mindset provide information network club webelieve diversity promote innovation allow social organisation career support enable flexibility inspire creativity help roche tackle asuccessful job search future challenge roche business report corporate responsibility tolerate form discrimination woman career barrier wefoster inclusion integrate diversity vesna cizej adriatic management centre head employee management system general manager slovenia dif ferent intelligence independent race gender diversity flourish environment exist geography say strength acknowledge understand value talent combine difference foster reflect process structure foundation success encourage employee diversity formal acknowledging diversity roche workforce training diversity management allow vesna cizej adapt leadership trainingprogramme policy include style meet need individual employee prevention abuse power workplace know importance overall wealso embe inclusion process vision team communicate vision dailyactivitie require finetune fully engage communicating vision person basel example ensure diversity way meaningful motivational recruiting process mix gender interview vesna cizej say panel ongoing improvement family support flexible work arrangement ensure constant high ultimately employer offer return rate maternity leave example staff keeps inspire roche open second day care centre opportunity offer emergency day care support important contribution make real difference people live number woman key position level renew passion energy ofthe organisation continue increase work vesna cizej conclude corporate executive committee welcome female member silvia ayyoubi global head human roche represent nationality worldwide resource woman account total work headquarters basel half employee force manager senior originate switzerland roche manager approximately employee affiliate local national account majority woman compare respec workforce approximately tively previous year management team help ensure ourgroup policy work reflect diversity gender diversity ofour global operation employee engagement woman total communicate employee feature workforce intranet internal newsletter woman management town hall meeting employee magazine number woman language hexagon worldwide employee magazine management appear quarterly language avail position able roche intranet restate reporting error annual report hold facetoface lunch meeting seven time year employee meet member wwwglobalreportscom corporate executive committee senior man ager ask question employee abroad canattend live webcast human right roche comprehensive employment policy cover human right define united nations group compliance officer monitor policy roche serve contact employee end roche company recognise realize right business human right resource centre public commitment human right roche respect right employee freedom ofassociation collective bargaining employee represent colleague union membership member organisation freely represent include roche europe forum represent ouremployee country directive protection personal datum pro tect information employee comply relevant local legislation appropriate negotiate datum privacy agreement different part business work council web employee wwwrochecomemployee group policy position guideline wwwrochecompoliciesguidelinesandposition global career portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf core standard wwwrochecomcommitment roche business report corporate responsibility society support community corporate donation support scientist future sponsorship employee volunteering extend roche foundation include fondation philanthropy promote sciencebase dentreprise roche france roche foundation industry inspire staff help roche global roche organ transplantation successful sustainable business commit research foundation support research edu corporate citizen focus program cation programme world promote align business model innovation advance science medical scientific education sustainability impact collaboration support young scientist encourage innovation business depend business enable help need nurture generation scientist need world promote sustainable access tosustain success medicine diagnostic drug donation donot generally form access strategy offer twopart genetic donate medicine disaster relief education programme educator switzerland pandemic situation value forexample germany combine genetic science roche shanghai supply vial theory education practical laboratory exercise rocephin antibiotic treat infection course raise awareness ethic provide fund local red cross assistance policy relevant genetic science demon programme wake sichuan earthquake strate science modern lifesave inchina medicine publish detailed financial information roche collaborate science community investment instead education leader year provide twoday measure success support impact workshop resource teach bioethic example roche children walk secondary school teacher teacher enable child village malawi participate challenging student receive hot meal health checkup education innovative approach contemporary science atday centre primary school child learn benefit new classroom student toattend secondary school partnership new jersey institute tech nology roche support oneday continue educa set standard communicate measure tion programme primary secondary teacher impact donation noncommercial sponsor session engage teacher ship development guide align andprovide handson activity address good practice organisation national standard science mathematic education community support area roche research foundation conclude total itssponsorship activity new distinct initiative humanitarian social project launch promote young talent research science education excellence globally international roche postdoc arts culture fellowship programme aim support outstanding community environment young scientist cooperative research devel opment project roche academic institution wwwglobalreportscom programme strengthen international scientific vision material need rebuild house exchange nurture development specialist local community building enable knowledge new idea creative talent construction dam aid economic far award fellowship year social recovery plan award scientific discipline roche children walk global encourage innovation art roche employee aid walk extend scope roche patron contemporary art vulnerable child employ music inception believe innovation ee site walk kilometre music art closely relate scientific raise estimate swiss franc includ innovation heart business ing match company contribute company affiliate local chil roche continent launch collabora drens charity balance donate tion salzburg festival austria encourage react longterm partner european young people explore contemporary classical music coalition positive people wwwecppcouk invite second group student unicef switzerland work malawi european universities festival partici pant attend series lecture workshop roche provide fund phelophepa creativity art science concert health care train begin year ago year mobile clinic deliver health care roche commissionssponsor new musical work rural south africans outstanding contemporary composer thecountry remote areas george benjamins duet piano orchestra justone doctor patient receive premiere commission wasawarde toshio hosokawa roche sponsor number initiative encourage involvement science promote aware support community ness health issue help address critical com roche strive difference local munity need example include community encourage employee identify brighton science festival uk community local project valuable contri base promotion science creative artistic bution contribution novel way people age volunteer fundraising world kidney day spread message kidney disease common harmful treatable employee donation diverse community project roche blue bicycle project turkey public globally disaster relief coordinate awareness campaign cancer roche employee action charity trust react heart stopper challenge raise fund set independent charitable heart child new zealand organisation join smile outreach programme localchildren family suffer poverty example roche employee support emergency inargentina relief effort peru react devastat e earthquake continue web support longterm project reconstruct roche n jazz httpwwwrochenjazznet destroy village chocos continue partnership react httpreactrochecom react provide skill technical super roche business report corporate responsibility safety security health environmental protection safety security health environmental protection hold global conference integral business success officer ensure roche corporate policy responsibility area seriously guideline revise guidance note issue lifecycle product corporate principle implement appropriately policy commit high standard conference discuss progress ofshe invest million swiss franc corporate goal infrastructure million swiss franc operating cost include service personnel important employee embrace standard group sitespecific training management include lecture practical handson course roche responsible ensure employee take hour health safety training minimise environmental impact ofour operation dedicated team handle chemical inherent risk pharmaceuti fulltime employee department cal diagnostic research development manu roche group include people facture employee handle chemical corporate team coordinate role train use appropriately roche corporate security officer appoint havepublishe safetydata sheet detail theproper function build tie correct handle specific network local security officer coordinate chemical security activity business threeyearly ecompetition encourage employ local site ensure policy guide ee suggest innovative way reduce environ line implement appropriately individ mental impact annual responsible care ual site manager officer ecodelegate network award ask individual site come work diagnostic pharmaceutical solution improve energy efficiency division raise awareness environmental issue environmentally friendly initiative colleague lead number innovative proposal implement risk identify assess business affiliate list webbase health safety inventory enable evaluate risk safe healthy workforce essential ensure develop measure mitigate corporate employee wellbee productivity level goal reduce roche accident rate monitor policy regular site baseline audits audit site major defi ciencie uncover finding relate roche accident rate rar measure site risk analysis process require update number work day lose occupational insufficient training emergency management accident employee year oroccupational hygiene assessment need update use audits improve rar represent formance recommendation audit increase exclude fatal traffic accident site implementation supervise year remain track achieve audit team goal wwwglobalreportscom health safety performance environmental footprint busi ness calculate basis ecobalance method design swiss agency roche accident rate environment bafu ecobalance reflect occupational total environmental impact operation accident use resource raw material energy occupational illness generation emission waste workrelate fatality workrelate ecobalance improvement accident million reflect reduction work hour achieve environmental indicator nitrous oxide air emission particulate number accident associate contractor increase slightly year currently increase reduce number operate target ecobalance hour work contractor associate injury maintain level recognise need frequency rate increase contractor work tocontinuously cut resource use reduce ing premise oblige follow waste emission generate safety rule employee important understand environmental expen case occupational illness drop diture relation sale allow number lose day reduce quantify environmental impact operation disease musculoskeletal use information target investment system account twothird area great impact theselost work day ecoefficiency rate eer combine datum strive reduce number severity occu energy use waste emission air water pational accident illnesse incident expenditure environmental protection investigate relevant finding communi sale explanation eer find cat company onour website eer improvement individual site play vital role achieve long term global goal set site ecoefficiency rate follow action plan develop atthe conference september help achieve goal plan assess sale corporate measure continuously millions chf implement environmental expenditure environmental footprint millions chf monitor environmental footprint research environmental production packaging transport distribution damage million use disposal environmental damage unit goal improve total ecobalance eer baseline pointsemployee roche business report corporate responsibility energy climate change greenhouse gas emission relative sale aim reduce energy use emission green increase year tonne million swiss house gas carbon dioxide co franc sale equate total decrease operation approximately exceed reduction goal end goal reduce total energy consumption baseline gjemployee greenhouse gas emission tonne co equivalent goal reduce greenhouse gas emission baseline co equivalent unitsale total emission performance roche terajoule total emission energy decrease terajoule million chf previous year equivalent gigajoule sale employee slight decrease group strategy decrease greenhouse energy use terajoule gasemission guide position paper greenhouse gas climate change paper stress connection co emission total energy use andenergy use implement measure total energy use toreduce energy consumption improve effi million chf sale ciency total energy use employee believe allow individual site develop theirown emission reduction strategy maximise emission energy use effort familiar greenhouse gas emission total million tonne withlocal condition site guide group co equivalent absolute increase directive energy conservation enforce rise emission despite low energy asystematic approach include energy effi consumption increase car plane travel ciencystandard onthe design new equipment optimisation ofexiste energy consume item energy use type directive require site energy audits carry fuel issue guidance ensure structured company vehicle approach audits carry oil party site select site fuel business audit accord circumstance air travel energy consumption result audits cover entire site concentrate particular waste system use result develop initiative grid electricity goal reduce future energy use district heating win entry roche respon renewable energy siblecare network award come natural gas headquarters basel adjust site air wwwglobalreportscom conditioning room slightly high tempera ozone depletion ture aslightly low humidity energy use halogenate hydrocarbon cfc cut increase risk damage hcfcs damage ozone layer affect cli toour equipment mate roche directive phase cfc hcfcs commit eliminate entry shortlist award coolingsystem fire extinguish system year include roche carolina energy monitoring system fordata collection datum analysis allow project replace hcfcs thesitetomonitor manage optimise energy refrigeration unit hold lack use ofaccepted alternative country roche burgdorf new heating system wood reorganisation plan phasingout project pellet fossil fuel cut co emis onhold important site target date sion total energy eliminate compound beingrenewable extend roche brussels new building include special sun shading prevent office get hot hfcs hydrofluorocarbon pfc perfluorinate summer use rain water toilet flush carbon replacement energy efficient lighting car park tohcfc cfc affect ozone layer considerable global warming encourage employee toconsolidate travel potential persistent atmosphere destination trip invest video consider suitable longterm teleconferencing facility travel alternative aim phase com necessary promote use oftrain poundsby appropriate plan place flight investment project implement meet goal change rule invest energy saving world business council sustainable ozonedeplete chemical tonne development wbcsd exemplified roche case study effort analyse lifecycle costsand impact energy efficiency investment halogenate wbcsd publish study stimulate similar hydrocarbon approach company paper highlight holding roche innovative method calculate value halogenate ofenergyefficiency investment hydrocarbon emission wbcsd note convert social environmental economic benefit time emission air asingle financial figure compare volatile organic compound vocs particulate upfront cost valuable tool promote contribute air pollution smog nitrogen business case investment energyefficiency oxide sulphur dioxide x initiative roche enable manager contribute acid rain emission air business rigorously assess include overall goal reduce total envi feasibility energy efficiency investment ronmental impact pursue opportunity value creation roche business report corporate responsibility performance manufacturing process ment necessary landfill sustainably remedi combustion plant emit tonne voc ate approximately million swiss mean surpass franc available purpose ourgoal reduce voc emission tonne unit sale baseline level waste tonne ofparticulate continue fluctuate x atalow level total emission tonne tonne tonne respectively general waste produce emission air tonne general waste million chf sale voc chemical waste particulate produce nitrogen oxides chemical waste sulphur dioxide million chf sale waste roche operation produce chemical waste water need dispose safely clean water integral roche manufacturing process withdraw million mfor chemical waste amount thesepurpose source approximately tonne decrease reflect year small production volume incinerate waste isthe responsible way dispose global reporting initiative define water con majority deal manner sumption water product cool air conditioning irrigation increase waste stream originate particular manu consumption base definition facture process reuse compa million continually strive reduce ny sell tonne waste water consumption globally recycle chemical waste amount tonne consist mainly solvent manufacturing process release contaminate wastewater byproduct treat wastewater produce tonne general waste toensure safe environment human previous year considerable release watercourse aim increase mainly construction waste increase capacity treat wastewater building activity different site count business continue grow approximately tonne incinerate send landfill mainly build rubble extension biotechnological production werecycle tonne general waste roche penzberg example required increase year capacity treat wastewater instal innova tive membrane technology increase capacity landfill site contain chemical waste require space energy premise monitor regularly sure previous installation solution win pose risk human health environ entry year responsible care network award wwwglobalreportscom discharge tonne organic roche aim minimise release pharmaceuti materialinto water course treatment cal environment possible decrease compare heavy metal manufacturing site design operate aschromium copper zinc remove ensure far practicable active pharmaceuti frompipe wastewater year release cal ingredient discharge waste kilogram heavy metal decrease water compare offer financial incentive encourage retailer water value chain return unused date product ensure incinerate dispose landfill promote new water withdraw takeback programme million cubic metre exist water million cubic metre roche publish global position statement wastewater discharged pharmaceutical environment outline treatment plant intention monitor risk human health million cubic metre environment organic matter discharge acknowledge longterm effect pharma watercourse ceutical environment need research treatment tonne participate international local heavy metal body dedicate study impact trace chemi discharge cal include pharmaceutical surface watercourse groundwater treatment kilogram compliance incident pharmaceutical environment goal receive significant sherelate fine concern raise trace pharma ceutical active ingredient detect environ performance significant fine report ment current research show quantity find river lake water supply generally far level thera integrity business compromise peutic adverse effect human health aquatic fail comply relevant legislation regula life watercourse tion group policy surpass local law regulation minimum roche commit manufacturing process improper disposal comply local requirement unused medicine lead pharmaceutical enter ing environment normal patient use recog substance biological material nise main contributor risk pharma pharmaceutical manufacturing regulate ceutical enter environment important potential misuse element lifecycle approach environmental forexample production narcotic toxin protection product development chemical weapon substance small quantity rigorous control line applicable legislation roche business report corporate responsibility web performance wwwrochecomkeyfiguresandfact safety security health environmental protection wwwrochecomenvironment safety security health environmental protection policy wwwrochecomreportingandindice group fact sheet position policy guideline wwwrochecompoliciesguidelinesandposition wwwglobalreportscom independent assurance report corporate sustainability committee roche corporate sustainability committee roche holding ltd basel roche responsible subject matter evaluation criterion responsibility provide perform assurance procedure provide aconclusion subject matter base assurance follow aspect sus assurance procedure accordance interna tainability report roche tional standard assurance engagement isae subject matter datum information disclose sustainability main assurance procedure report roche consolidated subsidiary assurance procedure include follow exclude chugai pharmaceutical co ltd genen work tech inc year end december evaluation application group follow aspect guideline review application management reporting process roche internal sustainability report guideline respect sustainability reporting site visit visit select site roche preparation people key figure pharmaceutical diagnostic division wellas control environment relation switzerland france uk canada mexico data aggregation key figure brazil selection base quantitative key figure table page qualitative criterion interview personnel respon select people key figure sible internal reporting datum collection disclose page roche atthe site visit group level business report todetermine understanding application ofthe guideline criterion assessment key figure perform test roche group internal sustainability report ona sample basis evidence support select guideline base responsible care health people key figure roche accident rate safety environmental reporting guideline pub energy consumption co emission relate lishe european chemical industry council energy consumption general waste use water cefic sustainability report guide fine inrelation safety environmental line g publish october global protection headcount datum staff turnover woman report initiative gri senior management position cost define procedure training concern completeness accuracy people key figure gather collate adequacy andconsistency aggregated internally review documentation analysis ofrelevant policy basic principle responsibility methodology review relevant documentation sample accuracy completeness sustainability indi basis include group sustainability policy cator subject inherent limitation give management reporting structure nature method determine calculate documentation estimate datum assurance assessment process data forebe read connection roche internal consolidation review appropriateness guideline definition procedure report ofthe management reporting process e sustainability performance sustainability report assess consolidation process datum group level roche business report independent assurance report conclusion global reporting opinion initiative sustainability internal sustainability report guideline apply properly report guideline internal reporting system collect aggre gate people key figure function previous year align design provide appropriate basis sustainability report guideline global forit disclosure reporting initiative gri base work describe report second time roche opinion assessment criterion come thea level gri g guideline apply attention cause believe datum annual report check information mention subject matter confirm gri disclose sustainability report roche business report fair detail report indicator picture roche performance find wwwrochecomreportingandindice zurich january pricewaterhousecoopers ag dr thomas scheiwiller juerg hutter severin schwan wwwglobalreportscompublishe cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooke state tel ment forwardlooke statement identify fax word believe expect anticipate project intend seek estimate future similar expression discussion thing medium office strategy goal plan intention factor corporate communication causeactual result differ materially future basel switzerland reflect forwardlooke statement contain tel inthis annual report price product fax initiative competitor legislative regulatory development economic condition delay inability investor relation obtain regulatory approval bring product market fluctuation currency exchange rate basel switzerland general financial market condition uncertaintie tel discovery development marketing new product fax new use exist product include limitation negative result clinical trial research project world wide web unexpected effect pipeline market product wwwrochecom increase government pricing pressure interrup tion inproduction loss ofor inability obtain adequate corporate sustainability committee protection intellectual property right litigation loss key executive orother employee tel adverse publicity news coverage email corporatesustainabilityrochecom statement earning share growth order publication aprofit forecast interpret mean tel thatroche earning earning share fax subsequent period necessarily match exceed email baselwebmasterrochecom historical publish earning earning share roche trademark mention enjoy legal protection annual general meeting march roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel corporate communicationspharmaceutical pipeline pharmaceutical division rd activity focus create clinically differen tiate medicine division continue build value research development portfoliotwelve major phase iii project initiate include clinical trial novel compound pertuzumab taspoglutide dalcetrapib wwwglobalreportscomrd pipeline pharma partnering pharmaceutical division file major licensing target acquisition play impor new marketing application gain major tantrole strengthen roche rd portfolio regulatory approval begin expand company technology capability division rd pipeline comprise clinical roche pharmaceutical sign total new project include new molecular entity nmes agreement include seven product transaction additional indication nme research technology collaboration currently phase phase ii inphase iii file regulatory review roche acquire pirame limited uk company therapeutic research programme roche pharmaceutical research project target pikinase pathway oncology major therapeutic area january andinflammatory disease june roche consolidate lead position antiangiogenesis field licensing agreement thrombogenic central nervous bioinvent jointly develop anticancer system disease agent tb r acquisition mirus cardiovascular biocorporation roche madison inc sep metabolic disease tember enable roche advance research field ribonucleic acid interference rnai delivery viral disease oncology september roche complete acquisition inflammatory ofarius research inc proprietary autoimmune disease antibody platform rapidly identify selectsantibodie base functional ability toaffect disease follow merger agreement roche pharmaceutical currently project andsuccessful tender offer january roche inpreclinical research therapeutic area acquire usbased memory pharmaceutical development project therapeutic area whichdevelop innovative drug candidate include phase transition preclinical treatment debilitate central nervous system toclinical development disorder alzheimer disease schizo phrenia memory nicotinic alpha agonist rochemanage project drugcandidate disease area terminate phase phase ii andtwo partner programme roche inphase iii project revert ourrd partner decision take tooutlicense quarterlypharmaceutical pipelineupdate post wwwrochecompipelinepharmaceutical pipeline building value opportunitie growth project d projectproduct pharmacological class indication phase partner generic oncology cid r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line file eu genentech biogen idec cid r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapse file eu genentech biogen idec cid r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo approve eu file cid r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo approve eu file cid r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma approve genentech eu file cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line file eu genentech combo docetaxel cid r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme relapse file genentech eu cid r avastin bevacizumab antivegf monoclonal antibody nonsmall cell lung cancer nsclc ii genentech previously treat cns metastasis file eu cid r avastinherceptin antivegf monoclonal antibody metastatic breast cancer st line iii genentech cid r bevacizumabtrastuzumab antiher monoclonal herpositive antibody cid r avastin bevacizumab antivegf monoclonal antibody ovarian cancer st line iii genentech cid r avastin bevacizumab antivegf monoclonal antibody prostate cancer hormonerefractory iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line iii genentech combo standard chemotherapy cid r avastin bevacizumab antivegf monoclonal antibody metastatic gastric cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant nsclc iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer hernegative iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer herpositive iii genentech cid r avastinmabtherarituxan antivegf monoclonal antibody aggressive nonhodgkin lymphoma iii genentech cid r bevacizumabrituximab anticd monoclonal antibody cid r herceptin trastuzumab antiher monoclonal antibody gastric cancer herpositive iii cid r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkin lymphoma iii genentech maintenance st line biogen idec cid r tarceva erlotinib egfr inhibitor nsclc st line maintenance iii genentech osi pharmaceutical cid r tarceva erlotinib egfr inhibitor adjuvant nsclc iii genentech osi pharmaceutical cid r avastintarceva antivegf monoclonal antibody nsclc st line maintenance iii genentech cid r bevacizumaberlotinib egfr inhibitor osi pharmaceutical cid r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii cid r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo oxaliplatin iii cid r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo avastin iii cid r pertuzumab dimerisation inhibitor metastatic breast cancer herpositive st line iii genentech cid r pertuzumab dimerisation inhibitor neoadjuvant breast cancer herpositive ii genentech cid r pertuzumab dimerisation inhibitor ovarian cancer ii genentech cid r trastuzumabdm antiher monoclonal metastatic breast cancer herpositive ii genentech antibodycytotoxic conjugate cid r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech cid r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme st line ii genentech cid r tarcevaavastin egfr inhibitor antivegf nsclc st line ii genentech cid r erlotinibbevacizumab monoclonal antibody cid r antiigfr monoclonal antibody ewing sarcoma ii genmab cid r antiigfr monoclonal antibody metastatic breast cancer ii genmab cid r antiigfr monoclonal antibody nsclc ii genmab cid r rdgeneration anticd nonhodgkin lymphoma ii glycartga antibody cid r hedgehog pathway inhibitor cancer ii genentech cid r solid tumour cid r braf kinase inhibitor malignant melanoma plexxikon cid r mdm antagonist cancer cid r solid tumour glycartga cid r solid tumor chugai cid r solid tumor chugai cid r solid tumor genentech cid r antiplgf humab solid tumor thrombogenic bioinvent tb glycart whollyowne subsidiary roche wwwglobalreportscomproject d projectproduct pharmacological class indication phase partner generic inflammatory autoimmune disease cid r actemra tocilizumab humanise antiil receptor rheumatoid arthritis file chugai monoclonal antibody approve jpn eu cid r actemra tocilizumab humanise antiil receptor systemic onset juvenile idiopathic arthritis iii chugai monoclonal antibody approve jpn cid r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate iii genentech responder file biogen idec cid r ocrelizumab humanise anticd rheumatoid arthritis iii genentech monoclonal antibody cid r ocrelizumab humanise anticd lupus nephritis iii genentech monoclonal antibody cid r cellcept impdh inhibitor pemphigus vulgaris iii aspreva mycophenolate mofetil cid r nuclear receptor agonist emphysema ii cid r sp receptor agonist autoimmune disease actelion cid r chronic obstructive pulmonary disease cid r asthma cid r oxl humab asthma genentech cardiovascular metabolic disease cid r taspoglutide glp analogue type diabetes iii ipsen bim cid r dalcetrapib cetp inhibitor dyslipidemia iii japan tobacco jtt cid r aleglitazar dual ppar agonist cardiovascular risk reduction ii cid r type diabete chugai cid r glucokinase activator type diabete cid r type diabetes cid r type diabetes cid r type diabetes cid r peripheral vascular disease genmab cid r dyslipidemia cid r polycystic kidney disease plexxikon plx viral infectious disease cid r valcyte valganciclovir inhibitor cmv replication cytomegalovirus extension treatment iii cid r hpv vaccine cervical neoplasia ii transgene tg cid r polymerase inhibitor hepatitis c pharmasset cid r protease inhibitor hepatitis c intermune itmn central nervous system cid r ocrelizumab humanise anticd relapse remit multiple sclerosis ii genentech monoclonal antibody cid r glyt inhibitor schizophrenia ii cid r nicotinic alpha receptor alzheimer disease schizophrenia ii memorymem agonist cid r antiamyloid peptide alzheimer disease morphosys antibody cid r pain cid r nicotinic alpha receptor alzheimer disease memory agonist mem cid r alzheimer disease optin opportunity cid r avastin bevacizumab antivegf monoclonal antibody gastrointestinal stromal tumour iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant rectal cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer nd line iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic hernegative breast cancer iii genentech combo hormonal therapy cid r avastin bevacizumab antivegf monoclonal antibody high risk carcinoid iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic head neck cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody ovarian cancer nd line iii genentech cid r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis iii genentech cid r mabtherarituxan rituximab anticd monoclonal antibody ancaassociate vasculitis iii genentech memory pharmaceutical acquire roche january project d projectproduct pharmacological class indication phase partner generic cid r avastin bevacizumab antivegf monoclonal antibody relapse refractory multiple myeloma ii genentech cid r avastin bevacizumab antivegf monoclonal antibody extensive smallcell lung cancer ii genentech cid anticd dacetuzumab anticd monoclonal antibody diffuse large b cell lymphoma ii genentech seattle genetics cid apoltrail cancer ii genentech cid apomab nonsmall cell lung cancer nonhodgkin ii genentech lymphoma cid arq cancer ii arqule cid anticd dacetuzumab anticd monoclonal antibody diffuse large b cell lymphoma nonhodgkin genentech lymphoma multiple myeloma seattle genetics cid apomab colorectal cancer genentech cid mek inhibitor cancer genentech cid iap antagonist cancer genentech cid rdgeneration anticd hematologic malignancy genentech antibody cid anticmet cancer genentech cid pik alpha pi kinase inhibitor cancer genentech cid tp colorectal cancer chugai cid antiil antiil asthma ii genentech cid antiifn alfa systemic lupus erythematosus genentech cid vap inflammatory disease biotie cid antioxldl antioxldl secondary prevention cardiovascular event genentech cid na hepatitis c chugai cid rhumab rhumab beta ulcerative colitis genentech beta cid anticd anticd rheumatoid arthritis genentech cid antiabeta antiabeta alzheimer disease genentech participation chugai cid epoch epogin epoetin beta chemotherapyinduce anemia iii cid ed activate vitamin derivative osteoporosis iii cid gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii participation genentech cid lucentis ranibizumab antibody fragment vegf diabetic macular edema iii cid lucentis ranibizumab antibody fragment vegf retinal vein occlusion iii cid tnkase tenecteplase thrombolytic agent catheter clearance iii cid xolair omalizumab antiige antibody pediatric asthma file novartis cid raptiva efalizumab humanise anticda renal transplant ii merck serono monoclonal antibody cid abt solid tumours ii abbott cid abt solid tumour hematologic malignancy abbott begin division rd pipeline comprise clinical project include new molecular entity nme additional indication nme currently phase phase ii phase iii file regulatory review cid therapeutic protein indication blue type phase initial study healthy volunteer possibly patient cid small molecule additional indication black type phase ii efficacy tolerability dosefinde study patient cid peptide current january phase iiilargescale study patient statistical confirmation safety cid therapeutic vaccine efficacy cid antibody fragment wwwglobalreportscomdiagnostic pipeline roche diagnostic division work raise rd productivity increase percentage young product portfolio launch new test high medical valuethe division rd spend nearly sale measure determination launch list measure successproduct launch diagnostic division major product launch business area product professional diagnostic additional cobas configuration suit wide range laboratory workload cobas euus cobaseu cobas c clinical chemistry analyser complete cobas series serum work area instrument forsmall tomediumworkload laboratory ex accuchek inform ii wireless hospital blood glucose meter ex elecsys antihcv immunoassay hepatitis c infection eu elecsys anticcp anticyclic citrullinate peptide antibody assay diagnosis rheumatoid arthritis eu elecsys antitshr antithyroid stimulate hormone receptor assay diagnosis grave disease euus brahms procalcitonin assay aid early detection monitoring sepsis select eu markets elecsys anticmv igg anticmv igm assays detection cytomegalovirus infection eu roche cystatin c test clinical chemistry test early detection impair kidney function eu elecsys toxo igg immunoassay detect acute latent infection parasite toxoplasma gondii secondgeneration elecsys not probnp immunoassay use aid diagnose heart failure assess risk patient stable coronary artery disease eu diabete care accu chek compact plus blood glucose monitor builtin lance device test strip drum asiapacific japan molecular diagnostic cobas ampliprepcobas taqman hcv test fully automate realtime pcr test monitor hepatitis c viralload cobas taqman hbv test automate realtime pcr test monitor hepatitis b viral load cobas taqscreen mpx test detect multiple viral pathogen hiv group hiv hepatitis b hepatitis c inasingle fully automate assay japan cobas taqman tb test automate realtime pcr test tuberculosis eu cobas taqman ct test v nextgeneration automate realtime pcr test chlamydia trachomatis eu cobas ampliprepcobas taqman hiv test v nextgeneration fully automate realtime pcr test monitor hiv viral load eu cobas ampliprepcobas taqman hbv test v nextgeneration fully automate realtime pcr test monitor hbv viral load eu therascreen kras mutation test aid doctor determine patient suitability certain cancer therapy eu applied science titanium series software reagent genome sequencer flx worldwide lightcycler system ii enhance platform realtime pcr detection analysis worldwide nimblegen seqcap array microarray enable preparation target genomic region sample dna sequence worldwide xcelligence system single multiplate version enable noninvasive realtime analysis cellular event worldwide magna pure lc enhance automate system pcr sample preparation worldwide nimblegen cgh hd array generation highdensity highthroughput microarray comparative genomic analysis worldwide tissue diagnostic vantage workflow optimisation instrument integration software anatomical pathology laboratorie benchmark ultra advanced staining system continuous random processing stat capabilitie canada eu new confirm antibodie immunohistochemcial stainingmonitore major cancer canada japan major eu markets wwwglobalreportscommajor product launch schedule business area product professional diagnostic cobas analyser series nextgeneration modular serum work area instrument highvolume laboratory series include clinical chemistry immunoassay analyser offer choice configuration eu select key market cobas b benchtop multiparameter analyser blood gas electrolyte cooximetry metabolite foruse point care worldwide sysmex xti newgeneration automate hematology analyser test capability additional body fluid contractual territory emea cobas academy elearning platform deliver customise user training certification course pointofcare instrument worldwide cobas elabperformance portal online benchmarke laboratory result obtain serum work area analyser worldwide cobas p cobas p automate storage retrieval module barcode primary secondary sample tube worldwide novel elecsys immunoassay plgf placenta growth factor sflt soluble fmslike tyrosine kinase diagnosis preeclampsia eu elecsys il interleukin immunoassay aid management critically ill patient eu highsensitivity elecsys troponin immunoassay diagnosis heart attack cardiac risk stratifi cation eu elecsys troponin assay test cardiacspecific troponin level predict mortality risk patient acute coronary syndrome eu crp gen nextgeneration clinical chemistry reagent inflammation marker creactive protein eu clinical chemistry drug monitoring reagent amphetamine benzodiazepine eu ddimer gen secondgeneration clinical chemistry test exclude deep vein thrombosis pulmonary embolism worldwide diabetes care accuchek mobile integrate lance blood glucose monitor device employ unique strip technology replace singleuse test strip continuous tape test eu accuchek aviva nano accuchek performa nano sleeker version accuchek aviva andaccuchek performa meter offer enhance feature set accuchek aviva nano eu accuchek performa nano eu accuchek active new version exist meter feature extended test memory number failsafe capability eu accuchek combo diabete management system combine insulin pump glucose meter function pump remote control eu molecular diagnostic cobas platform automate dna extraction realtime pcr amplification detection withtest human papillomavirus chlamydia trachomatisneisseria gonorrhoeaeeu mrsa advanced test realtime pcrbase test methicillinresistant stapholococcus aureusus eu therascreen egfr mutation test aid doctor determine patient suitability certain cancer therapy eu cobas taqman mai test automate realtime pcr test mycobacterium avium intracellulareinfection japan amplichip cyp test comprehensive microarraybased detection variation cytochrome p c gene japan apply science new titanium kit software reagent enhance resequencing pcramplifie dna genome sequencer flx worldwide magna pure highthroughput system prepare nucleic acid sample worldwide ms highresolution microarray scanner use nimblegen hd highdensity microarray worldwide tissue diagnostic benchmark ultra advanced staining system continuous random processing stat capabilitie additional european markets latin america australia japan benchmark xt advance stain instrument latin america asiapacific symphony primary stain instrument major eu markets australia vantage workflow optimisation instrument integration software anatomical pathology laboratorie major european market australia immunohistochemistry probe assess status meet egfr oncogene cancer patient launch clinical use eu asiapacific wwwglobalreportscomroche finance report table content roche group finance brief finance brief financial review roche group consolidated financial statement note roche group consolidated financial statement report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement include board executive remuneration disclosure require swiss law appropriation available earning report statutory auditor financial statement wwwglobalreportscom roche finance report roche group finance brief finance brief key result local sale growth operate profit margin sale pharmaceutical diagnostic group change sales mchf mchf chf lc sales research development operating profit operate free cash flow net income free cash flow core ep chf dividend sharein chf december december change chf net cash equity equity ratio definition core ep propose board director lc local currency finance executive committee erich hunziker chief financial officer hubert buck management development peter eisenre tax insurance marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relation carole nuechterlein venture fund erwin schneider accounting control finance brief roche finance report finance brief sale group sale increase local currency billion swiss franc exclude tamiflu pandemic sale decline sharply expect increase local currency pharmaceutical sale increase billion swiss franc local currency exclude tamiflu pandemic sale twice global market growth thank key oncology product bonvivaboniva cellcept oncology sale grow local currency billion swiss franc represent pharmaceutical sale diagnostic sale increase local currency billion swiss franc organic growth acquisition ventana tissue diagnostic business add percentage point operating result operate profit increase local currency billion swiss franc thank strong underlie sale growth continue productivity improvement despite substantially low tamiflu pandemic sale strong increase rd operating profit margin decrease percentage point mainly drive low diagnostic margin follow recent acquisition competition diabete care market increase ofthe pharma margin rd expenditure increase local currency billion swiss franc represent ofgroup sale substantial unfavourable exchange rate impact swiss franc denominate consolidated result july roche offer purchase outstanding share genentech dollar share cash announce reorganisation pharmaceuticals business treasury minimal adverse effect financial crisis conservative investment approach limited exposure equity net financial income reach billion swiss franc reduction billion swiss franc compare primarily low interest income result low liquid fund reduction interest rate redemption maturity billion swiss franc capital market debt financial condition strong financial condition free cash flow billion swiss franc net cash billion swissfranc increase equity ratio follow announcement intent genentech fully private moodys roches aa rating review downgrade standard poor lower roche rating aa aa net income core ep net income billion swiss franc primarily drive strong exchange rate impact core ep constant exchange rate record level shareholder return roche market capitalisation decrease billion swiss franc broadly line european global pharmaceutical sector increase propose dividend swiss franc represent ndconsecutive year dividend growth approve shareholder result increase payout ratio high dividend yield roche share nonvoting equity security base yearend price wwwglobalreportscom roche finance report roche group financial review roche group financial review group operating result sale billion chf operating profit billion chf lc growth sale group continue strong underlying operating performance previous year pharma ceutical division increase operate profit margin growth underlie business compensate expect sharp decline tamiflu pandemic sale plan increase research development diagnostic division impact recent acquisition competition diabete care market result decline operating profit margin strengthen swiss franc currency substantial negative impact group overall operating result translate local currency swiss franc total sale grow local currency swiss franc dollar billion swiss franc pharmaceutical division represent group sale diagnostic division con tribute sale increase underlying business compensate anticipate fall tamiflu pandemic government corporate sale billion swiss franc million swiss franc local currency sale growth exclude tamiflu pandemic sale strength theswiss franc month result approximately billion low sale translate swiss franc demand group oncology drug avastin mabtherarituxan herceptin tarceva xeloda con tinuedto grow strongly additional growth driver pharmaceutical division bonvivaboniva metabolismbone cellcept transplantation diagnostic division main growth area professional diagnostic apply science tissue diagnostic business area grow respective market follow acquisition ventana begin february sale new tissue diagnostic business area million swiss franc contribute percentage point localcurrency sale growth diagnostic division group operating profit increase local currency billion swiss franc operating profit margin decline percentage point margin reduction diagnostic division percentage point pharmaceutical margin increase despite signifi cantly low tamiflu pandemic sale increase investment strong development pipeline half fall margin diagnostic division impact recent acquisition onetime charge amortisation acquire intangible asset investment develop acquire business rest mainly strong competition diabete care market portfolio mix effect average dollar exchange rate swiss franc low comparative period euro lower japanese yen high movement exchange rate significant impact swiss franc growth rate sale operate profit growth rate report inswiss franc percentage point local currency growth respectively natural hedge inthe structure group operation mean group operating margin significantly impact foreign exchange movement pharmaceutical division exceptional item income million swiss franc thesettlement genentech litigation city hope medical center expense million swiss franc initial stage pharmaceutical division reorganisation net impact onthe group divisional result significant group operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale operating profit exceptional item margin sale operate free cash flow margin sale group operating result development result compare pharmaceutical diagnostic corporate group sale increase local currency operate profit exceptional item increase local currency margin percentage point increase operate free cash flow increase local currency margin percentage point increase pharmaceutical operating result pharmaceutical division increase sale local currency swiss franc usdollar billion swiss franc exclude tamiflu pandemic government corporate sale local sale growth outpace global market growth factor operating profit exceptional item billion swiss franc correspond margin increase centage point compare despite significantly low tamiflu pandemic sale increase investment research development marketing cost increase moderately local currency spite continue support grow oncology rheumatoid arthritis portfolio investment broad indication particularly foravastin investment launch actemraroactemra strong expect increase inresearch development expense significantly increase sale continue high investment strong pipeline expand portfolio large number clinical trial information divisional business pipeline business report annual report wwwglobalreportscom roche finance report roche group financial review pharmaceutical division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration operating profit exceptional item margin sale operate free cash flow margin sale sale major growth driver key product therapeutic area oncology inflammation autoimmunetransplantationvirology exclude tamiflu pandemic sale metabolismbone sale thetherapeutic area renal anemia decrease increasingly competitive costsensitive market pharmaceutical division sale therapeutic area sale change therapeutic area mchf sale local currency oncology virology inflammationautoimmunetransplantation metabolismbone renal anemia total exclude tamiflu pandemic government corporate sale pharmaceutical product represent pharmaceutical portfolio grew exclude tamiflu pandemic sale majority product show sale growth local sale growth pharmaceutical division drive seven product avastin mabtherarituxan herceptin bonvivaboniva cellcept tarceva xeloda product represent portfolio generate billion swiss franc additional sale compare despite strong negative currency impact mainly dollar sale tamiflu decline nonrecurre pandemic sale sale decline primarily generic erosion follow patent expiry strong competition certain franchise return chugai group market product injapan sanofiaventis pharmaceutical division sale product sale change product mchf sale local currency franchise mabtherarituxan oncologyiat avastin oncology herceptin oncology cellcept iat neorecormonepogin renal anemia oncology pegasys virology tarceva oncology xeloda oncology bonvivaboniva metabolismbone lucentis ophthalmology tamiflu virology pandemic virology xolair respiratory disease valcytecymevene virology xenical metabolismbone pulmozyme respiratory disease nutropin metabolismbone neutrogin oncology rocephin infectious disease activasetnkase cardiovascular disease madopar nervous system total product product total exclude tamiflu pandemic government corporate sale total product product total inflammationautoimmunetransplantation mabtherarituxan doubledigit sale growth drive increase use oncology indication rheumatoid arthritis europe oncology sale growth increase usage ofmabtherarituxan follow firstline therapy indolent nonhodgkin lymphoma nhl include maintenance use high penetration rate firstline treatment indolent aggressive nhl sustain europe large market france germany italy spain united kingdom increase adoption setting see emerge market adoption rheumatoid arthritis ra continue increase europer world row estimate mil lion swiss franc sale generate ra indication avastin sale increase worldwide compare strong growth region particularly europerow growth drive primarily increase usage metastatic breast cancer follow accelerate approval food drug administration fda february sale growth europe drive primarily increase use medicine metastatic colorectal breast cancer sale europe benefit rollout new indication increase uptake nonsmall cell lung cancer renal cell carcinoma wwwglobalreportscom roche finance report roche group financial review herceptin growth continue drive increase adoption adjuvant early stage herpositive breast cancer roche estimate end product market share adjuvant setting approximately versus year early large european market market penetration setting continue build penetration market flatten early rapid adoption herceptin adjuvant treatment metastatic set adoption rate treatment duration remain stable european market cellcept immunosuppressant cellcept continue record double digit sale growth worldwide drive solid demand europe growth continues drive physicians recognition longterm protective benefit cellcept transplant patient compare moretoxic therapeutic option neorecormonepogin combine sale roche neorecormon chugais epogin epoetin beta market remain highly competitive pricing pressure brand compe titor entry biosimilar version epoetin alfa europe market share neorecormon decrease slightly global sale japan epogin remain market leader decline sale medicine primarily sustained pricing pressure pegasys pegasys maintain clear leadership global pegylate interferon market con tinue gain market share global sale increase billion swiss franc drive strong growth japan growth key emerge market combine solid growth united states pegasys account new prescription hepatitis c tarceva tarceva record strong growth particularly europerow sale region account overall sale sale increase competitive market environment tarceva epidermal growth factor receptor inhibitor prove survival benefit advanced lung pancreatic cancer xeloda xeloda record sustain doubledigit sale growth growth japan partic ularly strong solid increase record europerow sale drive expand indication approve notably stomach cancer advance colorectal cancer uptake breast cancer bonvivaboniva highly competitive market sale bonvivaboniva ibandronic acid treatment postmenopausal osteoporosis increase million swiss franc billion swiss franc compare majority sale come product market share remain robust despite entry generic version competitor product bonviva gain reimbursement status launch european market lucentis sale lucentis treatment neovascular wet agerelate macular degeneration wet amd grew drive primarily increase number lucentis dosage patient new patient share broadly stable offlabel usage unapproved therapy wet amd remain high outside lucentis market novartis tamiflu sale tamiflu decline billion swiss franc versus seasonal sale million swiss franc high pandemic sale decrease billion swiss franc compare stockpile programme government corporation complete seasonal sale tamiflu japan negatively affect mild flu season addition asubstantial decrease pandemic sale japanese government business report information roche pharmaceutical product include rd pipeline end page business report sale region sale exclude tamiflu pandemic government corporate sale continue grow region growth north america local currency compare stagnant market drive product market genentech oncology product lucentis xolair pulmozyme roche pharmaceutical product tamiflu seasonal sale bonvivaboniva cellcept pegasy andxeloda roche pharmaceutical continue gain market share western europe latin america region drive strong sale growth avastin mabtherarituxan herceptin bonvivaboniva tarceva cellcept sale japan increase launch avastin combination therapy pegasys plus copegus tarceva compensate normal biennial price cut japan effective april return group market product sanofiaventis tamiflu sale decrease sharply completion pandemic stockpile order government corporation particularly western europe japan cemai region pharmaceutical division sale region sale change region mchf sale local currency north america western europe cemai japan latin america asiapacific region total central eastern europe middle east africa central asia indian subcontinent exclude tamiflu pandemic government corporate sale operating result royalty operating income increase million swiss franc local currency high royalty income gain disposal product offset million swiss franc low income outlicense agreement fall outlicense income mainly number significant milestone payment orlistat otc right glaxosmithkline million swiss franc thirdparty collaboration agreement genentech million swiss franc relate lucentis approval european union file japan gain product divestment mil lion swiss franc higher include gain million swiss franc second stage disposal product actavis gain million swiss franc disposal product turkey gain million swiss franc meda gain million swiss franc sale product right continuous realignment product portfolio increase royalty income drive genentech royalty operating income percentage sale increase percentage point pharmaceutical division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total wwwglobalreportscom roche finance report roche group financial review cost sale cost remain stable local currency mainly drive decline manufacturing cost good sell period cost manufacturing efficiency favourable product mix effect comparison period include million swiss franc viracept recall cost amorti sation intangible asset decrease local currency intangible asset fully amortise compensate local currency increase collaboration profit sharing agreement local currency increase royalty expense product sale million swiss franc million swiss franc genentech collaboration profitsharing expense partner biogen idec novartis osi increase high sale mabtherarituxan tarceva xolair respectively reach million swiss franc million swiss franc despite impact weak dollar gross profit share glaxosmithkline increase million swiss franc million swiss franc follow increase bonvivaboniva sale royalty expense tamiflu lower pandemic sale offset strong growth royaltybeare product particular cellcept autoimmune tarceva herceptin avastin additionally royalty rate tiere certain sale level percentage sale cost sale decrease pharmaceutical division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement amortisation intangible asset impairment property plant equipment impairment intangible asset total marketing distribution cost increase local currency reach billion swiss franc billion swiss franc significant investment continue leverage rich oncology portfolio rollout additional approve indication particular pantumour position avastin heavy level investment continue bonvivaboniva pegasy additionally preparation launch actemraroactemra rheumatoid arthritis increase offset absence oflast year prelaunch preparation mircera united states marketing distribution cost apercentage sale decrease percentage point research development increase local currency billion swiss franc reflectscontinue investment realise potential strong development portfolio investment include latestage clinical testing promise compound dalcetrapib cetp inhibitor dyslipidemia ocrelizumab autoimmune disorder pertuzumab breast cancer taspoglutide glp analogue type diabete investment numerous programme aim expand use roche lead anticancer medicine additional indication avastin adjuvant colon cancer impairment intangible asset high comparative period research development cost percentage sale compare half pharmaceutical division total spend million swiss franc inlicense pipeline compound technology capitalise intangible asset require ifrs total division spend billion swiss franc internal purchase rd inlicense alliance deal represent sale addition roche pharmaceutical spend million swiss franc acquisition biotechnology company pirame mirus arius pharmaceutical division investment research development change mchf mchf local currency research development expense noncash item amortisation intangible asset impairment intangible asset research development expense exclude noncash item product intangible available use technology intangible research development relate capital expenditure total investment research development general administration overall cost remain stable local currency low legal restructuring expense low implementation cost business harmonisation project include establishment european share services centre budapest spite loss divestment ofmillion swiss franc cenexi business france general administration expense percentage sale decrease pharmaceutical division general administration change mchf mchf local currency administration legal environmental settlement business combination transaction expense gain loss divestment business restructure expense gain loss disposal property plant equipment general item total subdivisional result pharmaceutical subdivisional result operate operate profit profit exceptional exceptional operate operate sale item item free cash flow free cash flow mchf mchf sale mchf sale roche pharmaceutical genentech chugai elimination division pharmaceutical division unrealise internal profit inventory sell subdivision sell toexternal customer balance sheet date eliminate consolidation entry wwwglobalreportscom roche finance report roche group financial review operate operate profit profit exceptional exceptional operate operate sale item item free cash flow free cash flow mchf mchf sale mchf sale roche pharmaceutical genentech chugai elimination division pharmaceutical division unrealise internal profit inventory sell subdivision sell toexternal customer balance sheet date eliminate consolidation entry roche pharmaceutical sale increase local currency despite impact decline tamiflu pandemic government corporate sale exclude local sale growth operate profit margin exceptional item decrease percentage point high investment research development high expense alliance collaboration partner low income outlicense agreement outweigh favourable development cost sale manufacturing efficiency product mix impact inclusion viracept recall cost result royalty expense party million swiss franc million swiss franc royalty expense genentech million swiss franc million swiss franc follow thecontinue success ofthe oncology portfolio outside genentech sale grow local currency operate profit margin exceptional item improve percentage point main driver strong sale growth high royalty operating income party roche pharmaceutical compensate continued heavy investment research development high collaboration profit sharing expense biogen idec chugai sale decrease local currency drive primarily governmental tamiflu pandemic stockpiling exclude tamiflu pandemic sale increase local currency drive successful launch avastin combination therapy pegasys plus copegus tarceva outweigh lower epogin sale decline sale return group market prod uctsto sanofiaventis early product group sale value million swiss franc reduced chugais report sale growth percentage point operating profit decrease local currency drive low sale spite low sale increase support prod uct launch stable high level research development expense operate profit margin slightly low compare june group increase ownership interest chugais outstanding share tender offer additional information pharmaceutical division subdivisional result give note con solidated financial statement information genentech chugai give note exceptional item major legal case follow california supreme court decision april genentech litigation city hope national medical center settle positive net impact operating result million swiss franc additional information give note consolidated financial statement change group organisation july group announce proposal purchase outstanding share genentech reorganisation group pharmaceutical business expense million swiss franc incur commit cost mainly termination cost closure manufacturing operation nutley new jersey research site atpalo alto california additional information give note consolidated financial statement pharmaceutical division total operating result roche pharmaceutical pharmaceutical genentech chugai division mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional item major legal case change group organisation operating profit include unrealised internal profit million swiss franc million swiss franc inventory sell fromone subdivision sell external customer balance sheet date eliminate consolidation entry operate free cash flow subdivision pharmaceutical division continue generate strong cash flow cash gener ate support expansion business investment new production facility intellectual property inlicense deal genentech particular asignificant free cash flow usually equity compensation plan include thepurchase equity maintain roche ownership percentage equivalent million swiss franc million swiss franc considerable fall theprepayment repurchase genen tech end increase cash inflow exercise option genentech employee overall operate free cash flow increase local currency drive improved net work capital management low capital expenditure outflow equity compensation plan percentage sale operate free cash flow pharmaceutical division increase compare pharmaceutical division operate free cash flow roche elimination pharmaceutical pharmaceutical genentech chugai division division mchf mchf mchf mchf mchf operating profit operate profit cash adjustment increasedecrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operating profit operating profit cash adjustment increasedecrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale unrealise internal profit inventory sell subdivision sell ontoexternal customer balance sheet date eliminate consolidation entry operating profit cash adjustment consist elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent adetaile breakdown provide page wwwglobalreportscom roche finance report roche group financial review diagnostic operating result diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar leverage additional sale ventana acquisition strength ene lead market position exist business operate profit decrease inlocal currency billion swiss franc correspond margin decline percentage point half decline acquisition impact include amortisation acquire intan gible asset investment develop acquire business remainder decline strong competition diabete care market portfolio mix effect half division complete acquisition ventana total consideration billion swiss franc information divisional business pipeline business report annual report diagnostic division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale operate free cash flow margin sale sale diagnostic continue grow market increase local currency previous year major driver sale growth professional diagnostic leverage immunodiagnostic apply science particular dna sequence business tissue diagnostic sale advance stain instrument reagent roche diabete care sale decrease mainly result strong competition diabete care market molecular diagnostic sale increase drive sale automate realtime pcr virology blood screen product acquisition ventana complete begin february sale new tissue diagnostic business area million swiss franc month december contribute percentage point local currency sale growth diagnostic division diagnostic division sale business area sale change business area mchf sale local currency professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic na total professional diagnostic roche professional diagnostic continue gain market share sale increase local currency billion swiss franc immunochemistry sale rise local currency billion swiss franc show doubledigit sale growth eighth consecutive year growth fuel strong uptake antihcv assay diagnosis hepatitis c infection launch half outside growth drive continued demand elecsys ntprobnp troponin cardiac test new immunoassay launch early wererolle european market provide growth include test antitsh receptor thyroid marker toxo igg toxoplasmosis vitamin osteoporosis anticcp rheumatoid arthritis anticmv iggigm diagnosis cmv infection brahms procalcitonin sepsis approve quarter strengthen offer large market launch new test roche broad immunoassay menu rollout new market continue drive growth clinical chemistry business grow line market amid continue price erosion mature segment demand cobas analyser series mediumworkload laboratory remain strong additional configuration launch increase competitiveness rollout small cobas instrument small mediumsize laboratory continue thejuly launch cobas c clinical chemistry analyser market outside sale decentralise testing product rise local currency million swiss franc help continue test pointofcare poc coagulation monitoring sale grow doubledigit drive coaguchek xs monitor healthcare professional patient selftesting accutrend plus handheld device capable measure cholesterol glucose triglyceride lactate impor tant indicator cardiac risk available market initial release end poccardiac assay post doubledigit growth fuel continual uptake roche cardiac probnp assay cobas h portable cardiac testing system run test troponin ddimer heart type creatine kinase myoglobin july accuchek inform ii wireless system hospital glucose testing launch outside diabete care roche diabetes care maintain market leadership sale billion swiss franc adecrease local currency primarily impact strong competition market new blood glucose monitoring product accuchek aviva accuchek performa accuchek compact plus compensate decline sale old accuchek advantage old product process phase account diabete care sale accuchek aviva large selling system strong doubledigit growth accuchek compact plus launch theus japan april june respectively global rollout complete system roche insulin delivery business decline strong competition market important new product launch plan support sale accuchek aviva nano accuchek performa nano meter start rollout market quarter meter sleeker discreetly versione target young tester segment accuchek mobile offer complete integration testing lance single device feature unique stripfree technology employ continuous tape test instead singleuse strip rollout commence quarter schedule eu market begin accuchek combo system combine accuchek spirit insulin pump glucose meter remotecontrol bolus calculator capabilitie molecular diagnostic roche molecular diagnostic remain market leader increasingly competitive market sale billion swiss franc overall increase local currency sale virology product large segment grow local currency drive continued demand forthe automate cobas ampliprepcobas taqman capctm platform europe japan asiapacific fda approve automate cobas taqman hbv test fullyautomate hcv test september october respectively combine cobas taqman hiv test launch initial automation virology trio complete blood screening sale increase local currency additional blood centre europe asiapacific latin america convert fully automate cobas platform comprehensive cobas taqscreen mpx multiplex test detect hiv group mo hiv hcv hbv donate blood plasma december fda approve multiplex test use cobas system early september japanese red cross jrc complete transition fully automate cobas system cobas taqscreen mpx multiplex test screen japanese blood supply june roche sign exclusive deal dxs ltd uk distribution therascreen kras mutation test therascreen egfr mutation test test realtime pcr assay ce mark certification conjunction clinically relevant information kras egfr mutation testing aid doctor determine patient suitability certain cancer therapy wwwglobalreportscom roche finance report roche group financial review apply science roche apply science sale grow time life science market rise local currency million swiss franc main growth driver lightcycler system reagent highthroughput realtime pcr ultrafast genome sequencer system dna sequence business area gain significant market share leader instrument placement biochemical industrial reagent show moderate growth market impact byflat government research funding decrease biotech spending microarray system contribute strongly increase demand roche acquire nimblegen august tissue diagnostic roche tissue diagnostic sale total million swiss franc represent salesfrom date acquisition february december contribute percentage point division localcurrency sale growth standalone basis roche tissue diagnostic sale entire year reach million dollar increase local currency significantly exceed estimate market growth rate increase robust instrumentation sale benchmark xt lt immunohistochemistry reagent sale advance staining segment commercial operation outside north america largely integrate roche focus market expansion europe andlatin america significant number distributor relationship replace dedicated roche sale team major new system benchmark ultra vantage launch benchmark ultra automate system simultaneously perform immunohistochemistry situ hybridisation single platform launch unite states canada europe second half year vantage workflow solution launch april complete workflow information management system anatomical pathology lab provide tracking capability streamline integrate lab work information flow great productivity patient safety addition new antibodie cancer diagnostic launch complement portfolio business report information roche diagnostic product business area sale region overall sale continue grow ahead line total market region innorth america increase include percentage point ventana drive theprofessional diagnostic apply science tissue diagnostic business area compensate decline diabete care north american market japan grow significantly market increase strong performance see emerge market europe asiapacific latin america diagnostic division sale region sale change region mchf sale local currency emea north america asiapacific latin america japan region total europe middle east africa operating result royalty operating income income million swiss franc low local curren cie compare include high outlicense income diagnostic division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total cost sale overall increase local currency considerably high sale growth primarily result number impact acquisition division year firstly amortisation product intangible increase local currency partly include month amortisation charge acquisition month ventana secondly manufacture cost good sell period cost include acquisition accounting effect million swiss franc expense relate fairvalue writeup ventanas inventory fully write half finally royalty expense include reversal million swiss francs bioveris royalty accrual exclude acquisition accounting impact underlie manufacturing cost good sell period cost grow local currency primarily drive continued investment instrument meter placement expand market share total cost sale percentage sale increase comparedto diagnostic division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement amortisation product intangible impairment property plant equipment impairment product intangible total marketing distribution increase local currency mainly investment increase market share especially diabetes care competitively fund sequence array business apply science exclude impact newly acquire tissue diagnostic business marketing distribution cost grow local currency marketing distribution percentage ofsale compare research development cost increase local currency reflect investment sequence array business molecular oncology test tissue diagnostic contribute percentage point growth percentage sale research development cost increase diagnostic division investment research development change mchf mchf local currency research development expense noncash item amortisation intangible asset impairment intangible asset research development expense exclude noncash item wwwglobalreportscom roche finance report roche group financial review general administration general administration cost decrease local currency administration growth local currency exclusively acquire tissue diagnostic business half million swiss franc transaction expense relate ventana acquisition restructuring cost low mainly include million swiss franc postacquisition restructuring expense bioveris restructuring cost million swiss franc mainly relate transfer production professional diagnostic united states germany switzerland expense legal environmental settlement significantly low diagnostic division general administration change mchf mchf local currency administration legal environmental settlement business combination transaction expense restructuring expense gain loss disposal property plant equipment general item total operate free cash flow low operating profit main driver decline operate free cash flow high investment property plant equipment particularly instrument placement compensate lower invest ment intangible asset diagnostic division operate free cash flow mchf mchf operating profit operate profit cash adjustment increasedecrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operate profit cash adjustment consist elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent adetaile breakdown provide page corporate operating cost general administration cost high million swiss franc million swissfranc result include million swiss franc cost realignment divisional human resource activity corporate human resource cost pharmaceutical diagnostic divisional result operate free cash flow net outflow million swiss franc net outflow million swiss franc foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth change local currency change chf sale operating profit exceptional item exchange rate swiss franc december average december average usd eur jpy dollar significantly weaken swiss franc year recover final quarter swiss franc strengthen euro economy currency weaken yen particularly fourth quarter result sale growth operat ing profit growth express swiss franc percentage point respectively low local currency sensitivity group sale operating profit exceptional item absolute term movement foreign currency swiss franc show table currency sensitivity operate profit impact change average exchange rate sale exceptional item versus swiss franc mchf mchf dollar euro japanese yen currency nonoperate result nonoperate result change mchf mchf chf operating profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest wwwglobalreportscom roche finance report roche group financial review group treasury operation deliver positive net financial income net income financial asset foreign exchange management exceeding financing cost million swiss franc group effective tax rate decline compare mainly decline local tax rate net income decrease unfavourable exchange rate impact low net financial income partially compensate low effective tax rate net financial income millions chf financing cost financial income net financial income financial income financial income million swiss franc decline compare interest income income debt security million swiss franc low holding lower interest rate weak dollar compare swiss franc contribute low result loss onthesale debt security cause limited investor demand current financial market crisis loss million swiss franc incur fix income security carry fairvaluethrough profitandloss loss million swiss franc incur derivative relate todebt security impairment million swiss franc record debt security net income equity security million swiss franc compare million swiss franc result include impairment million swiss franc equity security fund continue invest aconservative risk profile low exposure equity expect return pension plan asset million swiss franc compare net foreign exchange loss million swiss franc compare loss mil lion swiss franc second half erosion certainemerge market currency cause significant increase correspond hedge expense afullanalysis financial income give note consolidated financial statement financial cost finance cost million swiss franc lower compare reflect redemption debt instrument weak dollar compare swiss franc time cost provision million swiss franc million swiss franc lower reflect settlement ofthe city hope litigation second quarter interest cost pension plan million swiss franc increase compare change discount rate actuarial calculation analysis financing cost give note consolidated financial statement income taxis group effective tax rate decline compare rate main driver sig nificantly low tax rate roche underlie effective tax rate compare reflect low taxable profit certain high tax jurisdiction certain onetime effect notably favourable change tax rate basel effective improvement despite increase pretax profit contribution genentech analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf roche excl genentech chugai genentech chugai group effective tax rate net income earning share net income billion chf core eps chf group net income decrease billion swiss franc total million swiss franc noncontrolle interest million swiss franc attributable genentech noncontrolle interest million swiss franc chugai noncontrolle interest net impact ofexceptional item net income minor impact net income growth rate absolute billion swiss franc dilute eps chf chf change group core decrease dilute eps decrease net income attributable roche shareholder asdescribed core ep exclude exceptional item amortisation impairment intangible asset decrease local currency core ep increase supplementary net income ep information give include calculation core ep reconcile group publish ifrs result cash flow net cash free cash flow billion chf net cash billion chf free cash flow pharmaceutical diagnostic corporate group mchf mchf mchf mchf operating profit operate profit cash adjustment increasedecrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow wwwglobalreportscom roche finance report roche group financial review pharmaceutical diagnostic corporate group mchf mchf mchf mchf operating profit operate profit cash adjustment increasedecrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow free cash flow group strong increase billion swiss franc billion swiss franc increase primarily high operating free cash flow low tax payment factor compensate low cash generation treasury activity high dividend payment operate free cash flow increase mainly significantly low net cash outflow equity compensation plan despite strong currency translation effect underlying business continue good cash generation partly absorb growth net work capital business expand operate profit cash adjustment consist elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent include net impact group equity compensation plan include cash receive employee exercise cash roche purchase equity delivery employee cash genentech stock repurchase programme maintain roche ownership percentage detailed breakdown pro vide page operate free cash flow include cash movement work capital thecash payment capital expenditure property plant equipment intangible asset mainly arise inlicense deal treasury operation show positive cash generation mainly interest income cash flow treasury activity decrease low interest receive drive low fund hold low interest rate weak dollar swiss franc total taxis pay decrease considerably compare include significant final settlement payment previously accrue amount dividend payment increase billion swiss franc compare net cash roche genentech chugai group mchf mchf mchf mchf december cash cash equivalent marketable security longterm debt shortterm debt net cash beginning period free cash flow transaction equity instrument business combination change ownership interest subsidiarie currency translation fair value movement net change net cash roche genentech chugai group mchf mchf mchf mchf december cash cash equivalent marketable security longterm debt shortterm debt net cash end period net cash position group billion swiss franc billion swiss franc free cash flow billion swiss franc primarily finance acquisition ventana billion swiss franc increase ownership chugai billion swiss franc release previously restrict cash relate city hope litigation genentech increase net cash billion swiss franc offset billion swiss franc pay city hope include operate free cash flow group repay debt billion swiss franc mainly rodeo bond eurodenominate european medium term note reduce debt liquid asset impact net cash balance sheet balance sheet billion chf liability asset net asset equity condense balance sheet december december mchf mchf change property plant equipment goodwill intangible asset noncurrent asset cash marketable security current asset total asset debt current noncurrent noncurrent liability current liability total liability total net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity consolidated balance sheet give consolidated financial statement wwwglobalreportscom roche finance report roche group financial review noncurrent asset property plant equipment increase capital expenditure new production facility genentech diagnostic division chugai partly offset exchange rate impact primarily dollar euro low december compare december goodwill intangible asset increase billion swiss franc mainly ventana pirame mirus arius acquisition inlicense transaction current asset current asset inventory account receivable slightly high local currency significant decrease cash marketable security show net cash debt reduction debt billion swiss franc billion swiss franc relate redemption maturity rodeo swiss franc bond billion swiss franc redemption maturity eurodenominate european medium term note remain decrease exchange rate impact noncurrent current liability overall balance stable increase billion swiss franc pension obligation largely offset reduction billion swiss franc legal provision follow settlement notably genentech city hope litigation total net assetsequity significant movement equity net income billion swiss franc dividend payment billion swiss franc currency translation loss billion swiss franc impact change ownership interest ventana chugai billion swiss franc total impact actuarial loss postemployment plan billion swiss franc net tax strong financial condition group remain solidly finance equity include noncontrolle interest represent total asset total asset finance longterm pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribu tion separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise fund asset management group vari ous define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource funding status define benefit pension postemployment benefit plan mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation funding status overall group define benefit plan continue adequately fund despite financial turbulence funding status compare begin year main movement come reduction fair value plan asset follow decline global financial market expense record income statement total pension expense relate group define benefit plan million swiss franc compare million swiss franc decrease mainly change discount rate adopt end base revise actuarial assumption end total pension expense expect increase compare lower expect return plan asset detail group pension postemployment benefit give note consolidated financial statement roche security roche security perform broadly line msci europe pharmaceutical index global pharmaceutical sector share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation billion chf roche rank number peer group healthcare companiesas list term total shareholder return tsr ie share price growth plus dividend measure swiss franc actual exchange rate yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare aweighte average return peer group actual exchange rate peer group abbott laboratories amgen astella astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis scheringplough takeda wyeth total shareholder return development dec march june sept dec roche share roche gs peer set index wwwglobalreportscom roche finance report roche group financial review propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting ndconsecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base price year end dividend yield roche share yield nonvoting equity security information roche security give page finance report information share nonvoting equity security chf chf change basic eps dilute eps core eps equity attributable roche shareholder share dividend share detail refer note consolidated financial statement ofthe finance report financial risk group manage financial asset liability conservative way treasury activity service group business requirement materially affect group risk profile asset allocation surplus liquid fund hold cash invest highquality investment grade fix income security majority holding liquid short term instrument maturity ofupto month longerterm holding roche experience wide credit spread reduce liquidity cause current financial market situation quarter roche sell almostall remain equity position classify marketable security share decline onepercent december total liquid fund addition group own equity security classify financial longterm asset note consolidated financial statement venture capital position connection group strategic alliance effort position total billion swiss franc december billion swiss franc cash marketable security mchf total mchf total cash cash equivalent money market instrument bond debenture investment share total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group despite significant market difficulty rate profile group billion swiss franc fix income marketable security remain strong invest aaaa range counterparty profile group billion swiss franc tradereceivable remain diversified type customer region wholesaler concentration market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change foreign exchange rate interest rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate apreset probability result movement market price var datum table indicate theloss level period month probability exceed actual future gainsand loss associate treasury activity differ materially var analyse performeddue inherent limitation associate predict timing change tointer rate foreign currency exchange rate equity investment price particularly period highmarket volatility furthermore var number include credit risk component market risk financial instrument december december mchf mchf var foreign exchange component var interest rate component var price component diversification var total december total var financial asset liabilitie million swiss franc december million swiss franc foreign exchange var increase come mainly hedge nonus dollar cash flow future royalty income year genentech thelower contribution interest rate component cause age fixedterm liability price risk arise mainly movement price equity security decrease price component significantly reduce equity security holding december group hold equity security market value billion swiss franc december billion swiss franc number include holding biotechnology company acquire contextof licensing transaction scientific collaboration low holding equity security result ina low var price risk information financial risk management financial risk var methodology include innote consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report con solidate result group change accounting policy respect new andrevise international financial reporting standard interpretation group implement therevise version ifrs business combination ias consolidated separate financial statement main impact result transaction cost business combination expense instead include acquisition price group alsoimplemente ifric interpretation relate ias employee benefit result anincrease pension asset record group balance sheet correspond increase inthegroup equity wwwglobalreportscom roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit exceptional item major legal case change group organisation operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf reference number indicate corresponding note consolidated financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf wwwglobalreportscom roche finance report roche group roche group consolidate financial statement roche group consolidate balance sheet million chf december december noncurrent asset property plant equipment goodwill intangible asset associate financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity disclose note postemployment benefit asset defer tax liability equity restatedin december balance sheet follow adoption ifric interpretation areconciliation previously publish balance sheet provide note roche group consolidate cash flow statement million chf year end december cash flow operating activity cash generate operation increase decrease work capital payment define benefit postemployment plan utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product business combination divestment subsidiarie interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue longterm debt instrument repayment redemption longterm debt instrument increase decrease longterm debt increase decrease shortterm borrowing transaction equity instrument change ownership interest subsidiary chugai ventana interest dividend pay exercise equitysettle equity compensation plan genentech chugai share repurchase finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december wwwglobalreportscom roche finance report roche group roche group consolidate financial statement roche group consolidate statement recognise income expense million chf year end december availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item currency translation foreign operation exchange difference accumulate difference transfer income statement divestment define benefit postemployment plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity net income recognise directly equity net income recognise income statement total recognise income expense attributable roche shareholder noncontrolle interest total effect change accounting policy attributable roche shareholder noncontrolle interest total disclose note entry define benefit postemployment plan restate statement recognise income expense follow adoption ifric interpretation reconciliation previously publish statement ofrecognise income expense provide note roche group consolidate statement change equity millions chf roche noncontrolle shareholder interest total year end december january previously publish change accounting policy january restate net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change noncontrolle interest december year end december january net income recognise directly equity net income recognise income statement total recognise income expense ventana acquisition dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase change ownership interest subsidiary chugai ventana change noncontrolle interest december disclose note equity january entry define benefit postemployment plan restate inthestatement recognise income expense follow adoption ifric interpretation reconciliation tothe previously publish statement recognise income expense provide note wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain itemsincluding derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder march preparation consolidate financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year inwhich circumstance change change accounting policy arise application new revise standard interpreta tion apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result ofthe comparative period opening balance period restate new accounting policy apply insome case transitional requirement particular standard interpretation specify change apply prospectively prospective application require new accounting policy onlybe apply result current period comparative period isnot restate addition comparative reclassify extend previously report result account anypresentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control isdefine power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right currently exercisable potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include thedate control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account asequity transaction occur control obtain result alossof control reference number indicate corresponding note consolidated financial statement investment associate account equity method company group exercise power exercise significant influence control normally evidence group own voting right currently exercisable potential voting right company balance transaction associate result unrealised income areeliminate extent group interest associate interest joint venture report linebyline proportionate consolidation method segment report determination group operate segment base organisation unit infor mationis report group management group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product anddiagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party pharmaceutical division sub division roche pharmaceutical genentech chugai subdivision separate management reporting structure pharmaceutical division consider separately reportable operat ing segment certain headquarter activity report corporate consist ofcorporate headquarters include corporate executive committee corporate communication corporate human resource corporate finance include treasury taxis pension fund management corporate legal corporate safety environmental service transfer price operate segment set arm length basis operate asset liabi litiesconsist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge orarise monetary item substance form group net investment foreign entity insuch case gain loss defer equity consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity disposal foreign entity identify cumulative currency translation difference equity relate foreign entity recognise income gain loss divestment revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risksand reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record accrue liability provision deduction account receiv able estimate base analyse exist contractual legislatively mandate obligation historical trend group experience revenue record earn service wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead goodssold service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation andthe achievement normal production capacity expense incur research development addition internal research development activity group party inlicense similar arrangement alliance partner group acquire inprocess research develop ment asset business combination purchase specific asset internal research cost charge income incur internal development cost capitalise asintangible asset identifiable asset complete generate probable future economic benefit cost asset measure reliably group currently internal development cost qualify capitalisation intangible asset internal development cost charge income incur criterion recognition asset meet inprocess research development asset acquire inlicense arrangement business combination separate purchase capitalise intangible asset describe available use intangible asset amortise straightline basis period expect benefit review impairment reporting date license milestone upfront receipt payment royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive party upfront milestone similar payment relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period develop ment collaboration manufacturing obligation payment group company party associate item capitalise intangible asset accounting reporting transaction roche genentech chugai group consolidated financial statement transaction balance consolidate subsidiary genentech chugai roche group subsidiary eliminate consolidation genentech chugai consider separately reportable operating segment purpose group operating segment disclosure note additional information relate genentech chugai result give note respectively profit product sale roche pharmaceutical genentech chugai operating segment arerecorde segment result operating segment make sale unrealise internal profit inventory sell operating segment beensold external customer balance sheet date eliminate consolidation entry atapharmaceutical division level additionally result operating segment include income receive operating segment respect royalty license milestone upfront payment transfer respect research collaboration recognise income segment result operating segment receive income consistently accounting policy apply thirdparty transaction set financial statement corresponding expense record operating segment eliminate atapharmaceutical division level employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering theservice employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corpo rate bond country concern past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate leveland settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly equity pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value ofany future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity equity compensation plan certain employee group participate equity compensation plan include separate plan genentech chugai fair value equity compensation award grant employee estimate atthe grant date record expense vest period expense charge appro priate income statement head operating result equitysettle plan increase equity isrecorde expense subsequent cash flow exercise vested award record aschange equity cashsettle plan liability record measure fair value balance sheet date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction include costsdirectly attributable bring asset location condition necessary capable ofoperating manner intended management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obliga tion net finance charge report debt asset acquire finance lease depreciate inaccordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate short ofthe lease term useful life interest element lease payment charge income overthe lease term base effective interest rate method lease substantially risk andrewards ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor primarily occur diagnostic division asset subject finance lease initially report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease subsequently recognise earn income term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account purchase method accounting cost acquisition consideration give exchange control identifiable asset liability contingent liability acquire company consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group contingent con sideration arrangement include cost acquisition fair value directly attributable transaction cost expense current period report general administration expense acquire net asset identifiable asset liability contingent liability initially recognise fair value group acquire ownership acquire company noncontrolle interest record proportion fair value acquire net asset attributable noncontrolle interest goodwill record surplus cost acquisition group interest fair value acquire net asset goodwill fair value adjustment record asset liabil itie acquire company functional currency company goodwill amortise assess possible impairment balance sheet date additionally test annually impairment goodwill arise investment associate surplus cost investment thegroup share fair value net identifiable asset goodwill record investment associate change ownership interest subsidiary account equity transaction occur control obtain result loss control intangible asset purchase patent licence trademark intangible asset initially record cost theseasset acquire business combination fair value allocate theacquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally overa fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy impairment goodwill goodwill assess possible impairment balance sheet date additionally test annually impairment goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use isless carry value carry value goodwill reduce recoverable reduction report income statement impairment loss methodology impairment testing describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base uponthe normal capacity production facility cost determine weighted average method netrealisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record difference carry value recoverable objective evidence group able collect amount trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition cash flow statement wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement provision provision recognise legal constructive obligation incur probably leadto outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available valuation technique typically derivative financial instrument fair value financial asset liability balance sheet date materially different report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify fairvalue throughprofitorloss availableforsale heldtomaturity loan receivables fairvaluethrough profitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethroughprofitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset aresecuritie fix maturity group intent ability hold maturity loan receivables financial asset create group acquire issuer primary market theyare nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale financial asset initially record fair value include transaction cost asset fairvaluethroughprofitorloss exclude transaction cost purchase sale recognise onthe settlement date fairvaluethroughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldto maturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose thecumulative gain loss previously recognise equity include financial income current period loan receivables subsequently carry amortise cost effective interestrate method financial asset individually assess possible impairment balance sheet date impair ment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity security market value original cost net previous impairment consider impair availableforsale equity security market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment arealso sustained sixmonth period consider objective evidence ofimpairment movement fair value record equity objective evidence impair ment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate usingestimated future cash flow discount original effective interest rate availableforsale financialasset impairment charge currently carry equity difference original cost net previous impairment fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly equity financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer interest trans ferre financial asset create retain group recognise separate asset liability derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedging instrument discuss hedge policy change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract iscarrie amortise cost hedging purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time future cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition documenta tion probability occurrence cash flow hedge hedge effectiveness reliability measurement ifthese condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item isrecorde previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion report infinancial income hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial asset liability thecumulative change fair value hedge instrument record equity include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument recordedin equity include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair valuethe portion change fair value effective hedge include equity remain ing ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrumentthat record equity reclassify income wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement debt instrument debt instrument initially record cost proceed receive net transaction cost sub sequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise aspart financing cost effective interest rate method certain debt instrument designate fairvaluethroughprofitorloss result relevant information eliminate significantly reduce measurement recognition inconsistency debt instrument report fair value base quote price active market movement fair value report financial income debt instrument designate fairvaluethroughprofitorloss disclose note group derecognise financial liability contractual obligation discharge cancel expired taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income suchasproperty capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning willbe remit foreseeable future deferred income tax asset liability recognise temporary difference tax basis asset liability carry value financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy sametaxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction groupoperate discontinue business noncurrent asset hold sale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion tobe classify hold sale early disposal group group assets dispose group single transaction liability directly associate asset transfer transaction asset liability disposal group reclassify held sale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification hold sale measurement asset liability disposal group update accordance applicable accounting policy initial classification heldforsale disposal group recognise low carrying value fair value cost sell impairment loss initial classification hold sale include income statement equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet potential obligation employee arise respect certain group equity compensation plan management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated finan cial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement consolidation subsidiary associate group periodically undertake transaction involve obtain right control significantly influence operation company tran action include acquisition equity company purchase certain asset assumption certain liability contingent liability company enter alliance agreement company include transaction involve special purpose entity similar vehicle case management make assessment group right tocontrol significantly influence company operation base assessment company consolidated subsidiary associate company make assessment management consider underlie economic substance transaction contractual term business combination group acquire control business cost acquisition hasto allocate asset liability contingent liability acquire business residual record goodwill process involve management make assessment fair value item management judgement particularly involve recognition measurement follow item intellectual property include patent licence trademark similar right currently market product right scientific knowledge associate project currently inresearch development phase contingency legal environmental matter contingent consideration arrangement recoverability accumulate tax loss previously incur acquire company case management make assessment base underlying economic substance item concern contractual term order fairly present item lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider bean operate lease finance lease make assessment management look substance ofthe lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management tomake estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base onhistorical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base orasa result new information experience change recognise period whichtheestimate revise key assumption future key source estimation uncertainty significant risk ofcause material adjustment carry value asset liability month describe sale allowance group provision accrual expect sale return chargeback andother rebate include medicaid united states similar rebate country atdecember total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total provision accrual item adequate base currently available information deduction base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently level sale recognise income statement future period property plant equipment intangible asset include goodwill group property plantand equipment carry value million swiss franc disclose note goodwill hasa carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan useof building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result inshortene useful life impairment change discount rate lead impairment pension postemployment benefit group employee participate post employment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset orliabilitie recognise balance sheet future period legal provision group company party legal proceeding include claim arise trade significant matter describe note legal provision december total million swiss franc additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site themethod extent remediation percentage waste material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure change arise impact provision recognise balance sheet future period income taxis december net liability current income taxis million swiss franc net asset defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis ofthese estimate base interpretation exist tax law regulation management believe theestimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy group early adopt ifrs operating segment ias revised borrowing cost require implement january late group early adopt revise version ifrs business combination ias consolidated separate financial state ment publish early require implement january atthe late group implement amendment ias financial instrument recognition andmeasurement ifrs financial instrument disclosure publish october relate reclassification financial asset group adopt ifric interpretation relate toias employee benefit group currently assess potential impact new revise standard interpre tation effective january group early adopt include revision ias presentation financial statement revision ifrs share base payment group anticipate material impact group overall result financial position ifrs revise business combination matter revise standard require directly attributable transaction cost expense current period include inthe cost acquisition previously revise standard require contingent consideration arrange ment include acquisition accounting fair value expand disclosure requirement business combination group apply revise standard prospectively business combination january directly attributable transaction cost total million swiss franc expense include cost acquisition previous accounting policy business combination prior period restate new accounting policy apply group expense additional million swiss franc directly attributable transaction cost year goodwill reduced change negative impact swiss franc earning share nonvoting equity security basic diluted negative impact swiss franc revise standard apply retrospectively ia revise consolidated separate financial statement matter revise standard require change ownership interest subsidiary account equity transaction occur control obtain result loss control additionally revise standard renames minority interest noncontrolle interest group apply revise standard retrospectively transaction require restatement wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement ias financial instrument recognition measurement ifrs financial instrument disclosure amendment relate reclassification financial asset apply prospectively group july application amendment significant impactonthe group result ifric interpretation ias employee benefit interpretation add exist require ment ias interaction limit recognition asset define benefit postemployment plan minimum funding requirement plan group plan dohave minimum funding requirement application interpretation result increase theasset record group balance sheet correspond increase group equity thegroup apply revise standard retrospectively result impact million swiss franc equity january impact previously publish december balance sheet statement recognise income expense year end show table application interpretation impact net income earning share restate balance sheet select item december millions chf originally application group publish ifric restate postemployment benefit asset defer tax liability capital reserve attributable roche shareholder restate statement recognise income expense year end december millions chf originally application group publish ifric restate availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation define benefit postemployment plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity net income recognise directly equity net income recognise income statement total recognise income expense attributable roche shareholder noncontrolle interest total operating segment information divisional information millions chf pharmaceutical diagnostic division division corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit exceptional item major legal case change group organisation operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement pharmaceutical subdivisional information millions chf roche pharmaceutical pharmaceutical genentech chugai division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination revenue division total segment result operate profit exceptional item elimination profit division subtotal major legal case change group organisation operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense net operating asset millions chf asset liability net asset roche pharmaceutical genentech chugai elimination division pharmaceutical division diagnostic division corporate total operating nonoperating group information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members eu december major customer national wholesale distributor amerisourcebergen corp represent approximately billion swissfranc billion swiss franc group revenue revenues genentech operating segment residual roche pharmaceutical diagnostic segment thegroup report substantial revenue national wholesale distributor cardinal health inc mckesson corp total customer represent approximately quarter group revenue majority genentech genentech effective september roche group acquire majority interest approximately genentech inc biotechnology company united states june group exercise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock reduce group majority interest group ownership genentech decrease conversion redemption ofthelyon iv dollar exchangeable note december group interest genentech common stock genentech publicly trade list new york stock exchange symbol dna genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission sec roche proposal fully purchase genentech july group announce proposal purchase outstanding share genentech common stock own roche price usd cash share equivalent total cash payment approximately billion dollar roche proposal july genentech announce special committee board director compose independent director thespecial committee form review evaluate special committee discretion negotiate recommend recommend acceptance roche proposal august genentech announce special committee support proposal impact roche proposal result describe note roche relationship genentech genentech enter certain agreement roche discuss affiliation arrangement result june redemption genentechs special common stock subsequent public offering genentech amend certificate incorporation bylaw entered amend certain affiliation arrangement roche matter cover thefollowing area roche right shareholder roche right nominate member genentechs board director certain limitation roche ability buy sell genentech common stock process roche effect merger genentech roche approval director designate roche genentech seek significant business acquisition divestment approval director designate roche genentech seek issue repurchase redeem capital stock genentech issue additional share common stock connection equity compensation plan andmay issue additional share purpose affect roche percentage ownership interest theaffiliation agreement roche genentech provide matter genentech establish stock repurchase programme maintain roche percentage ownership interest genentech licensing agreement july roche genentech agreed amend restate licensing andmarketing agreement grant roche option license use sell genentech product nonusmarket license marketing agreement subsequently amend delete add certaingenentech product roche commercialisation marketing right canada addition rocheand genentech july licensing marketing agreement relate antiher antibodie herceptin pertuzumab provide roche exclusive marketing right outside depend specific circumstance term agreement result payment anarmslength basis roche genentech follow matter fee extend roche option license product partial reimbursement genentech previously incur development cost roche exercise option license product milestone similar payment dependent achievement agree objective performance target royalty roche aggregate sale product manufacture agreement genentech agree general manufacture supply roche itsclinical requirement cost commercial requirement cost plus basis roche right tomanufacture genentech product certain circumstance july roche genentech sign new product supply agreement umbrella manufacturing supply agreement umbrella agreement supersede exist product supply agreement agreement roche agree topurchase specify amount herceptin avastin perpetual basis partymay order collaboration product include herceptin avastin wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement theshortterm supply agreement shortterm agreement supplement term umbrella agreement agreement roche agree purchase specify amount herceptin avastin mabtherarituxan research collaboration agreement april roche genentech enter research collabo ration agreement outline process party agree conduct share cost jointresearch certain molecule agreement outline development commercial isation effort coordinate respect select molecule include financial provision anumber ofdifferent development commercialisation scenario undertake party tax sharing agreement roche genentech tax sharing agreement relate state andlocal tax return consolidate combine genentech calculate tax liability orrefund group state local jurisdiction genentech standalone entity difference ifrs gaap certain consolidation entry difference requirement international financial reporting stan dard ifrs gaap difference genentech standalone financial result aus gaap basis financial result genentech consolidate roche group accordance ifrs reconciliation genentech result usd chf usd chf million million million million operating income gaap basis redemption tanox cost equity compensation plan expense gaap basis tanox acquisition account gaap basis special litigation item roche proposal cost operate income nonus gaap basis add deduct difference consolidation entry add redemption tanox cost equity compensation plan expense ifrs basis capitalise inprocess research development change group organisation reclassification difference consolidation entry operating profit exceptional item ifrs basis add deduct exceptional item major legal case change group organisation segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income financing cost consolidation entry income taxis net income ifrs basis noncontrolle interest calculation noncontrolle interest percentage average year income applicable noncontrolle interest ifrs basis translate usd chf usd chf effective january group implement ifrs sharebase payment ifrs financial state ment matter standard require fair value equity compensation plan award employee estimate grant date record expense vest period expense charge appropriate income statement head standard require retro spective application certain transitional requirement pretax expense million usdollar million swiss franc relate plan genentech record million usdollar million swiss franc effective january genentech implement statement financial accounting standard r sharebase payment fas r gaap financial statement matter require company report gaap recognise com pensation expense plan different date application measurement requirement transitional arrangement fas r ifrs expense record genentech usgaapfinancial statement equity compensation plan expense record inthe roche group ifrs financial statement plan group implement ias revise intangible asset ifrs financial statement amongstother matter revise standard typically result intangible asset recognise frominlicensing arrangement similar research development alliance genentech gaap financial statement expenditure usually record research development expense difference ifrs gaap relatively minor impact genentech share repurchase april genentechs board director approve extension exist stock repurchase programme authorise genentech repurchase million share genentech common stock foratotal billion dollar june programme inception genentech repurchase approximately million share total approximately billion dollar net cash outflow repurchase genentech common stock million dollar million swiss franc million dollar million swiss franc include million dollar prepay share repurchase program manufacturing agreement lonza effective december genentech sell whollyowne subsidiary genentech espaa include themanufacture facility porrio spain lonza group ltd lonza million dollar ofthis agreement genentech enter shortterm supply contract lonza production ofavastin portion production capacity porrio facility time genentech enter supply agreement manufacture certain genentech product lonzas facility construction singapore currently expect receive food drug administration fda licensure genentech commit fund precommissione production qualification cost atthis facility fda licensure genentech commit purchase product successfully manufacture facility period year commission facility estimate totalcost pre postcommissione commitment approximately million dollar genentech receive exclusive option purchase lonza singapore facility period year fda licensure purchase price million usdollar regardless ofwhether purchase option exercise genentech oblige amilestone payment ofmillion dollar certain performance milestone meet facility construct foraccounte purpose nature supply agreement genentech involvement construction building genentech consider owner asset theconstruction period fund construct building shell infrastructure cost pay lonza wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement genentech enter loan agreement lonza advance million dollar lonza construction singapore facility december total million dollar advance million dollar genentech exercise option purchase facility outstanding advance offset purchase price genentech exercise purchase option advance offset supply purchase december construction progress total million swiss franc million swiss franc capitalise net financing obligation total million swiss franc million swiss franc record leasing arrangement december genentech enter master lease agreement slough ssf llc subsequently acquire health care property hcp development property adjacent genentechs south san francisco site development include total building subject separate agreement contemplate master lease agreement hcp developer construct building shell building genentech finish interior building labora tory office space applicable construction building complete point lease term building deem begin construction final building com plete lease term expire year occupation final building genentech fiveyear renewal option building option purchase building different date genentech right refusal respect build ortheentire development hcp consider sell development december base status development date total carrying value property plant equipment agreement million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc estimate total future minimum lease payment anticipate entire master lease agreement show estimate total future minimum lease payment hcp lease millions chf total minimum principal ground lease interest lease payment year year year total matter detail genentech matter give follow note acquisition tanox note change group organisation note genentechs equity compensation plan note genentech legal case note genentech senior note commercial paper program note chugai effective october roche group chugai complete alliance create lead research drive japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche andchugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guaranteeroche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai hasexclusive right market roche pharmaceutical product japan chugai right refusalon development marketing japan development compound advanced roche rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result inpayment armslength basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product tomeet party clinical andor commercial requirement armslength basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnology base drug discovery difference ifrs jgaap certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone financial result onajgaap basis financial result chugai consolidated roche group accordance withifrs acquisition roche interest chugai treat business combination ifrs forjgaap alliance treat merger chugai nippon roche jgaap result chugai include goodwill fair value adjustment record roche result quantify table acquisition accounting include roche fair value adjustment base applicable ifrs time impact net income need add noncontrolle interest calculation roche ifrs result wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement roche ifrs result depreciation property plant equipment calculate straightline method chugais jgaap result reduce balance method additionally certain income andexpense notably restructure cost require jgaap report extraordinary item inchugais jgaap result extraordinary item report operate profit line rochesifrs result item normally include operating profit treat extraordinary orexceptional item difference ifrs jgaap havearelatively minor impact reconciliation chugai result jpy chf jpy chf billion million billion million operate profit jgaap basis depreciation basis difference classification extraordinary item difference consolidation entry operate profit acquisition accounting impact ifrs basis depreciation property plant equipment amortisation intangible asset arise business combination operating profit ifrs basis add deduct corporate nonoperating item ifrs basis financial income financing cost income taxis net income ifrs basis noncontrolle interest calculation add acquisition accounting impact net income net income exclude acquisition accounting noncontrolle interest percentage average year income applicable noncontrolle interest ifrs basis translate jpy chf chf dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item tender offer chugai share group announce tender offer acquire additional common share chugai increase group ownership chugais issue share tender offer fully subscribe offer price japanese yen share june group acquire million common share chugai cash consideration billion japanese yen million swiss franc take account share previously repurchase chugai retire thegroup ownership chugais outstanding share increase total cash outflow mil lion swiss franc include directly attributable cost million swiss franc record equity change ownership interest subsidiary chugai share repurchase share repurchase chugai repurchase million common sharesfor total consideration billion japanese yen million swiss franc result group ownership chugai increase matter detail chugais equity compensation plan give note detail series chugai pharmaceutical unsecured convertible bond give note financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity security derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security gain loss debt security derivative net net gain loss financial asset fairvaluethroughprofitorloss writedown impairment debt security net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation discount debt instrument gain loss debt derivative net net gain loss financial liability fairvaluethroughprofitorloss time cost provision interest cost define benefit plan total financing cost wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income net gain loss financial liability fairvaluethroughprofitorloss includes change fair value attributable change liabilitie credit risk component calculate compare difference present value future cash flow bond discount swap yield curve base libor market price bond widen credit spread relative swap yield curve change fair value attributable change liabilitie credit risk component gain million swiss franc gain million swiss franc cumulative change fair value attributable change credit risk issuance instrument gain million swiss franc gain million swiss franc interest expense onliabilitie fairvaluethroughprofitorloss million swiss franc million swiss franc interest income include interest financial asset hold fairvaluethroughprofitandloss million swiss franc million swiss franc income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total income expense group operate internationally subject income taxis different tax jurisdiction thegroup calculate average expect tax rate weight average tax rate tax juris diction group operate rate change year year change mix group taxable income change local tax rate average expect rate decrease compare low taxable profit certain high tax jurisdiction certain onetime effect notably favourable change tax rate basel effective group effective tax rate canbe reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect utilisation previously unrecognise tax loss nontaxable incomenondeductible expense genentech equity compensation plan difference group effective tax rate exceptional item profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf roche exclude genentech chugai genentech chugai group effective tax rate exceptional item major legal case change group organisation group effective tax rate income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer income taxis asset liability net defer income tax asset liability disclose note postemployment benefit asset defer tax liability equity restate december balance sheet follow adoption ifric interpretation reconciliation previously publish balance sheet provide note defer income tax asset recognise tax loss carry forwards extent realisation oftherelate tax benefit probable group unrecognised tax loss include valuation allowance asfollow unrecognised tax loss expiry millions chf applicable applicable tax rate tax rate year year year total unrecognised tax loss defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable tothe follow item wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement defer income taxis movement recognise net asset liability millions chf property plant equipment temporary intangible asset difference total year end december net defer income tax asset liability january restate bioveris acquisition tanox acquisition business combination charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december year end december net defer income tax asset liability january ventana acquisition business combination charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december business combination acquisition ventana ventana medical systems inc ventana publicly own company base tucson arizona list nasdaq symbol vmsi prior february group own share ventana represent outstanding share ventana effective february group acquire outstanding share ventana obtain control ventana ventana develop manufacture market instrumentreagent system automate slide preparation andstaine clinical histology drug discovery laboratorie ventanas clinical system diagnosis treatment cancer infectious disease drug discovery system pharmaceutical biotechnology company accelerate discovery new drug target evaluate safety new drug compound ventana report diagnostic operating segment acquisition ventana leader fastgrowe histopathology tissuebase diagnostic business segment allow group broaden diagnostic offering complement world leadership bothinvitro diagnostic system oncology therapy purchase consideration million swiss franc cash allocate follow ventana acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment goodwill intangible asset product intangible use product intangible available use inventory defer income taxis cash net asset liability net identifiable asset noncontrolle interest goodwill purchase consideration goodwill represent strategic value group enter tissue diagnostic business area italsorepresent premium pay trade market price obtain control business goodwill recognise expect deductible income tax purpose noncontrolle interest ventana measure proportionate share ventanas identifiable net asset fair value net asset liability include receivables fair value million swiss franc include fair value allowance doubtful trade account receivable million swiss franc finance lease receivables total million swiss franc include total gross contract million swiss franc group recognise gain million swiss franc result measure fair value equity interest ventana hold prior acquisition date gain include financial income directly attributable acquisitionrelated cost million swiss franc incur transaction report general administration expense current period operating result diagnostic operating segment subsequent effective date acquisition february group purchase remain share ventana hold party group interest ventana cash consideration million swiss franc record equity change ownership interest subsidiary acquisition effective group acquire control interest piramed ltd pirame privately own biotechnology company base uk pirame discover develop newmedicines primarily treatment cancer immune inflammatory disorder arthritis asthma pirame lead company discovery highly selective drug inhibit different isoform pik enzyme increasingly recognise key player wide variety disease process pirame report roche pharmaceutical operating segment acquisition strengthen group research development pipeline oncology inflammatory disease purchase consideration million swiss franc consist million swiss franc pay cash million swiss franc contingent consideration arrangement contingent consideration arrangement consist potential milestone payment million dollar commencement phase ii clinical trial piramed oncology programme liability million dollar million swiss franc recognise acquisition date base management good estimate theprobabilityadjuste expect cash outflow arrangement december recognise arrangement unchanged base recent management estimate wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement effective september group acquire control interest arius research inc arius publicly own canadian biotechnology company list tsx symbol ari arius discover develop antibody therapeutic treat cancer disease include proprietary antibody platform rapidly identify select antibodie base functional ability affect disease progress clinical development arius report ofthe roche pharmaceutical operating segment acquisition strengthen group develop mental portfolio initially area oncology inflammatory disease new technique offer potentially broad therapeutic application purchase consideration million swiss franc pay cash effective september group acquire control interest mirus bio corporation mirus privately own biotechnology company base madison wisconsin mirus rename roche madison inc focus discovery development innovative nucleic acid base techno logie include proprietary rnai ribonucleic acid interference delivery platform mirus report roche pharmaceutical operating segment acquisition strengthen group research development pipeline rnai therapeutic provide capability target complex disease cancer respiratory metabolic disorder purchase consideration million swiss franc pay cash minor business combination total purchase consideration million swiss franc combine purchase consideration acquisition allocate show acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use technology intangible use deferred income taxis cash net asset liability net identifiable asset goodwill purchase consideration goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc expect fully collectable directly attributable transaction cost million swiss franc incur transaction arereporte general administration expense current period operating result roche pharmaceutical operating segment acquisition impact result million chf revenue inventory external fair value amortisation customer adjustment intangible asset operating profit net income impact report result pirame arius mirus pharmaceutical division ventana minor business combination diagnostic division group estimate impact result acquisition assume effective january pirame arius mirus pharmaceutical division ventanaa minor business combination diagnostic division group figure exclude directly attributable transaction cost million swiss franc relate acquisition pharmaceutical division million swiss franc relate acquisition diagnostic division correspond tax impact exclude figure exclude inventory fair value adjustment million swiss franc integration cost million swiss franc relate ventana correspond tax impact exclude acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow ventana acquisition total cash consideration pay ventana include subsequent payment million swiss franc purchase remain share ventana hold party group interest ventana report finance cash flow cash flow statement head change ownership interest subsidiary wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement future acquisition group announce number minor business combination expect complete half subject shareholder approval regulatory clearance appropriate total purchase consideration exclude transaction cost estimate approximately million swiss franc cash fund provide group cash hand time closing acquisition bioveris effective june group acquire control interest bioveris corporation bioveris publicly own company list nasdaq symbol biov bioveris healthcare biosecurity company base gaithersburg maryland specialise develop proprietary technology diagnostic bioveris report diagnostic operating segment purchase consideration million swiss franc consist million swiss franc cash million swiss franc directly attributable cost allocate asfollow bioveris acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use deferred income taxis cash net asset liability net identifiable asset goodwill purchase consideration goodwill represent asset recognise separately measure reliably synergy canbe obtain group exist electrochemiluminescence ecl immunochemistry business italso represent premium pay trade market price obtain control business follow acquisition restructuring expense million swiss franc incur report general administration expense operating result diagnostic operating segment tanox effective august genentech acquire control interest tanox inc tanox apublicly own company list nasdaq symbol tnox tanox isabiotechnology company base houston texas specialise discovery development biotherapeutic base monoclonal antibody technology genentech tanox work collaboration novartis develop commercialise xolair purchase consideration million swiss franc consist million swiss franc cash million swiss franc directly attributable cost allocate follow tanox acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use defer income taxis cash marketable security net asset liability net identifiable asset goodwill purchase consideration goodwill represent asset recognise separately measure reliably earlystage research project represent premium pay trade market price obtain control business acquisition effective march group acquire control interest therapeutic human polyclonal inc thp privately own biotechnology company base california germany thp report roche pharmaceutical operating segment purchase considera tion pay million swiss franc cash effective group acquire control interest life sciences majorityowne subsidiary curagen corporation life science develop commercialise novel instrumentation highthroughput dna sequence base branford connecticut life science report aspart diagnostic operating segment purchase consideration pay million swiss franc cash consist million swiss franc cash million swiss franc directly attributable cost effective august group acquire control interest nimblegen systems inc nimblegen privately own company nimblegen develop commercialise high density dna microarray base madison wisconsin nimblegen report diagnostic operating segment purchase consideration million swiss franc cash minor business combination total purchase consideration million swiss franc combine purchase consideration acquisition allocate show acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use technology intangible use deferred income taxis cash net asset liability net identifiable asset goodwill purchase consideration wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement goodwill represent asset recognise separately measure reliably earlystage research project control premium synergy obtain group exist business acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow bioveris tanox acquisition total change group organisation describe note july group announce offer purchase outstanding share ofgenentech follow closing transaction genentech south san francisco site theheadquarter group combine pharmaceutical operation united states july group announce roche pharmaceutical business close manufacturing operation site nutley new jersey commercial operation move genentech theresearch site palo alto california closed research activity transfer nutley genentech current status offer describe note significant cost incur connec tion propose genentech transaction reorganisation describe disclose separately income statement materiality amount order fairly present group result cost restructure programme material anddo funda mentally change group organisation expense current period report general andadministration expense change group organisation millions chf roche pharmaceutical operating segment reorganisation cost total roche pharmaceutical operating segment genentech operating segment genentech employee retention program expense total genentech operating segment total pharmaceutical division total income tax benefit record respect change group organisation million swiss franc note roche pharmaceutical reorganisation cost incur show table independent completion propose genentech transaction mainly relate theclosure palo alto site closure manufacturing nutley site include cost associate reorganisation include transfer research operation palo alto activity roche pharmaceutical reorganisation cost millions chf employeerelate cost termination cost pension postemployment benefit retention plan employee benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment site closure cost total site closure cost reorganisation expense total reorganisation cost genentech employee retention program august genentech announce broadbase employee retention program consist retention plan cover substantially employee company program estimate cost approximately million dollar payable cash implement lieu genentech annual stock option grant timing payment relate program depend outcome roche proposal merger genentech roche oran affiliate roche occur june genentech pay retention bonus time accordance term program cost retention program currently recognise straightline basis period august june merger genentech roche affiliate roche occur june time thepayment recognition expense depend term merger totalcost retention program million swiss franc million swiss franc expense million swiss franc capitalise inventory recognise cost ofsale product manufacture initiation retention program sell genentech grant annual stock option award previous year total value retention pro gram cost expensed year vest period expense approximately million swiss franc accordingly additional incremental cost incur retention plan report change group organisation aredirectly attributable announcement roche proposal genentech employee retention program expense millions chf marketing distribution research development general administration total include operating profit exceptional item change group organisation total genentech employee retention program expense wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan genentech employee retention program termination cost roche pharmaceutical reorganisation employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit charge employee benefit operating result include relevant expenditure line function expect returnon plan asset interest cost define benefit plan include financial income andfinance cost respectively note pension postemployment benefit group objective provide attractive competitive postemployment benefit employee whileat time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan forthe purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund admin istere party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apartfrom regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan ingermany plan unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly equity recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity define benefit plan expense millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement funding group define benefit plan oversee corporate level qualified independ ent actuary carry valuation regular basis major plan annually balance sheet datefor fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan amount recognise balance sheet postemployment benefit predominantly noncurrent report noncurrent asset liability wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement define benefit plan fund status december millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report define benefit plan reimbursement right postemployment benefit asset postemployment benefit liability net recognise asset liability disclose note postemployment benefit asset defer tax liability equity restate december balance sheet follow adoption ifric interpretation reconciliation previously publish balance sheet provide note detailed information plan asset define benefit obligation give define benefit plan fair value plan asset reimbursement right millions chf fair value reim fair value reim plan bursement plan bursement asset right total asset right total january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost business combination divestment subsidiary curtailment settlement december invest share equity instrument bond debenture debt instrument property asset total include fair value plan asset thousand group nonvoting equity security fair value million swiss franc thousand nonvoting equity security total fair value million swiss franc define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost business combination divestment subsidiary curtailment settlement december fund plan unfunded plan actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover andfinancial assumption matter salary benefit level interest rate return investment cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate thegroup actuary use mortality table account historic pattern expect change increase longevity mortality table major scheme germany heubeck table g japan national census life table switzerland bvg united kingdom nonpensioner pac rate year united kingdom pensioner pac rate year united states rp project rate employee turnover disability early retirement base historical behaviour group company financial assumption base market expectation period obligation settle range assumption actuarial valuation significant plan country stable currency interest rate show wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase medical cost trend rate discount rate calculate discount present value define benefit obligation aredetermine reference market yield high quality corporate bond government bond incountrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement iscalculate multiply discount rate define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis adminis tration cost bear plan base longterm market expectation actual formance continually monitor corporate management longterm nature obligation assumption matter return investment necessarily consistent withrecent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference bet ween expect return actual return month period actuarial gainloss record directly equity actual return plan asset loss million swiss franc gain million swiss franc expect rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company medical cost trend rate calculate define benefit obligation current service cost include income statement postemployment medical plan account benefit setout plan term expect future change medical cost group major post employment medical plan employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation funding summary fiveyear summary funding status group define benefit plan show table define benefit plan summary funding status millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation increase decrease funding status arise experience adjustment fair value plan asset define benefit obligation increase decrease funding status arise change actuarial assumption fair value plan asset define benefit obligation cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution benefit pay unfunded plan estimate approximately million swiss franc amount record equity actuarial gain loss recognise statement recognise income expense loss million swiss franc gain million swiss franc total december accumulate loss million swiss franc accumulate gain million swiss franc addition recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit asset recognition record directly equity adjustment increase million swiss franc decrease million swiss franc wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement employee stock option equity compensation benefit group operate equity compensation plan include separate plan genentech chugai effective january group adopt ifrs sharebased payment matter standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge againstthe appropriate income statement heading expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total cash inflow outflow equitysettle cashsettle roche longterm group implement new global longterm incentive programme whichisavailable certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan share option plan roche option plan award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche option plan movement number option outstanding number weight average number weight average option exercise price option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement roche option plan term option outstanding december option outstanding option exercisable number weight average weight average number weight average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total genentech stock option plan genentech stock option plan adopt amend april genentechs shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right employee director consultant genentech incentive stock option stock purchase right grant plan date option grant nontradable equitysettle award tenyear duration vest phase basis year subject continued employment genentech stock option plan movement number option outstanding number weight average number weight average option exercise price option exercise price million usd million usd outstanding january grant forfeit exercise expired outstanding december exercisable genentech stock option plan term option outstanding december option outstanding option exercisable number weight average weight average number weight average outstanding year remain exercise exercisable exercise range exercise price usd millions contractual life price usd million price usd total chugai stock acquisition right chugai adopt stock acquisition right programme theprogramme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price option nontradable equitysettle award tenyear duration vest year chugai stock acquisition right movement number right outstanding weighted average weight average number exercise price number exercise price option jpy option jpy outstanding january grant forfeit exercise expired outstanding december exercisable chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted average weighted average weight average number year remain exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total issue share option issue share option include methodology calculate fair value main input valuation model describe issue share option plan roche genentech stock option plan option plan number option grant thousand million underlying equity roche nonvoting equity security genentech common stock currency swiss franc dollar vest period progressively progressively year year contractual life year year weight average fair value option issue option pricing model binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor expect exit rate volatility roche option determine primarily reference historically observe price lie equity volatility genentech option determine primarily reference imply volatility genentech trade option riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement equity compensation plan roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million programme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date total million share genentech common stock purchase million share result cash inflow million swiss franc million swiss franc year cost plan million swiss franc million swiss franc report relevant expenditure line function roche stocksettle stock appreciation right introduction roche longterm thegroup offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity securi tie grant date exercise date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon seenote roche ssar movement number right outstanding number weight average number weight average right exercise price right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted weight number weight average average number average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total weight average fair value option grant calculate binomial model input model consistent roche option plan award give previously result weight average fair value right chf give total fair value million swiss franc charge vest period year roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager theprogramme establish begin effect year theboard director approve new threeyear cycle roche performance share plan psp operatedure additional cycle psp similar condition approve operate term award set table nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate valuation take account define rank performance structure determine payout psp roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar nontradable cashsettle award exercise vest period year cash payment base market price group american depositary receipt adr point exercise exceed strike price grant price issuance follow implementa tion roche longterm group plan award cashsettle sar award january ratio adr nonvoting equity security genussscheinewas change information restate change roche stock appreciation right millions chf liability december intrinsic value vest right december roche stock appreciation right term right outstanding december right outstanding exercisable number outstanding exercisable weighted average year grant thousand expiry price usd feb feb total fair value december calculate binomial model input model theadr price december usd change exchange ratio january exercise price give table input consistent roche option plan award give previously wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal bioveris acquisition tanox acquisition business combination transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal ventana acquisition business combination divestment subsidiarie transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment impairment charge million swiss franc million swiss franc report cost sale impairment charge million swiss franc zero report change group organisation note borrowing cost total million swiss franc rate million swiss franc arate capitalise property plant equipment leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease payment undiscounte addition genentech leasing arrangement disclose note operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swissfranc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment thelease lease income finance lease recognise term lease base effective interest rate method wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement finance lease future minimum lease payment noncancellable lease millions chf present value future gross investment lease minimum lease payment year year year total unearned finance income na na unguaranteed residual value na na net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straight line basis operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc addition genentech capital commitment respect manufacturing agreement lonza leasing arrangement describe note goodwill goodwill movement carry value asset millions chf january bioveris acquisition tanox acquisition ventana acquisition business combination impairment charge currency translation effect december allocate follow cashgenerating unit pharmaceutical division roche pharmaceutical genentech chugai total pharmaceutical division diagnostic division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic strategic goodwill hold divisional level allocate business area total diagnostic division total group accumulate impairment loss goodwill goodwill arise investment associate classify investment associate note goodwill impairment testing pharmaceutical division division reportable operating segment cashgenerate unit test goodwill genentech chugai recoverable base fair value cost sell determined reference publicly quote share price genentech chugai share goodwill roche pharmaceutical significant comparison group total carrying value goodwill diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cash generating unit goodwill entire division recoverable impairment testing isbase value use cash flow projection base recent business plan approve management assume significant change organisation division include manage ment late estimate sale volume pricing production operating cost reflect past experience project year estimate tissue diagnostic business area project year management believe reflect longterm nature business cash flow projection extend management recent business plan discount rate base rate derive capital asset pricing model datum swiss capital market include swiss federal government tenyear bond swiss market index weight average tax rate calculation management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement intangible asset intangible asset movement carry value asset millions chf product product intangible technology intangible available intangible use use use total january cost accumulate amortisation impairment net book value year end december january bioveris acquisition tanox acquisition business combination addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical genentech chugai diagnostic total group year end december january ventana acquisition business combination addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical genentech chugai diagnostic total group significant intangible asset december millions chf operate net book remain segment value amortisation period product intangible use tanox acquisition genentech year chugai acquisition chugai year corangeboehringer mannheim acquisition diagnostic year igen acquisition diagnostic year ventana acquisition diagnostic year product intangible available use alnylam alliance roche pharmaceutical na ventana acquisition diagnostic na classification amortisation impairment expense millions chf amortisation impairment amortisation impairment cost sale pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful life impairment intangible asset impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment roche pharmaceutical operating segment impairment charge million swiss franc record half million swiss franc record second half relate product intangible available use follow decision terminate development compound alliance partner asset concern amortise fully writtendown charge diagnostic operating segment impairment charge million swiss franc record second half relate product intangible asset use follow theregular updating division business plan technology assessment second half theasset write recoverable million swiss franc base value usecalculation discount rate genentech operating segment impairment charge million swiss franc record second half relate decision terminate development compound alliance partner roche pharmaceutical operating segment impairment charge million swiss franc record half relate decision terminate development compound alliance partner asset concern amortise fully writtendown charge wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase asat december carry value asset pharmaceutical division million swiss franc approximately represent project potential decision point withinthe month certain circumstance lead toimpairment inherent uncertainty research development process asset particularly risk impairment theproject question result commercialise product potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure risk adjust meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group mayarise roche pharmaceutical genentech chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total associate group investment associate account equity method goodwill arise investment associate classify investment associate investments associate millions chf share net income balance sheet value total investment associate group significant investment associate material transaction thegroup associate additional information associate give note financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset longterm employee benefit total longterm asset financial longterm asset hold strategic purpose classify noncurrent available forsale investment mainly equity investment unquote equity investment classify available forsale generally measure cost fair value measure reliably primarily investment private biotechnology company keep group strategic alliance effort carry value equity investment hold cost million swiss franc million swissfranc average effective interest rate heldtomaturity investment loansreceivable comprise loan party term year inventory inventory million chf raw material supply work process finish good intermediate provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc million swiss franc account receivable account receivable million chf trade account receivable note receivable allowance total account receivable wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc net bad debt expense million swiss franc million swiss franc significant concentration trade receivables counterparty credit risk describe note current asset current asset millions chf accrue interest income derivative financial instrument restrict cash total financial current asset prepaid expense total nonfinancial current asset total current asset restrict cash include million swiss franc surety bond post genentech con nection city hope litigation note follow settlement litigation entirety ofthepledge unrestricted cash available use genentech operation thethird quarter marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss heldfortrade investment bond debenture designate fairvaluethroughprofitorloss bond debenture money market instrument time account month investment total financial asset fairvaluethroughprofitorloss availableforsale financial asset share bond debenture money market instrument time account month investment total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarilydenominate dollar euros investment hold strategic purpose classify asnoncurrent note share consist primarily readily saleable equity security bond debenture carry value contract maturity average effective interest rate debt security show bond debenture millions chf average effective average effective contract maturity interest rate interest rate year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate contract tomature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent account payable account payable million chf trade account payable taxis payable dividend payable account payable total account payable wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement accrue current liability accrue liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability derivative financial instrument group use derivative financial instrument risk management trading strategy thisisdiscusse note derivative financial instrument carry fair value method fordetermine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk aremanage use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change infairvalue include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment eign entity meet strict requirement qualify hedge accounting apart describe group hedge fixedterm debt instrument interest rate swap december instrument designate qualify fair value hedge record balance sheet asset fair value million swiss franc asset million swiss franc gain million swiss franc record interest rate swap gain mil lion swiss francs fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument genentech nonus dollar cash flow future royalty income development expense expect year hedge foreign exchange risk genentech enter derivative financial instrument option forward contract genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure genentech enter derivative financial instrument zero cost collar forward contract december instrument designate qualify hedge accounting record asset fair value million swiss franc asset million swiss matter describe genentech annual report quarterly sec filing movement fair value reserve designate cash flow hedge include note provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion noncurrent portion total provision year end december january additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion noncurrent portion total provision expect outflow resource year year year year total provision wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement major legal case income expense major legal case disclose separately income statement mate riality amount order fairly present group result income million swiss franc wasrecorde follow april california supreme court decision city hope litigation consist million dollar release income favourable litigation settlement net amount record respect final settlement negotiation city hope national medical center cost litigation matter material expense current period andreporte general administration expense total income tax expense record respect ofmajor legal case million swiss franc note legal provision legal provision consist number separate legal matter include claim arise trade group company majority cash outflow matter expect occur thenext year dependent development litigation significant provision discount time value money material environmental provision provision environmental matter include separate environmental issue number country nature amount time outflow difficult predict estimate timing cash outflow show table significant provision discount time value money material restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail bythe restructure associate recur activity group timing cash outflow reasonably certain global basis show table significant pro vision discount time value money material employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance areshown table significant provision discount time value money ismaterial provision provision relate sale return provision group company notfit category timing cash outflow nature uncertain good estimate show table provision discount time value money notmaterial matter contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protec tion country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define inthe collaboration agreement group good estimate future commitment payment give note roche pharmaceutical legal case hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action bring federal state court united states personal injury allegedly result use accutane action allege ibd result ofaccutane use action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation united states district court middle district florida tampa division injuly district court grant summary judgment favour hlr lead federal ibd case theplaintiff appeal august ruling affirm united states court appealsforthe eleventh circuit action pende state court new jersey allege ibd consolidated pretrial proceed ing superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar hlr appeal case superior court new jersey appellate division review posttrial option case october jury circuit court escambia county florida return verdict favour plaintiff assess total compensatory damage million dollar subsequently reduce million dollars court company hlr appeal district court appeal state offlorida december group record provision total million dollar million swiss franc respect matter additional trial schedule individual trial result depend ona variety factor include unique particular case trial result todate predictive future trial result group continue defend vigorously remain personal injury case claim genentech legal case june genentech announce los angeles county superior court jury vote award city hope national medical center city hope approximately million dollar compensatory damage base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal october court appeal affirm verdict damage award respect october genentech announce seek review california supreme court discretion case review november genentech file petition review california supreme court february california supreme court grant petition appeal california supreme court hear february april overturned award million dollar punitive damage city hope upheld award million dollar compensatory damage genentech pay million dollar city hope reflect compensatory damage award plus interest thereon date original decision june appeal process interest accrue total damage simple annual rate interest million swiss franc million swiss franc record time cost provision financing cost wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement provision total million dollar december record award result april california supreme court decision provision total million dollar release income favourable litigation settlement million dollar relate original award record exceptional major legal case expense million dollar relate interest accrue charge financing cost intervene period october genentech enter arrangement thirdparty insurance company post surety bond connection judgment arrangement genentech pledge million dollar cash investment secure bond equivalent million swiss franc december record restrict cash current asset annual financial statement quarter court complete certain administrative procedure dismiss case result restriction lift restrict cash investment fund available use genentech operation genentech city hope discussion reach agreement additional royalty amount genentech owe city hope agreement thirdparty product sale settlement thirdparty patent litigation occur judgement additional accrual represent management well estimate final obligation october genentech receive subpoena united states department justice request document relate promotion rituxan genentech cooperate associate investigation counsel genentech discussion government representative status investigation genentech view matter include potential resolution previously investigation civil criminal nature genentech inform august criminal prose cutor handle matter government decline prosecute genentech criminally connection investigation civil matter ongoing outcome matter determined time april medimmune inc medimmune file lawsuit genentech city hope national medical center celltech rd ltd district court central district california los angeles lawsuit relate patent cabilly patent coowne genentech city hope national medical center medimmune company license pay royalty lawsuit include claim violation antitrust patent unfair competition law june genentech announce settle patent litigation withmedimmune term settlement agreement litigation pende district court central district california fully resolve dismiss request file party reexamination cabilly patent july patent trademark office order reexamination patent september patent office issue initial nonfinal office action reject claim patent genentech file response november second reexamination request patent file december party january patent office grant examination request june reexamination combine patent office single reexamination august patent office issue nonfinal office action merge proceeding reject claim cabilly patent base issue raise reexamination request genentech file response october february patent office mail final office action reject thirty claim cabilly patent genentech respond tothe final office action petition continue reexamination patent office grant genentech petition withdraw finality february office action agree treat genentech file response office action february patent office mail final patent office action reject claim cabilly patent genentech file response tothat final patent office action june july patent office mail advisory action reply genentech response confirm rejection claim cabilly patent genentech file notice appeal challenge rejection august genentech opening appeal brief december cabilly patent expire relate method genentech certain antibody antibody fragment cell dna method genentech license cabilly patent company derive significant royalty licence claim cabilly patent remain valid enforceable reexamination appeal process provision record respect litigation outcome mat ter determine time fourth quarter process recognise revenue cabilly patent change estimate accrual basis cash basis result change net royalty decrease approximately million dollar equivalent million swiss franc fourth quarter compare quarter cabilly patent licence contribute operate profit million dollar equivalent million swiss franc million dollar equivalent million swiss franc centocor inc file patent lawsuit genentech city hope district court central district california lawsuit relate cabilly patent seek declara tory judgment patent invalidity unenforceability regard cabilly patent patent non infringement regard certain centocor product centocor file amend complaint september genentech answer complaint september file counterclaim centocor allege centocor product infringe certain genentech patent genentech filedanamendment counterclaims october centocor answer counterclaim november status conference set case february outcome thismatter determine time genentech development decision involve humanise anticd programme collaborator biogen idec inc disagree certain genentech development decision relate humanise anticd product genentech collaboration agreement biogen idec genentech believe permit proceed trial certain humanise anticd anti body biogen idec disagree genentech position dispute issue submit arbitration arbitration biogen idec file motion preliminary injunction summary judgment seek stop genentech proceed certain development activity include plan clinical trial april arbitration panel deny biogen idec motion preliminary injunction biogen idec motion summary judgment resolution arbitration require party agree certain development decision move forward humanise anticd antibody clinical trial possibly clinical trial collaboration product include rituxan case genentech alter cancel plan clinical trial order obtain biogen idec approval party seek monetary damage arbitrator hold hearing matter day september closing argument december hearing formally close january final decision arbitrator expect later july outcome matter determine time june mr ubaldo bao martinez file lawsuit porrio town council genentech espaa sl contentious administrative court number pontevedra spain lawsuit challenge town council decision grant license genentech espaa sl construction operation warehouse biopharmaceutical manufacturing facility porrio spain january administrative court rule favour mr bao claim lawsuit order closing demolition facility subject certain legal proceeding february genentech town council file appeals administrative court decision high court galicia spain addition genentech evaluate legal counsel spain administrative remedy available overcome administrative court rule genentech sell assets genentech espaa sl include porrio facility lonza group ltd lonza december lonza operate facility time term sale genentech retain control defence lawsuit agree indemnify lonza certain contractually define liability specify limit currently estimate approximately million dollar provision record respect litigation outcome matter genentech indemnification obligation lonza determine time wwwglobalreportscom roche finance report roche group note roche group consolidated financial statement june august september genentech name defendant intermune inc chief executive officer w scott harkonen separate classaction complaint file district court northern district california behalf plaintiff allegedly pay purchase price product license genentech connectic corporation subsequently assign intermune complaint relate royalty genentech receive june august complaint consolidate single amend complaint claim seek damage violation federal racketeering law unfair competition law consumer protection law unjust enrichment september complaint include claim name genentech defendant claim damage unjust enrichment matter formally related consolidated complaint december genentech motion dismiss matter currently schedule hear february outcome matter determined time subsequent roche proposal thirty shareholder lawsuit file genentech andor members board director roche entity include roche holdings inc rhi roche holding ltd roche holding ag lawsuit currently pende state court include delaware court chancery san mateo county superior court united states district court northern district california lawsuit generally assert classaction claim breach fiduciary duty aiding abet breach fiduciary duty base allegation connection roche offer purchase remain share defendant fail properly value genentech fail solicit potential acquirer engage improper selfdeale suit seek invalidation july affiliation agreement genentech rhi affiliation agreement order deeming article genentech amend restate certificate incorporation inapplicable invalid potential transaction roche outcome matter determined time october genentech biogen idec inc file complaint sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc northern district california seek declaratory judgement certain genentech product include rituxan infringe sanofis patent patent patent declaratory judgement patent invalid december sanofi file motion dismiss complaint lack jurisdiction discovery hearing relate motion currently set february october sanofi file suit genentech biogen idec eastern district texas lufkin division claim rituxan genentech product infringe patent january genentech file motion transfer matter northern district california sanofi seek preliminary permanent injunction compensatory exemplary damage relief addition october hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate agreement hoechst pre decessors genentech pertain patent relate patent outside united states genentechs answer arbitration request file january hoechst seek pay ment royalty sale genentech product damage breach contract relief genentech intends vigorously defend outcome matter determined time genentech annual report quarterly sec filing contain detailed disclosure litigation matter require gaap include detail matter include information litigation currently significant matter refer noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability debt debt recognise liability millions chf debt instrument amount bank financial institution genentech leasing obligation finance lease obligation borrowing total debt report longterm debt shortterm debt total debt debt repayment term millions chf year year year year year year total debt fair value debt instrument billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc calculate base theobservable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow andmaturity period pledge group asset connection debt amount bank financial institution amount denominate currency notably chinese renminbi average interest rate average interest rate balance primarily denominate ineuro repayment date year million swiss franc million swiss franc year wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement debt instrument recognise liability effective interest rate debt instrument million chf effective interest rate european medium term note programme bond october principal million euro bond august principal million pound sterling swiss franc bond rodeo march principal billion swiss franc dollar bond chameleon july principal million dollar genentech senior note senior note july principal million dollar senior note july principal billion dollar senior note july principal million dollar genentech commercial paper note date january principal million dollar principal million dollar january japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september outstanding principal million japanese yen total debt instrument unamortise discount include carry value debt instrument millions chf sterling bond total unamortised discount fair value option group apply fair value option outstanding debt instrument group apply fair value hedge accounting past debt instrument european medium term note programme euro bond chameleon dollar bond rodeo swiss franc bond fair value option treatment base elimination accounting mismatch recognise hedging swap report fair value hedge bond report atamortise cost difference carry value principal debt instrument total million swiss franc million swiss franc issuance new debt instrument genentech commercial paper program october genentech establish commercial paper pro gram issue billion dollar unsecured commercial paper note maturity program generally vary overnight week exceed day asat december unsecured commercial paper note principal million dollar million dollar average interest rate outstanding genentech intend use proceed general corporate purpose repayment redemption conversion debt instrument redemption rodeo swiss franc bond date march group redeem thesebond original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain orloss record redemption redemption european medium term note programme euro bond date october group redeem original issue plus accrue original issue discount oid theeffective interest rate bond cash outflow million swiss franc therewas gain loss record redemption conversion redemption series chugai pharmaceutical unsecured convertible bond remain outstanding bond face value million japanese yen million swissfranc convert share chugai redeem issue price date september group percentage ownership chugai unaffected conversion asthegroup bond convertible chugai share mirror chugai outstanding withthird party gain loss record income statement conversion andredemption cash outflow million swiss franc repayment redemption conversion debt instrument conversion redemption lyon v dollar exchangeable note june group announce exercise option note redemption july originalissue plus accrue original issue discount oid period july note aprincipal million dollar convert million nonvoting equity security andthe remain note redeem cash july total million swiss franc record equity consist million swiss franc cash purchase nonvoting equity security conversion redemption million swiss franc carry value ofthe convert bond relate tax effect million swiss franc gain loss record income statement conversion redemption redemption european medium term note programme dollar bond date october group redeem bonds principal value million dollar original issue plus accrue original issue discount oid cash outflow million swissfranc gain loss record income statement redemption partial conversion series chugai pharmaceutical unsecured convertible bond bond face value billion japanese yen million swiss franc convert share ofchugai group percentage ownership chugai unaffected conversion group hasbond convertible chugai share mirror chugai outstanding party gain loss record income statement partial conversion cash outflow repayment redemption conversion debt instrument million chf lyon v dollar exchangeable note european medium term note programme dollar bond rodeo swiss franc bond european medium term note programme euro bond genentech commercial paper net repayment japanese yen convertible bond issue chugai total cash outflow repayment redemption year wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf share equity retain fair value hedge translation year end december capital instrument earnings reserve reserve reserve total january restate availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statementa transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation define benefit plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity noncontrolle interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change noncontrolle interest december amount transfer income statement losse million swiss franc report royalty operate income gain million swiss franc financial income disclose note postemployment benefit asset defer tax liability equity restate december balance sheet follow adoption ifric interpretation reconciliation previously publish balance sheet provide note equity share instru retain fair value hedge translation year end december capital ment earnings reserve reserve reserve total january availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statementa transfer initial balance sheet carrying value hedge item currency translation foreign operation exchange difference accumulate difference transfer income statement divestment define benefit plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity noncontrolle interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase change ownership interest subsidiary chugai ventana change noncontrolle interest december amount transfer income statement losse million swiss franc report royalty operate income gain million swiss franc financial income wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement share capital december authorise issue share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share describe note base information supply group novartis ltd basel affiliates own participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repay ment nominal value share participation certificate accordance law andthe article incorporation roche holding ltd company entitle times exchange orsome nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security december december millions millions nonvoting equity security low exercise price option derivative instrument total equity instrument equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting equity security strike price market value millions maturity chf chf million nonvoting equity security na na low exercise price option derivative instrument feb feb total nonvoting equity security derivative instrument hold group potential conversion obligation arise roche option plan roche stocksettle stock appreciation right note mainly consist option exercisable time maturity net cash outflow transaction equity instrument million swiss franc net cashinflow million swiss franc large cash inflow mainly arise reduction equity instrument holding follow conversion redemption lyon v notes group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value available forsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security group net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement potential dilutive effect arise convertible debt instrument employee stock option plan ifthe outstanding convertible debt instrument convert lead reduction interest expense increase number share net dilutive effect earning share exercise outstanding vested employee stock option dilutive effect exer cise outstanding vested genentech employee stock option dilutive effect net income genentech positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure dilute earning share nonvoting equity security group net income attributable roche shareholder chf million elimination interest expense net tax convertible debt instrument dilutive chf million increase noncontrolle share group net income net tax assume outstanding genentech chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise directly equity net income recognise income statement genentech chugai noncontrolle interest total net income recognise income statement total recognise income expense ventana acquisition dividend pay noncontrolle shareholder chugai noncontrolle interest equity compensation plan genentech chugai share repurchase change ownership interest subsidiary chugai ventana change noncontrolle interest december genentech chugai noncontrolle interest total noncontrolle interest cash flow statement cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation andimpairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement cash generate operation million chf net income add nonoperate income expense associate financial income financing cost income taxis major legal case change group organisation operating profit exceptional item depreciation property plant equipment amortisation intangible asset impairment intangible asset impairment property plant equipment operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset andthe cash flow effect business combination divestment cash generate thegroup investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment groupsequity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow fromshortterm borrowing show net movement consist large number tran action short maturity interest dividend pay millions chf interest pay dividend pay total significant noncash transaction increase property plant equipment million swiss franc million swiss franc wasrecorde genentech leasing arrangement note correspond increase inlongterm debt risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director overall group risk management process include performance risk assessment describe detail business report onpage financial risk management specifically describe detail financial risk management group expose financial risk arise underlie operation corporate financeactivitie group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency ofthegroup counterpartie financial risk management group govern policy review board director ofroche genentech chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use ofderivative financial instrument speculative trading purpose policy implementation daytoday riskmanagement carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche genentech chugai carry value fair value financial asset millions chf carry value asset class fvtpla available fvtpla hold hold loan fair line item note forsale designate trading maturity receivables total value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement carry value asset class fvtpla available fvtpla hold hold loan fair line item note forsale designate trading maturity receivables total value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset trade receivables subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective management trade receivables sustain growth profitability group byoptimise asset utilisation whilst maintain risk acceptable level note significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie additionally group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold forloans receivables december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent nature geographical location trade receivables overdue counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable security subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest high qualitysecuritie adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution group sign net agreement isda international swap derivative association master agreement respective counterpartie inorder control exposure derivative position rate analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange total overdue asset financial asset past impair total billion swiss franc billion swiss franc analysis overdue impair financial asset class millions chf total overdue month month month month year year end december loan receivables year end december loan receivables december financial asset term renegotiate wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement liquidity risk liquidity risk arise surplus financial obligation available financial asset point intime group approach liquidity risk maintain sufficient readily available reserve order tomeet liquidity requirement point time group liquidity report senior management amonthly basis roche genentech chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement addition group unused committed credit line financial institution total billion swiss franc billion swiss franc decline change inforeign currency translation rate contractual maturity analysis financial liability millions chf total month month month year year year year year year end december total debta trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability year end december total debta trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability total debt table show undiscounted cash flow carry value consolidate balance sheet reflect discount cash flow market risk market risk arise change market price group financial asset financial liability market risk affect group financial result value group equity group use valueatrisk var measure impact market risk financial instrument rochehas define var limit manage market risk var datum report monthly basis indicate value range give financial instrument fluctuate preset probability result ofmovement market price var statistical measure implicitly assume value change recent past indicative value change future var figure represent actual expect loss possible worstcase loss state period var figure calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base ona confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appro priate long hold period increase probability high value change lead increase var figure actual future gain loss associate treasury activity differ materially var analy ses perform inherent limitation associate predict timing change tointer rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include effect change credit spread market risk financial instrument millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk december total var financial asset liabilitie million swiss franc million swiss franc foreign exchange var increase arise mainly hedge nonus dollar cash flow future royalty income year genentech low contribution interest rate component cause age fixedterm liability price risk arise mainly movement price equity security decrease significantly reduce equity security holding december group hold equity security market value billion swiss franc billion swiss franc number include holding biotechnology company acquire context licensing transaction scientific collaboration low holding equity security result low var price risk foreign exchange risk group operate world expose movement foreign currency affect groupfinancial result value group equity foreign exchange risk arise local currency pay receive transaction denominate foreign currency vary change inexchange rate transaction exposure foreign currency denominate financial state ment group foreign subsidiary vary consolidation swiss franc denominate group financial statement translation exposure objective group foreign exchange risk management activity preserve economic value ofit current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group currently hedge translation exposure financial instrument group monitor transaction exposure daily basis net foreign exchange result correspond var parameter report monthly basis group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement interest rate risk interest rate risk arise movement interest rate affect group financial result thevalue group equity change interest rate cause variation interest income expense inaddition affect market value certain financial asset liability hedge instrument primary objective group interest rate management protect net interest result interest rate exposure correspond var parameter report monthly basis group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix offixed float rate exposure price risk price risk arise mainly movement price equity security hold roche genentech chugai december group hold equity security market value billion swiss franc billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration nature business biotechnology company expose great equity volatility general stock market fluctuation group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment equity price risk report var figure monthly basis senior management impairment financial asset impairment share trigger significant prolong price decline cost value impairment debt security record significant financial difficulty issuer impairment loss asset class millions chf loan receivables availableforsale financial asset share investment debt security total impairment loss capital group define capital manage group total equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capital monitor basis equity ratio calculate equity include noncontrolle interest percentage total asset report senior management group regular internal management reporting group capital equity ratio show tablebelow capital million chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total asset equity ratio group subject regulatory capital adequacy requirement know financial service industry group majority shareholding genentech note chugai note genentech chugai public company objective policy process manage capital determine local management relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri ms maja oeri group hold share pre ceding year represents issue share figure include share pooled voting right hold outside group individual member group onjanuary pool member announce effective april ms beatrice oeri leave thepool mrjrg duschmal mr lukas duschmal join pool group continue hold total share pool voting right previously mr andr hoffmann dr andreas oeri members board director roche holding ltd mrhoffmann receive remuneration total swiss franc swiss francs dr oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation nosignificant transaction group associate wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board ofdirector exclude chairman total million swiss franc million swiss franc chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note remuneration chairman board director member corporate executive committee millions chf salary include bonus expense social security cost pension postemployment benefit equity compensation plan employee benefit total roche longterm member corporate executive committee grant stocksettle stock appreciation right ssar roche option plan rop award ssar rop award roche connect contribution pay group respect chairman boardofdirector member corporate executive committee total million swiss franc million swiss franc roche performance share plan member corporate executive committee target award cycle awards cycle eachaward result zero nonvoting equity security depend achievement ofthe performance target transaction member corporate executive committee pension total million swiss franc million swiss franc pay group corporate executive committee member detailed disclosure executive remuneration require swiss law include inthefinancial statement roche holding ltd basel page postemployment benefit plan transaction group postemployment define benefit plan employee ofthe group describe note subsidiary associate divestment subsidiary effective october group sell whollyowne subsidiary cenexi sas cenexi include manufacturing facility fontenaysousbois france million swiss franc cash loss divestment cenexi millions chf consideration net asset dispose property plant equipment cash net asset accumulate currency translation adjustment gain loss divestment total loss divestment report general administration expense current period segment result roche pharmaceutical operating segment net cash inflow divestment million swiss franc list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange zurich valor share valor genussscheine isin share ch isin genussscheine ch market capitalisation chf basilea pharmaceutica ltd basel chf stock exchange zurich valor isin ch market capitalisation chf united states genentech inc south san francisco usd stock exchange new york incorporate delaware isin market capitalisation usd japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonliste company share capital equity interest country company city millions argentina producto roche sa qumica e industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostic belgium sa brussels eur wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostic oy espoo eur roche oy espoo eur france roche diagnostic sa meylan eur roche sas neuillysurseine eur ventana medical systems sa illkirch eur germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic gmbh mannheim eur roche kulmbach gmbh kulmbach eur roche pharma ag grenzachwyhlen eur swisslab gmbh berlin eur greece roche hellas sa athens eur roche diagnostic hellas sa athens eur guatemala producto roche guatemala sa guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light luxembourg pharminvest sa luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad share capital equity interest country company city millions netherlands roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama producto roche interamericana sa panama city usd producto roche panam sa panama city pab syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru producto roche qumica farmacutica sa lima pen philippine roche philippines inc makati php poland roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd puerto rico branch ponce usd romania roche romania srl bucharest ron russian federation roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostic sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostic scandinavia ab bromma sek switzerland disetronic handel ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche capital market ltd basel chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic ag rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try united kingdom pirame limited berkshire gbp roche diagnostic ltd lewes gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp wwwglobalreportscom roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions united states life sciences corporation branford usd bioveris corporation gaithersburg usd disetronic medical systems inc fisher usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche diagnostic operation inc indianapoli usd roche finance america inc little fall usd roche finance usa inc little fall usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche madison inc madison usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc palo alto usd spring bioscience corp fremont usd therapeutic human polyclonals inc palo alto usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef share capital local currency unit roche group report roche management internal control overfinancial report roche finance report report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establishing maintain ing adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reason ableassurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate frameworkissued committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg klynveld peat marwick goerdeler sa audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz b humer erich hunziker chairman board director chief financial officer deputy head corporate executive committee basel january wwwglobalreportscom roche finance report roche group report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit consolidated financial statement income statement balance sheet cash flow statement statement recognise income expense statement change equity note page roche holding ltd year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement andmaintaine internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgment include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december atrue fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm aninternal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg klynveld peat marwick goerdeler sa john morris franois rouiller license audit expert license audit expert auditor charge basel january wwwglobalreportscom roche finance report roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entity asset amaterial effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide areasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree ofcompliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg klynveld peat marwick goerdeler sa john morris franois rouiller basel january wwwglobalreportscom roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard stock split apply retrospectively b b dividend include special dividend relate spinoff fragrance flavours division b dividend propose board director wwwglobalreportscom roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic consumer health otc total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic consumer health otc corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information base members eu december comparative information restate toinclude new eu member fiveyear period wwwglobalreportscom roche finance report roche group multiyear overview supplementary information supplementary net income ep information group basic diluted earning share information give note consolidated financial statement page supplementary eps information give net income exceptional item core net income additionally exclude amortisation intangible assetsand relate impact income taxis noncontrolle interest profit continue business exceptional item core net income millions chf net income major legal case income taxis change group organisation income taxis profit continue business exceptional item noncontrolle interest net income exceptional item major legal case exceptional item change group organisation net income attributable roche shareholder exceptional item amortisation impairment intangible asset income taxis noncontrolle interest core net income ep continue business exceptional item core eps ep continue business exceptional item core ep net income attributable roche shareholdersmillion chf elimination interest expense net tax convertible debt instrument dilutive increase noncontrolle share net income net tax assume outstanding genentech chugai stock option exercise net income calculate diluted earning share share informationmillion share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume conversion convertible debt instrument dilutive adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share earning share diluted chf supplementary operating free cash flow information divisional operate free cash flow information millions chf pharmaceutical diagnostic division division corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment intangible asset total adjustment add expense equitysettle equity compensation plan net incomeexpense provision net gain disposal deduct net cash flow equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda operate profit exceptional item depreciation amortisation impairment total group add exceptional item ebitda margin sale wwwglobalreportscom roche finance report roche group multiyear overview supplementary information pharmaceutical subdivisional operate free cash flow information million chf roche pharmaceutical pharmaceutical genentech chugai division depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment intangible asset total adjustment add expense equitysettle equity compensation plan net incomeexpense provision net gain disposal deduct net cash flow equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda operate profit exceptional item elimination division total depreciation amortisation impairment total group add exceptional item ebitda margin sale unrealise internal profit inventory sell subdivision sell ontoexternal customer balance sheet date eliminate consolidation entry roche group roche security roche finance report roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr sp index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate stock split roche share nonvoting equity security genussscheine effective change ratio adrs effective january change ratio adr effective january wwwglobalreportscom roche finance report roche group roche security number share nonvoting equity securitiesa number share nominal value chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity security chf net income equity dividend c stock price shareb open high low yearend stock price nonvoting equity security genussscheinb opening high low yearend market capitalisation millions chf year end key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussscheinconfer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction astoownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director ticker symbol share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby swiss exchange ro rog roche holding ltd basel financial statement roche finance report roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year wwwglobalreportscom roche finance report roche holding ltd basel financial statement balance sheet december millions chf noncurrent asset participation longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine pm pm general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pm pro memoria nonvoting equity security nominal value roche holding ltd basel note financial statement roche finance report note financial statement summary significant accounting policy basis preparation financial statement financial statement roche holding ltd basel prepare accordance provision ofswisslaw participation major participation company list note roche group consolidate financial statement valuation method translation foreign currency marketable security report low cost market value asset include partici pation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency aretranslate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security genussscheinconfer right share participate available earning remain proceed liquidation follow repayment ofthe nominal value share capital participation certificate wwwglobalreportscom roche finance report roche holding ltd basel note financial statement movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december contingent liability guarantee framework european medium term note emtn programme company issue guar antee favour group company amount million swiss franc million swiss franc significant shareholder share company bearer share reason company register ofshareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company share shareholder group pool voting right comprise ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri ms maja oeriab share participation novartis ltd basel include affiliate thereofc information supply shareholder figure share include share pooled voting right hold outside group individual member group b january pool member announce effective april ms beatrice oeri leave pool mr jrg duschmal mr lukas duschmal join pool group continue hold total share pool voting right previously c figure december supply novartis ltd basel risk management detailed disclosure risk management require swiss law include rochegroup consolidated financial statement page board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total remuneration board director chairman board directors dr franz b humer receive remuneration show table remuneration chairman board director thousands chf annual salary include bonus expense pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total dr humer receive remuneration indirect benefit participate certain equity compensation plan total millionswiss franc corporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan show table march dr franz b humer hand executive function ceo dr severin schwansince drschwan wasthe member corporate executive committee high total remuneration remu neration disclose dr humer member corporate executive committee thehighest total remuneration wwwglobalreportscom roche finance report roche holding ltd basel note financial statement remuneration member corporate executive committee thousands chf total ceca schwan annual salary include bonus expense pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total amount total cec include dr humer total remuneration corporate executive committee million swiss franc dr humer member corporate executive committee high total remuneration total remuneration million swiss franc employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension post employment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term andveste condition award disclose note consolidated financial statement fair value consolidated financial statement represent cost company grant dateand reflect matter observe exercise behaviour exit rate popula tion receive initial simulation performance condition purpose remuneration disclosure fair value calculate base fair value employee receive take account preliminary assessment complete performance condition chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee swiss franc calculate blackschole formula assume hold maturity deduct average year vest period chairman board director grant ssar member corporate executive committee member senior management participate roche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form partof employee remuneration equal annual amount threeyear cycle award willresult zero nonvoting equity security genussscheine depend achievement performance target discretion board director individual award relate show table number award calculate follow psp preliminary allocation base actual performance period show nonvoting equity security genussscheinper award psp nonvoting equity security genussscheinper award psp nonvoting equity security genussscheinper award result allocation multiply nonvoting equity security genussscheinprice december swiss franc fair value remuneration receive employee chairman board director grant psp cycle remuneration equity compensation plan thousand chf roche connect ssar awards psp award employer ssar ssar psp psp psp psp total contribution number fair value number number number fair value fair value total ceca schwan amount total cec include dr humer total remuneration corporate executive committee equity compensation plan million swiss franc million swiss attributable dr humer member corporate executive committee high total remuneration employee benefit include tax advisory cost remuneration dr hunziker mr burns prof knowle serve chugai board director transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc mr heino von prondzynski member corporate executive committee receive bonus million swiss franc respect service render andadditionally receive total nonvoting equity security base prorate roche performance share plan awards board executive shareholding board director director mr andr hoffmann dr andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition december member board director person closely associate hold share nonvoting equity security genussscheineas show table wwwglobalreportscom roche finance report roche holding ltd basel note financial statement shareholding member board director nonvoting equity security share genussscheine fb humer b b gehrig hoffmann c cd p baschera ji bell p brabeckletmathe ljr de vink e w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total figure include share hold shareholder group pool voting right b equity compensation award roche option plan ssar roche performance share plan c report swiss exchange august mr hoffmann enter option agreement ubs roche nonvoting equity security period august august mr hoffmann dr oeri hold ubs longshort certificate roche bearer share ro versus roche nonvoting equity security rog isin ch e mr de vink hold roche american depositary receipt adr rhhby isin corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security genussscheine show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ab ayyoubi na na wm burn e hunziker ga keller ac jkc knowles j schwiezer na na total equity compensation award roche option plan ssar roche performance share plan b dr schwans close relative hold roche nonvoting equity security genussscheine zero c dr kellers close relative hold roche nonvoting equity security genussscheine december chairman board director member corporate executive committee hold stocksettle stock appreciation right ssar issue roche option plan award issue show table option entitle holder purchase roche nonvoting equity security genussscheineat specify strike price term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report include business report page roche option plan ssar award hold december year issue total schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total cec fb humer total strike price chf expiry date jan feb feb feb feb feb feb december chairman board director member corporate executive com mittee hold psp award psp performance cycle show table term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report page business report award result zero nonvoting equity secu rities genussscheine depend achievement performance target discretion board director preliminary allocation ratio plan total target number ofaward cycle december show table roche performance share plan award hold december psp psp psp schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer total cec fb humer total award grant allocation date feb feb feb estimated allocation december total estimate award december december chairman board director member corporate executive com mittee time hold total stocksettle stock appreciation right roche option plan award outstanding total award grant roche performance share plan wwwglobalreportscom roche finance report roche holding ltd basel appropriation available earning appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year transfer free reserve total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche holding ltd basel report statutory auditor financial statement roche finance report report statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit financial statement income statement balance sheet note onpage roche holding ltd year end december board director responsibility board director responsible preparation finan cial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit weconducte audit accordance swiss law swiss auditing standard stan dards require plan perform audit obtain reasonable assurance financial state ment free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgment include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness account ing estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation wwwglobalreportscom roche finance report roche holding ltd basel report statutory auditor financial statement report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg klynveld peat marwick goerdeler sa john morris franois rouiller license audit expert license audit expert auditor charge basel january wwwglobalreportscompublishe cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking tel statement forwardlooke statement identi fax fie word believe expect anticipate project intend seek estimate future similar expression discussion thing medium office strategy goal plan intention factor corporate communication causeactual result differ materially future basel switzerland reflect forwardlooke statement contain tel annual report price product fax initiative competitor legislative regulatory devel opment economic condition delay inability investor relation obtain regulatory approval bring product market fluctuation currency exchange rate general basel switzerland financial market condition uncertaintie discovery tel development marketing new product new use fax exist product include limitation negative result clinical trial research project unexpected effect world wide web pipeline market product increase government httpwwwrochecom pricing pressure interruption production loss ofor inability obtain adequate protection intellectual order publication property right litigation loss key executive orother employee adverse publicity news tel coverage fax email baselwebmasterrochecom statement earning share growth aprofit forecast interpret mean annual general meeting march thatroche earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark mention enjoy legal protection roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel corporate communication wwwglobalreportscom